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ABSTRACT 
 
 
Molecular Design as a Tool to Understand and Manipulate Cell Death 
 
Michael McQuaid Gaschler 
 
 
 Phenotypic screening is a powerful technique for discovering small 
organic molecules with the ability to effect a desired change in biological 
systems. Yet, because of the diversity of ways that a small molecule can alter a 
biological system, phenotypic screens provide little to no insight into how a hit 
molecule elicits such a change. Understanding a molecule’s mechanism of 
action—which proteins it engages, where it localizes, and its reactivity—is critical 
to fully developing a hit molecule into a research tool or a therapeutic.  In this 
dissertation, strategic, hypothesis-driven molecular design is used as a 
cornerstone technique to understand the mechanism of action of molecules that 
regulate cell death. In the first part, we examine the structural requirements for 
ferroptotic death induction by the 1,2-dioxolane FINO2. Next, we create a panel 
of ferroptosis inhibiting molecules that are targeted to specific organelles and 
used as imaging agents in order to examine the contribution of different 
organelles to ferroptosis. I then apply molecular design in a target-based context 
to discover which molecular features of LOC14 promote association with its 
receptor protein. Finally, I discuss a computational approach to developing a 
ligand that inhibits protein-protein interactions mediated by the small GTPase 
Rheb.  
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Chapter 1 
Introduction1 
1.1 The Advent And Maturation Of Phenotypic Screens 
 At the turn of the last century infectious diseases were a leading cause of mortality and 
one of the foremost public health challenges.1 Among the infectious diseases, contracting the 
sexually transmitted disease syphilis was a particularly grim fate. As the disease progressed it 
would cause skin lesions, extreme facial deformation, and eventually death. Syphilis killed 
approximately 11 out of every 100,000 people in the United States in 1900, a rate similar to the 
mortality caused by AIDS in the early 1990s.2 In 1905 the bacterium responsible for syphilis was 
identified as Treponemia pallidum. Having had some limited success in treating infections caused 
by related bacteria, Paul Ehrlich, the director of the Georg-Speyer House research institute, set 
out to discover a molecule capable of curing syphilis. 
Nearly thirty years earlier as part of his doctoral work, Ehrlich observed that small-
molecule histological dyes were capable of selectively staining cells of a particular type in highly 
heterogeneous cell populations. For instance, Ehrlich observed that the dye methylene blue 
showed high affinity for staining cells in the nervous system even when administered to live 
animals.3 These observations and others led Ehrlich to hypothesize that different cell types had 
different receptors on their surface that allowed them to interact selectively with small molecules. 
Extending his hypothesis, Ehrlich reasoned that if cells could selectively interact with dyes, then 
they should be able to selectively interact with any type of molecule, including toxins. Ehrlich 
termed these selective toxins ‘magic bullets’—molecules that would be highly toxic to a parasite 
but had no adverse effect on the infected host.4 Erlich spent years looking for such magic bullets 
without much success until a colleague of Ehrlich’s suggested that he test a series of arsenic-
containing molecules for their ability to kill syphilis. With his colleague Sahachiro Hata, Ehrlich 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
1 Portions of this chapter are adapted from a published manuscript: Gaschler, M. M.; Stockwell, 
B. R., Lipid peroxidation in cell death. Biochem Biophys Res Commun 2017, 482 (3), 419-425 
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oversaw the testing of hundreds of these arsenic-containing molecules in rabbits infected with 
syphilis. Many compounds were ineffective, others were toxic to host and parasite in equal 
proportion. It wasn’t until compound number 606 that Ehrlich and Hata observed a significant 
therapeutic effect. The medical community’s excitement about compound 606 was immediate and 
intense. Ehrlich spent the spring of 1910 distributing 65,000 free samples of compound 606 for 
clinical trials in human patients. Later that year the chemical company Hoechst began 
manufacturing and marketing compound 606 as Salvarsan—the arsenic that saves.3 Salvarsan 
and its derivatives revolutionized syphilis treatment and remained the therapy of choice for 
treating syphilis for decades to come.5 
Eventually, Salvarsan therapy was supplanted the now-familiar (and less toxic) antibiotic 
penicillin. Nevertheless, the concepts and methods pioneered by Paul Ehrlich have become 
cornerstones of modern drug discovery efforts, regularly used by academic labs and 
pharmaceutical companies alike. Today, Ehrlich’s basic method of testing a large, diverse set of 
molecules for their ability to cause a desired and observable change in living biological systems is 
referred to as phenotypic screening. The development of high-throughput screening technologies 
and large chemical libraries in recent decades has further increased the speed and quantity of 
molecules that can be tested. Using appropriate experimental design, it is possible to test tens of 
thousands of unique molecules for their efficacy in a given disease.6 As a testament to the power 
of this experimental technique, it has been estimated that up to 37% of new molecular entities 
approved by the FDA between the years 1999-2008 originated from phenotypic screening 
programs.7 A major advantage of phenotypic screening is its ability to identify biological targets 
relevant to the disease being screened against in an unbiased way—no prior knowledge of how a 
the disease could be cured is required. In essence, phenotypic assays ‘prevalidate’ small 
molecule hits and their targets as being able to alter a disease state even if the exact molecular 
mechanism of how this is accomplished is unknown.7 
Despite the power of phenotypic screening, it also has challenges and limitations. The 
utility of phenotypic screening can be significantly limited by the quality of the disease model 
being used. High throughput screening experiments are usually incompatible with testing on 
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whole organisms and therefore rely on a simplified biological model of the disease or condition 
being interrogated. For example, in oncology research, instead of performing phenotypic screens 
on tumors growing in live organisms, screens are often carried out with immortalized cancer cell 
lines grown in culture. However, these immortalized cancer cell lines can possess significant 
differences from cancerous tumors in patients, limiting the ability to translate findings in cell lines 
to clinical uses.8 Another challenge in phenotypic screening is that any molecule that elicits the 
desired phenotypic change (a ‘hit’) does so via an unknown mechanism. Knowing the mechanism 
of action (MOA) of a molecule greatly aids rational optimization and guides the design of 
improved versions of the hit compound. Detailed understanding of the MOA also allows the hit 
molecules or their derivatives to be used as chemical probes for forward chemical genetic work. 
Analogous to phenotypic screening, forward chemical genetics uses small molecules with a 
known biological function as research tools to better understand biological systems.9 While a 
detailed understanding of a molecule’s MOA is not required for it to have useful applications, the 
high value placed on having a mechanistic understanding of molecular behavior is demonstrated 
by the fact that only 7% of drugs approved by the FDA operate via an unknown mechanism.10 
 
1.2 Molecular Design Strategies for Gaining Mechanistic Insight into 
Bioactive Molecules  
Because of the diversity of ways in which a small molecule can alter a biological system, 
discovering the MOA of a bioactive molecule is a complex and difficult task. As a result of this 
complexity, there is no canonical strategy for MOA discovery, and developing a full understanding 
of a molecule’s MOA often requires the use of multiple complimentary techniques11-12. One such 
strategy begins with structural modification and derivatization of the hit molecule. Strategically 
redesigning a hit molecule can generate mechanistic insights by revealing chemically reactive 
groups necessary for activity or structural features that contribute disproportionately to potency. 
Molecular design can also incorporate new chemical groups into the hit molecule that build in new 
function for biophysical techniques like target labeling, affinity chromatography, or imaging. 
Alternately, structural comparison of a newly discovered bioactive molecule with molecules with 
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well-known function can suggest potential cellular targets and furnish hypotheses directly testable 
using a target-based approach. Consequently, if a particular protein is hypothesized to be 
important in the biological state being manipulated, in silico screening and optimization of 
molecules can furnish previously undescribed molecules with superior affinity for a target protein. 
Though diverse, these methods all depend on analysis and design of molecules at the atomic 
level in order to gain insights into biological function.  
1.2.1 Structure Activity Relationships 
A common method used to gain insights into a molecule’s MOA involves developing an 
understanding of the relationship between structural variation and the activity of the molecule in a 
given assay. Using organic synthesis and biological testing, one can come to understand the 
structure activity relationship (SAR) of a given class of molecules. A common starting point in 
understanding the SAR of a compound is to determine the necessity of any chemically reactive 
groups. Chemically reactive groups have traditionally been viewed as undesirable molecular 
features as they may act through nonspecific mechanisms or cause or off-target toxicity.13 
Indeed, there is an increasing effort to remove these reactive and non-specific reactive 
compounds from screening libraries altogether.14 Even so, chemically reactive small molecules 
can demonstrate high selectivity for a target.  
The small molecule RSL3 was discovered in a chemical screen for molecules that 
exerted selective lethality for cells expressing an oncogenic version of the RAS gene.15 Further 
work identified RSL3 as an inducer of ferroptosis, a form of iron-dependent, non-apoptotic 
Figure 1.1. Structure of (1S, 3R)-RSL3 and select chemical analogs. Electrophilic 
moieties are highlighted in red. 
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regulated cell death.16 RSL3 contains a chloroacetamide group, which is susceptible to 
nucleophilic attack by serine, cysteine, and other biological nucleophiles. To test if this reactive 
group was necessary, a series of chemical analogues were synthesized (Figure 1.1). Removal of 
the chloroacetamide moiety or substitution with a weaker electrophile resulted in a complete loss 
of activity in most cases.17 RSL3 also contains two chiral carbons at positions 1 and 3. The three-
dimensional structure of small molecules containing chiral centers can promote favorable 
interactions when associating with other chiral molecules such as proteins. All four diastereomers 
of RSL3 were synthesized and only the (1S, 3R) conformation was active.17 Cumulatively, these 
structural variations led to the hypothesis that RSL3 selectively targeted a protein active site that 
contained a nucleophilic amino acid. Eventually, this hypothesis was confirmed when RSL3 was 
found to irreversibly and covalently inhibit the phospholipid hydroperoxidase GPX4, which 
contains a nucleophilic selenocysteine in its active site.18 
Other trends in molecular SAR only begin to emerge following more extensive synthesis 
of analogs. Unlike reactive groups whose removal often leads to a binary-type output (i.e. active 
vs. inactive), modifications of non-reactive groups often lead to small increases or losses in 
overall potency and activity. In this case, trends in the SAR begin to emerge after comparing a 
whole group of structurally related molecules. The lipophilic antioxidant ferrostatin-1 was 
discovered through a phenotypic screen for compounds that rescued cells from ferroptotic cell 
death selectively over other regulated death mechanisms.16 Following the synthesis of many 
structural analogs of ferrostatin-1, it was observed that increasing the overall lipophilicity of the 
molecule generally improved its potency.16, 19 As with most SAR trends, continued work on 
ferrostatins demonstrated that the correlation between lipophilicity and potency does not always 
hold up.20 However, the necessity of high lipophilicity for anti-ferroptotic activity led to the 
hypothesis that ferrostatins associate with lipid bilayers (a lipophilic cellular compartment) in order 
to prevent ferroptosis.20 
1.2.2 Building in New Functionality 
 Another strategy that relies on molecular design in order to understand molecular 
function involves deliberately adding new functional groups to molecules that possess specific 
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chemical properties needed for a particular experimental technique. Generally, these new 
structural modifications are inert to biological conditions but can be activated and manipulated 
precisely by the experimenter. Specifically, photoaffinity labeling and affinity chromatography are 
common techniques used to discover any protein targets of a hit molecule. Alternately, imaging 
techniques can provide insight into the distribution of hit molecules within tissues and cells. All 
these techniques require the addition of new functional groups within a molecule. A challenge 
common to all techniques in this class is ensuring that structural modifications do not alter the 
native behavior of the molecule being studied. Therefore, in the process of building in new 
functionality it is important to alter the native molecular structure as minimally as possible and 
validate any results experimentally using orthogonal techniques. 
 Photoaffinity labeling (PAL) is a popular technique for identifying proteins targeted by a 
small molecule of interest. In PAL, a chemical moiety such as benzophenones, azides, and 
diazirines are built into the molecule being studied (Figure 1.2A).21 Following irradiation with 
ultraviolet light each of these moieties decomposes into a reactive intermediate that can form a 
covalent adduct with any nearby molecule. If the molecule being studied is a ligand of any 
protein, then it will covalently modify the protein it is bound to. Following crosslinking with the 
target protein, it is necessary to retrieve the protein-molecule complex so that the target protein 
can be identified, usually using mass spectrometry-based techniques. Many elaborate systems 
Figure 1.2. Structure modification for photoaffinity labeling. (A) Common 
functional groups used for photoaffinity labeling. (B) Structure of apoptosis 
inducer MX-126374 and its analog MX-126911 with a photoreactive azide (red) 
and radioactive tritium atoms (green) for identification of protein-ligand complex.  
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for retrieving, isolating, and identifying this protein-molecule complex have been developed. Two 
conventional techniques use radioactive isotopes or “click-able” moieties added to the molecule 
being studied.22-23 For example, the small molecule MX-126374 was selected from a phenotypic 
screen for its ability to induce apoptotic cell death with good selectivity in tumorigenic cells 
relative to non-tumorigenic cells.24 To identify the target of this molecule, the analog MX-126911 
was developed for PAL, with an azide functional group acting as a reactive moiety for PAL 
(Figure 1.2B). After crosslinking with the target protein, the MX-126911-protein complex was 
isolated by identification of the spot on a two-dimensional gel with high radioactivity from the 
tritium atoms. The identity of the protein was positively identified as TRAIL-interacting protein 47 
(TIP47) by LC-MS/MS.24 Protein-ligand complexes can also be identified through strategic 
application of bioorthogonal click chemistry between an alkyne and any azide-containing probe of 
interest. Incorporation of a terminal alkyne in a molecule allows it to be covalently linked to a 
fluorophore for identification following gel electrophoresis.25 Owing to its versatility, PAL is a 
powerful tool for target identification, and can provide invaluable insights into the mechanism of 
action of a bioactive small molecule. 
Unlike PAL, which requires formation of a covalent bond between a small molecule and 
its target protein, affinity chromatography takes advantage of the natural affinity between a small 
molecule and its binding partner in order to isolate the target protein from a complex mixture. 
Successful application of affinity chromatography for target identification requires attachment of 
the small molecule to an immobilized resin via a chemical linker. Cellular proteins are washed 
over the ligand bound resin and proteins that bind the target molecule are retained while non-
binding proteins are eluted out. Running a solution of the native, unlinked molecule through the 
resin can then elute any bound proteins. Similar to PAL, any eluted target proteins can be 
identified by general proteomic methods such as LC-MS/MS.26 Affinity chromatography has been 
successfully used in order to discover the target of FIN56, an initiator of ferroptotic cell death.27 
The structure of FIN56 was modified to include a polyethylene glycol (PEG) linker that could be 
attached to an epoxide-containing resin. Importantly, incorporation of the PEG linker did not alter 
the potency of the molecule significantly, suggesting both the native FIN56 and the PEG-
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derivative shared the same MOA. A common challenge in affinity chromatography involves 
distinguishing a bona fide hit from non-specific binding proteins. To help eliminate these off target 
binding proteins SRS11-66, an inactive analog of FIN56, was attached to an epoxide resin similar 
to FIN56. Elimination of proteins that were enriched in both the FIN56 and SRS11-66 narrowed 
the possible targets to 70 proteins. To identify which of these proteins was responsible for 
ferroptosis induction by FIN56, an RNA-interference screen was performed to identify genes 
whose knockdown consistently altered the activity of FIN56 across multiple cell lines. Based on 
these results squalene synthase (SQS) was identified as the target protein of FIN56.27 
In addition to identifying any target proteins of a small molecule, its distribution within 
organisms, tissues, or sub-cellular regions can have a significant impact on its MOA. Imaging 
techniques allow the localization of a molecule to be visualized directly in biological systems. 
Fluorescence based imaging is a powerful and well developed imaging strategy. Covalently 
linking a fluorescent small molecule or fluorescent protein to a molecule being studied allows for it 
to be selectively visualized in a biological system. Given the large size of fluorescent proteins and 
most fluorescent small molecules, this technique has had the largest impact in studying biological 
macromolecules such as proteins, antibodies, and DNA where the large size of the fluorophore is 
not expected to alter the native function and distribution of the molecule being studied.28 
Fluorescence-based imaging studies of small molecules remain more challenging. The advent of 
smaller fluorophores such as 7-Nitrobenzofurazan (NBD) has allowed for the study of smaller 
molecules such as lipids, but still cause large-scale structural changes.29 As an alternate strategy, 
incorporating structural moieties compatible with bioorthogonal chemical reactions can allow for 
incorporation of a fluorescent moiety after the molecule of interest has had time to distribute.30  
To overcome the challenges associated with fluorescent small molecule imaging, new 
imaging technologies are emerging that involve minimal structural perturbation. For example, 
using stimulated Raman scattering (SRS) small molecule localization can be imaged in live cells. 
A Raman-based technique, SRS measures the vibrational energy of chemical moieties that do 
not overlap with signal from living systems (i.e. signals in the ‘cell-silent’ region). Commonly used 
moieties for SRS imaging include carbon-deuterium bonds and carbon-carbon triple bonds.31 
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Since neither of these bonding modes are found in naturally-produced biomolecules, SRS can be 
used to quantitatively measure small molecule concentrations in sub-cellular regions with high 
specificity. SRS has been successfully applied in imaging major classes of biological 
macromolecules32 as well as imaging small molecule uptake and distribution in cells and in vivo.33 
In all cases, the size of the moiety used for imaging is just a few atoms large, making the impact 
on the native structure of the molecule minimal. The ability of SRS to image small molecules in 
live cells with minimal structural perturbation to the molecule being studied makes it a powerful 
technique to study the accumulation and distribution of the molecule, and to gain insights into its 
MOA. 
1.2.3 Substrate Homology 
 Following a phenotypic screen, one of the most straightforward ways to gain insight into 
the MOA of hit molecules is to compare the structure of the hit molecule to the structures of 
molecules with a known and well-validated MOA. Since molecular structure is the primary 
determinant of function, structurally similar molecules often have very similar mechanisms of 
action. Far from being an ad-hoc technique, multiple computational tools have been developed to 
compare new small molecules to large databases of molecules with known functions.12 One such 
tool is the Similarity Ensemble Approach (SEA) which uses Tanimoto coefficients to quantitatively 
compare topologies of new small molecules to publicly available databases of molecules with 
known function.34 To validate SEA, researchers from the Shoichet laboratory performed a screen 
of 14,000 compounds in zebra fish and identified 681 that elicited the desired phenotype; 620 of 
which had no known MOA. Then, using SEA, they analyzed 20 compounds for any predicted 
interactions. Of the 20 compounds, 11 were confirmed to have activity on the protein receptor 
predicted by SEA.35 Though methods based on similarity comparisons are clearly not without 
limitations, a major advantage is the speed with which they generate testable hypotheses. 
Successful demonstration that (1) a newly discovered molecule interacts with a predicted protein 
and that (2) that protein is relevant to the biological system being studied provides a suitable 
framework to guide further optimization and development of molecules. 
1.2.4 Computational Target-Based Screening 
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 Computer aided drug design (CADD) involves the use of computational techniques to 
quantitatively evaluate the structure of ligands or ligand-protein complexes in order to predict 
which molecules have the most promise as ligands of a target protein. CADD can greatly reduce 
the time and cost of ligand optimization, and increase the overall hit rate from a screen. An early 
demonstration of the power of CADD came from two parallel screens for inhibitors of protein 
tyrosine phosphatase-11B (PTP1B).36 Traditional in vitro screening of 400,000 compounds 
against PTP1B yielded 85 hit molecules—a hit rate of 0.021%. Computational evaluation of a 
different set of 235,000 small molecules identified 365 molecules with predicted affinity toward 
PTP1B. Of those, 127 were active against PTP1B—a hit rate of 34.7%. CADD can be further 
divided into two distinct categories: ligand-based drug design and structure-based drug design. 
Whereas ligand-based methods can be used with and without knowledge of the three-
dimensional structure of the target protein, structure-based methods require the three-
dimensional receptor structure. 
 Ligand-based drug design (LBDD) is a computational method for improving the binding 
affinity of a series of molecules that does not require knowledge of the three-dimensional 
structure of the protein of interest. In principle, this means ligand-based drug design could be 
applied to hits from a phenotypic screen, but since there is no guarantee that phenotypic 
screening hits all target the same protein, LBDD is almost exclusively used as a follow up to in 
vitro high throughput screens against a specific protein—a so-called ‘target screen’. There are 
many methodological variations on LBDD, but all methods work by measuring the physical 
properties of active molecules such as the number of hydrogen bond donors and acceptors, 
overall polarity, lipophilicity, and steric factors.37 The three-dimensional arrangement of these 
molecular features can be overlaid and compared. If many molecules share similar features in the 
same space, these features are assumed to contribute most strongly to favorable bonding 
interactions. The whole of these features can then be mapped together to create a 
pharmacophore—a three-dimensional mapping of molecular features that promote binding to a 
target. New molecules can then be screened computationally against this pharmacophore to 
identify previously untested molecules that may associate with the protein. Pharmacophore 
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screening is particularly useful for ‘scaffold hopping’—discovering chemical moieties that possess 
the same constellation of physical properties as an initial hit but do not possess certain undesired 
properties of the original hit such as metabolic instability.38 
Structure-based drug design (SBDD) is an approach where the three-dimensional 
structure of the target protein has been solved with sufficient resolution by either X-ray 
crystallography or through NMR spectroscopy. Ligand-protein interactions in vivo are highly 
complex and consequently difficult to fully reproduce in silico. Therefore, approximations that 
reduce the computational cost and time of ligand evaluation are often made in the early stages of 
screening where potentially millions of molecules may be evaluated for their binding ability. One 
of the most common approximations involves constraining the flexibility of either the receptor or 
the ligand. Rigid docking entails keeping both the receptor and all ligands locked into a single 
conformation. Consequently, rigid docking is the least computationally expensive but does not 
sample most of the possible geometries of the ligand and receptor. Flexible ligand docking allows 
for sampling of all combinations of the small molecule ligand being docked, but holds the receptor 
protein rigid. Flexible docking is the most computationally expensive, but aims to recapitulate the 
full flexibility of both the ligand and the protein in order to simulate phenomena such as induced-fit 
effects.39 
Once a docking method is chosen, a scoring function must be decided upon. Scoring 
functions allow for the affinity of a ligand for a protein receptor to be represented quantitatively. 
Generally, scoring functions can be separated into three categories: force-field based, empirical 
based, and knowledge based functions.40 Force field based functions measure the energies of 
the receptor-ligand interaction and the internal energy from the ligand (e.g. steric effects induced 
by binding). These energies are calculated from Lennard-Jones potentials. A significant limitation 
of a purely force-field based approach is that energetic contributions from entropic factors such as 
desolvation or liberation of active site water molecules are not accounted for even though these 
forces can contribute significantly to binding in vivo. Empirical functions parameterize various 
molecular interactions to best reproduce potency data gathered from experiments. This often 
leads to more simple functions than force field based approaches, but the quality of functions is 
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wholly dependent on the quality of experimental data used to create them. Similar to empirical 
approaches, knowledge-based approaches are created off of data gathered from solved 
structures of ligand-protein complexes. Knowledge-based approaches then reward different 
atomic interaction types. A limitation of knowledge-based approaches is that molecular 
interactions that could be favorable but are lacking from the basis set will not be scored 
accordingly, leading to potential false negatives. Since no single docking method is without 
limitations, consensus docking is a strategy where docking scores from all three different 
methods are combined in a weighted average with the aim of improving overall data quality.40 
Ultimately, in choosing any computational method for docking and scoring, it is important to 
validate predictive computational results with experimental data. 
1.3 Cell Death Mechanisms And Their Modulation With Small Molecules 
 One area of biology where molecular screening and design has had significant impact is 
regulated cell death. Understanding how cells navigate the balance between life and death lays 
the foundation for developing strategies to therapeutically perturb that balance. At a very basic 
level many disease states can be viewed as a dysregulation of cell death— cancers can be 
regarded as a failure of cells to die properly while neurodegenerative diseases can be considered 
to have overabundance of cell death. The recognition that cell death could be regulated and have 
important roles in physiology occurred as early as 1842, but did not gain traction in the scientific 
community until the middle of the twentieth century.41 In the 1960s, developmental biologists 
studying silkworms pioneered the concept of programmed cell death, and in 1972 John Kerr and 
colleagues coined the term ‘apoptosis’ to describe a specific, genetically programmed form of cell 
death characterized by predictable morphological changes.42 Continued work in this field 
eventually established a paradigm that classified cell death into three general categories: 
apoptosis, cell death associated with autophagy, and necrosis. Whereas apoptosis and 
autophagy were viewed as highly regulated, genetically encoded functions, necrosis was widely 
considered to be an unregulated ‘chaotic’ cell death event. Only recently has this paradigm been 
significantly challenged by the recognition that many death events that present a necrotic 
phenotypic are genetically regulated.43  
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1.3.1 Apoptosis 
 Kerr and colleagues first coined the term apoptosis in 1972 as a form of programmed cell 
death that presented a specific morphological phenotype.42 An apoptotic cell initially separated 
from surrounding cells and its membrane took on an undulating (or bleb) shape. Next, the cell 
would condense and fragment into enclosed ‘apoptotic bodies’ that were then engulfed by 
phagocytic cells. Subsequent genetic work discovered that the Caenorhabditis elegans genes 
ced-3 and ced-4 are necessary to induce apoptosis in developing C. elegans, revealing a genetic 
basis for apoptotic cell death.44 The ced-3 and ced-4 genes had striking similarity to families of 
proteases in organisms across multiple phylogenetic groups. This family of proteases are 
cysteinyl-aspartate-cleaving proteases, or caspases, and are the master regulators of apoptosis. 
Caspases are synthesized as inactive zymogens (or pro-caspases), whose activation can 
irreversibly initiate apoptosis. Caspase activation occurs from two convergent pathways: the 
intrinsic pathway and the extrinsic pathway (Figure 1.3). As the names imply, each pathway is 
initiated by different factors originating from inside or outside of the cell.  
 In the extrinsic apoptotic pathway, apoptosis is initiated by an appropriate ligand binding 
to a so-called death receptor. Two of the best-studied ligand and death receptor pairs include 
tumor necrosis factor (TNF)-α and TNF receptor,45 Fas ligand (FasL) and Fas (sometimes also 
called Apo1 or CD95),46 though many others exist.47 In all cases, binding of a death ligand to a 
death receptor induces the formation of the death-inducing signaling complex (DISC), a multi-
protein complex that contains multiple copies of pro-caspase 8, which are activated by induced-
proximity effects.48 Active caspase 8 can then go on to cleave pro-caspase 3 and pro-caspase 7 
to form caspase 3 and caspase 7, respectively. Designated as “executioner caspases”, active 
caspase 3 and 7 proceed to cleave the remaining substrates in apoptosis. Active caspase 8 can 
also cleave the protein BID to form truncated-BID (tBID) which initiates mitochondrial outer 
membrane permeabilization (MOMP), an event that occurs in both intrinsic and extrinsic 
apoptosis.49 
 The intrinsic apoptotic pathway is initiated by cellular stresses including damaged DNA, 
misfolded protein, hypoxia, or cytoskeletal disruption. The Bcl-2 family of proteins is the most 
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important regulator activation of this pathway. The Bcl-2 family can be subdivided into three 
groups: anti-apoptotic proteins, pro-apoptotic proteins, and BH3-only proteins (which also 
promote apoptosis).50 Prior to apoptosis initiation, members of the anti-apoptotic family (Bcl-2, 
Bcl-XL, Mcl-1, and others) effectively antagonize the pro-apoptotic proteins (Bax, Bid, Bok). 
Stress conditions activate members of the BH3-only family (Bim, Bad, Puma, and others) which 
antagonize the anti-apoptotic proteins, liberating Bax, Bid, and/or Bok to initiate apoptosis by 
triggering MOMP. Permeabilization of the mitochondrial membrane allows for release of 
cytochrome c, which nucleates the formation of the apoptosome, a wheel-shaped heptameric 
complex consisting of cytochrome c, the nucleotide dATP, APAF-1, and pro-caspase 9.51 The 
apoptosome activates caspase 9, which then activates the executioner caspases 3 and 7.  
1.3.2 Autophagy 
 In the 1970s, around the same time that the morphology of apoptosis was defined, 
researchers noticed that some cell death events were not apoptotic but instead were 
Figure 1.3. Schematic overview of apoptosis pathways. In the extrinsic pathway (left) 
death ligands bind to their appropriate death receptor, activating caspase 8. In the 
intrinsic pathway (right), stress signals are sensed by BH3-only proteins that then 
inhibit anti-apoptotic Bcl proteins, promoting the release of cytochrome C from 
mitochondria and apoptosome formation, which activates caspases 9. Both pathways 
converge at the activation of executioner caspases 3 and 7. 
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accompanied by an abundance of large vacuole-like structures in cells. Eventually, this mode of 
cell death was termed autophagic cell death (ACD). The mechanistic role of autophagy in cell 
death has been the subject of significant debate, often focusing on whether autophagy is a cause 
or an accessory to death (i.e. cell death by autophagy vs. cell death with autophagy).52 Though 
the term autophagic cell death has been applied without rigor in some circumstances, there are 
some instances where it does truly contribute to cell death. Currently, the Nomenclature 
Committee on Cell Death recommends only applying the term autophagic cell death in instances 
where genetic or pharmacologic intervention on two distinct components of autophagy machinery 
alters the progression toward cell death.53 
 Though its role in cell death has been debated, autophagy is a critical mechanism for 
maintaining cell homeostasis. Autophagy can be sub-divided into three classes: chaperone-
mediated autophagy, microautophagy, and macroautophagy. Macroautophagy (hereafter simply 
“autophagy”) is the most widely studied type of autophagy and is also the process associated with 
cell death. At a fundamental level, autophagy is a process of ‘self-eating’ where cytosolic proteins 
and organelles are digested and recycled to provide nutrients to essential cellular functions during 
periods of starvation and stress.54 Central to autophagy is the formation of the autophagosome, a 
double-membrane organelle that encapsulates cargo to be digested. Initiation of autophagosome 
formation begins with activation of the Ulk complex. In nutrient-replete conditions, the Ulk 
complex is inactivated by negative regulators such as mTORC1.55 Following initiation, autophagy 
proceeds to the nucleation phase. During nucleation, active Ulk complex activates a class III PI3K 
(Vps34) complex, which begins production of phosphatidylinositol-3-phosphate lipids for 
autophagosome membrane assembly. Finally, in the expansion phase the ATG16L1 lipidates 
LC3 proteins with phosphatidylethanolamine.55 The cargo now enclosed, the autophagosome 
merges with a lysosome to form an autolysosome that digests the cargo. Far from being a non-
selective process, autophagy can target specific proteins and organelles with high specificity.56  
1.3.3 Necrosis and Regulated Necrosis 
 Generally, if cell death did not have the morphological hallmarks of apoptosis or 
autophagy, it presented a phenotype coined “necrosis”. Necrotic cell death presented as cell 
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swelling and eventual rupture, and was assumed to be a chaotic, unregulated, or accidental form 
of cell death. This view was challenged significantly with the observation that tumor necrosis 
factor (TNF) could initiate either apoptotic or necrotic death depending on the cell line being 
tested.57 Further research found that TNF-induced necrosis could be regulated by the RIP1 and 
RIP3 kinases and was dubbed necroptosis.58 This work demonstrated that while certain instances 
of necrosis could indeed be unregulated, there existed a subset of necrotic death that was 
regulated and served as the impetus for continued research in the field of regulated necrosis. 
Subsequent work described many types of regulated necrosis including pyroptosis, parathanatos, 
NETosis, and others.43 However, the relevance of each of these death modes to development, 
homeostasis, and disease in vivo is rarely described and may only be inducible under very 
specific conditions that may only exist in a laboratory setting.  
1.4 Ferroptosis 
 Against this diversifying backdrop of cell death mechanisms, researchers in the Stockwell 
laboratory developed a technique called modulatory profiling to begin mapping the cell death 
landscape. By measuring the potency of a panel of lethal molecules in the presence or absence 
of a panel of molecules with known biological activities, they were able to cluster the lethal 
molecules according to similarities in their patterns of potency changes. By performing 
modulatory profiling on a set of lethal molecules with a known mechanism of lethality, they found 
that the lethal molecules clustered based on their mechanism of action.59 The set of lethal 
molecules was then expanded to include molecules that killed cells with an unknown mechanism. 
Two of these lethal molecules with unknown function, erastin and RSL3, clustered together very 
tightly, suggesting that they had mechanistic similarities. In support of this observation, prior work 
had found that each molecule was lethal to an engineered cell line expressing oncogenic RAS, 
but not lethal to an isogenic line that did not overexpress RAS.15, 60 Subsequent interrogation of 
the mechanism of erastin and RSL3 found that they induced lethality through a non-apoptotic 
program dubbed ferroptosis that involved oxidative events and was dependent on iron 
availability.16 Ferroptosis does not involve activation of caspases,60 and cannot be rescued by 
apoptosis, autophagy, or necroptosis inhibitors.16 Additionally, ferroptosis sensitivity is regulated 
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by a set of genes and proteins unique from other forms of regulated cell death.16 Though multiple 
lethal stimuli can initiate ferroptosis, the common downstream effect of ferroptosis is unchecked 
peroxidation of membrane lipids, leading to loss of membrane integrity followed by death.61 
 Because unchecked lipid peroxidation is the most downstream event in ferroptotic death, 
the endogenous glutathione-dependent lipid peroxide reducing network is the key regulator of 
ferroptosis. Increasing the activity of this pathway provides resistance to ferroptosis while 
inhibiting it leads to ferroptotic cell death.61-62 Central to this lipid peroxide reducing network is the 
selenoprotein GPX4, which uses two equivalents of the cellular reducing agent glutathione (GSH) 
to reduce lipid hydroperoxides to lipid alcohols (Figure 1.4).17 Inhibition of GPX4 can initiate 
ferroptosis. The small molecule RSL3 forms an irreversible covalent bond with the selenocysteine 
residue in the active site of GPX4, ablating its ability to reduce lipid hydroperoxides.17-18 
Alternately, the small molecule FIN56 can induce the depletion of GPX4 protein in cells, similarly 
triggering ferroptosis.27 
 The amino acid cysteine is required for the synthesis of GSH. A major source of cysteine 
in cells is the glutamate/cystine antiporter system xc-. In healthy cells, system xc- imports the 
oxidized cysteine, cystine, into cells in exchange for glutamate. The cystine is promptly reduced 
and can be utilized for GSH synthesis. Inhibition of system xc- by erastin, sulfasalazine, sorafenib, 
Figure 1.4. Schematic of the GSH-dependent lipid peroxide reducing network and 
its inhibition by ferroptosis initiators.  
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or excess glutamate decreases the quantity of reduced GSH in cells.16, 63 Decreasing the 
availability of reduced GSH in cells inhibits the catalytic cycle of GPX4, as GSH is a necessary 
cofactor for GPX4-mediated lipid peroxide reduction. In this way erastin, sulfasalazine, sorafenib, 
and excess glutamate can all initiate ferroptosis. 
1.4.1 Ferroptosis and Lipid Peroxidation 
Unchecked accumulation of lipid peroxides is the defining hallmark of ferroptotic cell 
death. However, lipid peroxides are produced in many cellular contexts and can serve as 
signaling molecules through post-translational modification of proteins.64 The biosynthesis of lipid 
peroxides can be carried out by enzymes or via non-enzymatic processes. Yet, the substrate 
scope and general mechanism of lipid peroxidation is largely the same in both cases. Lipid 
peroxidation preferentially oxidizes polyunsaturated fatty acids (PUFAs) — long-chain fatty acids 
with more than one double bond, including linoleic, arachidonic, and docosahexaenoic acids. The 
PUFAs that are most susceptible to peroxidation contain a (1Z, 4Z) pentadiene moiety. In the first 
step of oxidation, a hydrogen atom is removed from the methylene carbon bridging the two 
double bonds. The weak C-H bond and the stability of the resulting bisallylic radical drive the 
selectivity in hydrogen atom removal. This resonance-stabilized pi system allows the lipid to 
isomerize into the more thermodynamically stable isomer, forming a (1E, 3Z) conjugated diene 
that reacts with molecular oxygen to form a lipid peroxide.   
1.4.2 Fenton-Type Chemistry  
Figure 1.5. General scheme of PUFA oxidation.  A bisallylic hydrogen atom is abstracted, 
creating a resonance-stabilized pentadienyl radical. Following isomerization of one double 
bond, an equivalent of oxygen is added, forming a peroxide.  
!
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The non-enzymatic peroxidation of lipids is a process mediated by carbon- and oxygen-centered 
radicals. Like all radical reactions, this process can be broken down into three discreet phases: 
initiation, propagation, and termination. The initiation step is any process that generates radical 
compounds from non-radical molecules. In cells, this is accomplished using iron and, less 
frequently, copper. Cellular iron is under tight regulation in cells. Most iron is ligated by heme, 
bound in FeS clusters, or stored in the iron storage protein ferritin. Nevertheless there exists a 
small amount of iron that is loosely ligated (“labile”) and able to participate in redox reactions.65 
These redox reactions catalyzed by the labile iron pool are collectively referred to as “Fenton 
chemistry”, a series of reactions where labile iron reacts with endogenously produced hydrogen 
peroxide or superoxide to form oxygen centered radicals.66 In the first step of Fenton chemistry, 
ferrous iron disproportionates hydrogen peroxide, oxidizing to ferric iron and generating a 
hydroxide anion and a highly reactive hydroxyl radical. If another equivalent of hydrogen peroxide 
is available, the ferric iron can be reduced back to its ferrous state and generate a peroxyl radical. 
Having completed the initiation step, lipid peroxidation can proceed to the propagation step. 
Both the hydroxyl and peroxyl radical produced in the Fenton reaction are able to 
abstract a hydrogen from the bisallylic methylene of a membrane PUFA, creating a resonance-
stabilized, carbon-centered radical that can react with molecular oxygen in solution to form a lipid-
peroxyl radical ROO• which can abstract another hydrogen from a different bisallylic methylene, 
Figure 1.6. General steps of non-enzymatic lipid peroxidation. In the initiation step 
(red, left) redox active, labile iron reacts with peroxides to form oxygen centered 
radicals. In propagation steps (purple, middle) oxygen centered radicals can react with 
new PUFA substrates. Propagation steps repeat until termination (green, right) where 
radicals are quenched by antioxidants or reaction with another radical. 
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generating a lipid peroxide (ROOH) and another carbon centered radical that can react with 
oxygen. Radical compounds giving rise to new radicals is the hallmark of the propagation step. In 
this way, non-enzymatic lipid peroxidation can be considered a chain reaction. If the 
concentration of radicals is high enough that two radicals can react with each other they will form 
a new bond between themselves, eliminating the radical. Alternately, molecules that are able to 
donate electrons to radical compounds without themselves becoming a radical can terminate 
radical propagation. These molecules, called antioxidants, are a primary mechanism of defense 
against uncontrolled lipid peroxidation and are often potent inhibitors of ferroptosis. 
1.4.3 Lipoxygenase Enzymes 
In addition to being formed through non-specific propagation of radicals, oxidized lipids 
can also be synthesized in a controlled manner by cyclooxygenases (COXs), cytochrome p450s 
(CYPs), and lipoxygenases (LOXs). LOX enzymes are the most significant contributor to the 
synthesis of lipid hydroperoxides. LOX activation has been observed during ferroptosis, and 
knockdown of specific LOX genes can protect cells from ferroptosis.18 The lipoxygenases are 
named and classified based on the positional specificity of oxidation of arachidonic acid. The 5-
lipoxygenase is an enzyme encoded by the ALOX5 gene that is responsible for oxidizing 
arachidonic acid at carbon 5, forming 5-hydroperoxyeicosatetraenoic acid (5-HPETE). 5-
lipoxygenase can further convert 5-HPETE into Leukotriene A4, initiating leukotriene 
biosynthesis.67 The expression and activity of 5-lipoxygenase is tissue specific and highly 
regulated.68-70 5-Lipoxygenase activity is stimulated specifically by elevated Ca2+ levels while 
other divalent metal cations such as Cu2+ and Co2+ inhibit 5-HPETE production.71 5-Lipoxygenase 
is also regulated by multiple protein kinases. Phosphorylation of 5-lipoxygenase by p38 MAPK 
and ERK1/2 increases enzyme activity in cells while phosphorylation by Protein Kinase A 
suppresses enzyme activity.70 Once 5-lipoxygenase is activated it migrates to the nuclear 
membrane where it associates with two additional proteins: the 5-lipoxygenase activating protein 
(FLAP) and cytosolic phospholipase A2 (cPLA2). cPLA2 is responsible for cleaving arachidonic 
acid from membrane phospholipids, increasing substrate availability for 5-lipoxygenase. The 
exact function of FLAP is still unclear, but it is believed that FLAP facilitates the delivery of 
! 21!
arachidonic acid to 5-lipoxygenase. Pharmacologic inhibition of FLAP function prevents oxidation 
of endogenous arachidonic acid by 5-lipoxygenase, demonstrating the necessary role of FLAP in 
lipid peroxide formation.70, 72 
The 12- and 15-lipoxygenases are a class of enzymes encoded by for genes in humans: 
ALOX12, ALOX12B, ALOX15, and ALOX15B.73 These enzymes synthesize 12-
hydroperoxyeicosatetraenoic acid (12-HPETE) and 15-hydroperoxyeicosatetraenoic acid (15-
HPETE) from arachidonic acid. In contrast to 5-lipoxygenase, some members of this class exhibit 
incomplete regioselectivity in forming lipid peroxides. For instance, 15-lipoxygenase 1 (encoded 
by ALOX15) converts 10-20% of the arachidonic acid it oxidizes to 12-HPETE where as 15-
lipoxygenase 2 (encoded by ALOX15B) specifically oxidizes carbon 15.74 The 12- and 15-
lipoxygenases also possess a greater substrate scope than the 5-lipoxygenase. Linoleic acid, a 
ubiquitous PUFA, can be oxidized to 13-hydroperoxyoctadecadienoic acid (13-HPODE) and 9-
hydroperoxyoctadecadienoic acid (9-HPODE) by 15- and 12-lipoxygenases.75-76 
Docosahexaenoic acid, an ω-3 PUFA is also oxidized by 15-lipoxygenase as part of the synthesis 
of resolvins and protectins.73, 75 In keeping with their broadened substrate scope the 12- and 15-
lipoxygenases are known to be reactive towards intact phospholipids, and do not require their 
hydrolysis for peroxidation.77-78 
1.4.4 Degradation, Toxicity, and Detection of Lipid Peroxides 
Though lipid peroxides are stable enough to persist and diffuse within lipid bilayers, they 
are still prone to degradation. These degradation products are often themselves reactive and can 
be broadly divided into two classes: hydroxy acids and reactive aldehydes. Lipid peroxide 
degradation products are the most useful tools for detecting and quantifying lipid peroxidation in 
biological samples.  
Hydroxy acids are the direct reduction products of a corresponding lipid peroxide. 
HPETEs and HPODEs can be reduced to the corresponding HETEs and HODEs with a strong 
enough reducing agent. Chemical reducing agents like triphenylphosphine can reduce the 
peroxide bond79, but the cell also possesses endogenous mechanisms to eliminate harmful 
peroxides on its own without creating additional radicals. The glutathione peroxidase (GPX) 
! 22!
enzymes, particularly GPX4, are key regulators of lipid peroxides in cells, using GSH as a co-
substrate to reduce lipid peroxides to the corresponding alcohol. Inactivation of this enzyme 
results in the accumulation of lipid peroxides and ferroptosis.17, 79 
 Aldehydes are the other major class of lipid peroxide degradation product, with 4-
hydroxynonenal (4-HNE) and malondialdehyde (MDA) being the most well described and 
thoroughly researched members of this class (Figure 1.7A).80-81 Multiple routes have been 
proposed for the biosynthesis of these molecules from lipid peroxides (Figure 1.7B).81-86 However, 
there is no clear consensus on how significantly each of these competing mechanisms may 
Figure 1.7. Degradation of lipid peroxides. (A) structures of common lipid peroxide 
degradation products. (B) Two mechanistic hypotheses to explain the formation of 4-
HNE from a peroxide intermediate. (C) Reactivity of malondialdehyde (MDA) toward 
primary amines. (D) Michael addition of a nucleophilic amino acid to 4-HNE. 
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contribute to the degradation of lipid peroxides in vivo. What is common between these 
mechanisms is that ubiquitous downstream degradation products such as 4-HNE and MDA both 
require multiple oxidations of the parent substrate. 4-HNE, for instance, is believed to arise 
directly from a peroxide precursor 4-hydroperoxynonenal (4-HPNE) and that all nine carbons 
originate from the methyl end of a fatty acid. In one mechanistic proposal the peroxyl radical of 9-
HPODE can attack the adjacent double bond, forming a dioxetane intermediate that reacts with 
another equivalent of oxygen. This strained intermediate can undergo retrocyclization to form 4-
HPNE and an aliphatic aldehyde.82, 87 Alternately, in sufficiently acidic environments, 9-HPODE 
can undergo Hock cleavage. 9-HPODE rearranges to form an intermediate hemiacetal that can 
cleave to furnish an aliphatic aldehyde and a β, γ-unsaturated aldehyde that can be further 
oxidized to 4-HPNE.85, 88 
 Peroxidation of membrane lipids is known to substantially alter the physical properties of 
lipid bilayers. In particular, peroxidation alters lipid-lipid interactions, membrane permeability, ion 
gradients, and membrane fluidity.89 Molecular dynamics simulations initially suggested that 
peroxidized phospholipids reoriented themselves in a lipid bilayer so that the oxidized chain 
moved towards the water/lipid head-group interface, decreasing membrane thickness.90 Later 
experimental evidence confirmed that the entire oxidized chain can protrude into the aqueous 
phase, allowing for macrophage recognition.91 Increasing the concentration of oxidized lipids in 
liposomal membranes has been observed to cause a corresponding decrease in membrane 
fluidity and slower lateral diffusion.92 PUFA oxidation by the 5-lipoxygenase is known to require 
the hydrolysis of a fatty acid chain from a parent phospholipid, leaving behind lysophospholipids. 
In vitro data on lipid monolayers has shown that the resulting lysophospholipids are readily 
solubilized into the cytosol.93 Both the desolvation of lysophospholipids as well as the 
conformational change of oxidized phospholipids is believed to contribute to an increase in 
membrane permeability.90, 93  
 Lipid peroxides exhibit additional toxicity from the degradation products they 
spontaneously form. Ferrous iron can react with a lipid peroxide to generate the corresponding 
alkoxy radical that can propagate new peroxidation reactions. The aldehyde degradation products 
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of lipid peroxides are toxic to cells. Both 4-HNE and MDA are highly reactive molecules. MDA is a 
dialdehyde able to crosslink proteins or DNA (Figure 1.7C). Additionally, MDA can form 1,4-
dihydropyridine adducts with primary amines.81, 94 4-HNE also contains an aldehyde functional 
group and can form Schiff base adducts with primary amines and cyclization products similar to 
MDA.87 4-HNE is also a Michael acceptor, and can form covalent adducts with the side chains of 
nucleophilic amino acids (Figure 1.7D). The covalent modifications carried out by these 
secondary messengers of lipid peroxidation alter the structure and function of proteins and 
nucleic acids and are responsible for the cytotoxicity of these molecules. 
1.4.5 Inhibitors of Ferroptosis 
 Because lipid peroxidation is likely the proximate executioner in ferroptosis, methods that 
prevent the peroxidation of PUFAs or actively work to reduce the peroxides can be very 
protective against ferroptosis. The small molecule antioxidants ferrostatin-1 and liproxstatin-1 
were some of the first molecules discovered that acted as specific inhibitors of ferroptosis.16, 79 
These molecules likely function as radical-trapping agents, effectively terminating radical 
propagation; still, much of their mechanism remains to be elucidated.95 Studies on the 
mechanism of ferrostatin-1 comprise a significant portion of chapter three of this thesis. Vitamin E 
is an example of a naturally produced radical-trapping agent. During the propagation of lipid 
peroxides, vitamin E can donate a single electron to the intermediate peroxyl radical, terminating 
the chain reaction propagation of peroxides. The radical vitamin E intermediate can be reduced 
by vitamin C.96 Supplementation with vitamin E is protective against ferroptotic cell death.16 The 
reduction of other reactive oxygen species (ROS) by vitamin E is quite limited, and vitamin E is 
believed to be a specific reductant of lipid peroxidation in vivo, and does not scavenge other 
radical intermediates such as the hydroxyl radical.96 
Another strategy to prevent ferroptosis is to inhibit the enzymes responsible for 
synthesizing lipid peroxides. Because of its roles in inflammatory disease, many inhibitors of 
ALOX5 have already been developed.97 One ALOX5 inhibitor, Zileuton, has been approved for 
clinical use, and is protective against ferroptosis.98 Zileuton is believed to ligate the active site iron 
through its N-hydroxy urea moiety.99 Other classes of 5-lipoxygenase inhibitors similarly focus on 
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the active site iron, targeting it with redox active inhibitors that prevent the iron from cycling 
between its ferrous and ferric states.100 With the recognition of the importance of the 12- and 15-
lipoxygenases in neurodegenerative diseases, efforts have increased to develop specific 
inhibitors of these lipoxygenases.101-102 
 An emerging strategy to prevent lipid peroxidation is supplementation with fatty acids 
labeled with heavier isotopes of hydrogen at sites prone to oxidation. The carbon-deuterium bond 
is stronger than the carbon-hydrogen bond, making it more difficult to remove deuterium atoms 
and thus slowing the rate of peroxide formation. The kinetic isotope effect is particularly large in 
lipoxygenase enzymes.103 The protective effect of these D-PUFAs has been shown in multiple 
disease contexts, rescuing cells from oxidative stress and death.18, 104-105 
1.5 Importance of Modulating Cell Death 
 Identification of an increasing number of cell death mechanisms increases the possibility 
of therapeutically manipulating such pathways to overcome disease. For example, resistance to 
apoptosis is a hallmark of cancer.106 However, because multiple forms of regulated necrosis and 
specifically ferroptosis are both genetically and biochemically orthogonal to apoptosis, it is likely 
that cancer cells could still be induced to die through these non-apoptotic mechanisms. In support 
of this, RSL3 was effective in significantly reducing the tumor size in mouse xenograft models of 
cancer.17 
 Alternately, in many disease models characterized by excess and undesired cell death, 
the specific death mechanisms involved are still not fully defined. Cell death events that were 
previously thought to arise from unregulated and necrotic death are increasingly becoming 
viewed as regulated and preventable. For example, kidney renal tube death caused by ischemia-
reperfusion injury can be prevented by an optimized analog of the ferroptosis inhibitor ferrostatin-
1.107 
1.6 Overview of Dissertation 
The work described in this thesis applies the principles of rational molecular design in the 
context of understanding and manipulating cell death, with a particular focus on ferroptosis. In the 
second chapter of my thesis I describe my work with the recently described ferroptosis initiator 
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FINO2. Using a combination of chemical biology techniques and evaluation of series of structural 
analogs of FINO2, I demonstrate that FINO2 initiates ferroptosis through a combination of pro-
oxidant events and loss of GPX4 activity—a mechanism unique from other ferroptosis initiators. 
In the third chapter of this thesis I use a set of cytosolic and mitochondrially-targeted nitroxide 
antioxidants to investigate the contribution of mitochondria to ferroptosis. In chapter four, I seek to 
gain a more global and unbiased understanding of the contribution of different organelles to 
ferroptosis signaling. By building in new chemical moieties in ferrostatin-1 that allow it to be used 
in live-cell SRS imaging, the subcellular distribution of ferrostatin can be imaged, offering insights 
into its anti-ferroptosis properties. In the fifth chapter, I apply the principles of molecular design in 
a more target-oriented manner, using substrate-guided design of a protein-disulfide Isomerase 
(PDI) inhibitor to demonstrate which features on the PDI inhibitor LOC14 are necessary for 
binding and death-suppression in models of Huntington’s Disease. Then, in the sixth chapter I 
use an in silico approach to make progress towards discovering small molecule inhibitors of the 
GTPase Rheb. As a necessary component of mTORC1 activation, inhibiting Rheb would help 
control growth and autophagy in biological systems. In the seventh and final chapter, I consider 
the future research directions suggested by the research described in the preceding chapters. In 
particular I focus on unanswered questions about ferroptosis signaling and regulation. 
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Chapter 2 
 
FINO2 initiates ferroptosis through Gpx4 
inactivation and iron oxidation1 
 
2.1 Introduction  
 Regulated cell death includes several processes that lead to the demise of cells through 
specific mechanisms that can be modulated with pharmacological and genetic tools. The 
recognition of cell death as a regulated process began with the discovery and characterization of 
apoptosis.1-2 Ongoing work has since uncovered several other regulated cell death processes, 
including ferroptosis. Ferroptosis is an iron-dependent, oxidative form of regulated cell death that 
is distinct from apoptosis, and characterized by the failure of the glutathione-(GSH)-dependent 
lipid peroxide defense network.3-5 Consequently, cells undergoing ferroptotic cell death exhibit an 
increased accumulation of lipid peroxides and cannot be rescued by inhibitors of apoptosis or 
other cell death processes.6 
 Organic peroxides, such as artemisinin (1) and artesunate (2), are used therapeutically 
as cytotoxic agents for the treatment of cancers.7-9 Recently, development of analogs based on 
the plakinic acid natural products (3) identified the 1,2-dioxolane FINO2 (4), which triggers 
ferroptosis.10 Further evaluation of ferroptosis induction by FINO2 against multiple cancer lines 
revealed that FINO2 selectively initiates ferroptosis in engineered BJ-eLR cancer cells compared 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
1 This chapter is adapted from a manuscript in preparation: Michael M. Gaschler, Alexander A. 
Andia, Joleen M. Csuka, Brisa Hurlocker, Christopher A. Vaiana, Daniel W. Heindel, Dylan S. 
Zuckerman, Hengrui Liu, Pieter H. Bos, Eduard Reznik, Ling Ye, Yulia Y. Tyurina, Annie J. Lin, 
Mikhail S. Shchepinov, Amy Y. Chan, Eveliz Peguero-Periera, Maksim A. Fomich, Andrei V. 
Bekish, Vadim V. Shmanai, Valerian E. Kagan, Lara K. Mahal, K. A. Woerpel, Brent R. Stockwell, 
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to the isogenic, non-cancerous BJ-hTERT cell line.10 Since evasion of apoptotic signaling is a 
hallmark of cancer,11 the ability of FINO2 to initiate a non-apoptotic programmed cell death 
process selectively in engineered tumorigenic cells makes it an attractive target for further study. 
 In collaboration with researchers from the Woerpel lab at New York University and other 
members of the Stockwell lab, we sought to define the mechanism by which FINO2 induces 
ferroptosis, and which structural features of FINO2 are necessary for its function.  These 
experiments demonstrate that, in contrast to other ferroptosis-inducing compounds, such as 
erastin, FINO2 does not deplete GSH through inhibiting system xc-. FINO2 instead bypasses GSH 
depletion to cause iron oxidation, as well as loss of activity of the lipid-peroxide-reducing enzyme 
GPX4 indirectly, by a mechanism that is distinct from other GPX4 inhibitors. Exploration of the 
structure-activity relationship around the FINO2 scaffold revealed that both the endoperoxide 
moiety and the pendant hydroxyethyl group are necessary to induce oxidative events leading to 
ferroptotic cell death. We thus found that FINO2 exerts dual effects involving iron oxidation and 
loss of GPX4 enzymatic activity to induce ferroptosis, and therefore represents a novel class of 
ferroptosis inducers. 
2.2 Results 
2.2.1 FINO2 induces ferroptosis 
 We initially sought to evaluate the lethality of FINO2 in a cell line in which ferroptosis had 
been extensively examined previously. Ferroptosis-sensitive HT-1080 fibrosarcoma cells3 were 
treated with a lethal concentration of FINO2 (10 µM) and co-treated with a panel of death-
suppressing compounds at varied concentrations (Figure 2.2A). The lethality of FINO2 was 
effectively suppressed by the ferroptosis inhibitor ferrostatin-1, which prevents the accumulation 
Figure 2.1 Structure of select biologically active peroxides 
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of lipid peroxides, likely through a radical trapping mechanism.12-13 Baicalein, an antioxidant 
flavone, also suppressed FINO2 lethality, as did Trolox, a water-soluble vitamin E analog capable 
of scavenging lipid radicals (Figure 2.2A); both compounds were previously reported to inhibit 
ferroptosis.6 The apoptosis inhibitor zVAD-FMK was unable to suppress death. Necrostatin-1, an 
inhibitor of necroptosis, an alternative form of regulated cell death, was similarly unable to prevent 
FINO2-induced death. We also evaluated the ability of nitroxide antioxidants XJB-5-131 and JP4-
039 to suppress FINO2 lethality, which were previously found to suppress ferroptosis.14 The 
mitochondria-targeted nitroxide XJB-5-131 was 39-fold more potent than the cytosolic JP4-039, 
highlighting the potential importance of mitochondrial lipid peroxidation in mediating FINO2 
lethality (Figure 2.2B). These nitroxide antioxidants are discussed in more detail in chapter three 
of this thesis.  
 We next aimed to validate that FINO2 causes lipid peroxidation, a defining event in 
ferroptosis. HT-1080 cells were treated with either FINO2 or the ferroptosis inducer erastin, and 
the increase in fluorescence intensity of the fluorescent lipid peroxidation probe C-11 BODIPY 
was monitored by flow cytometry (Figure 2.3A).3 Both erastin and FINO2 showed an increase in 
fluorescence 6 h after treatment, with FINO2 showing a much larger shift, suggesting FINO2 
causes a more rapid onset or overall greater quantity of lipid peroxidation. This increase was 
suppressed by co-treatment with deferoxamine (DFO), an iron chelator, demonstrating the iron 
dependence of lipid peroxidation induced by both FINO2 and erastin. In collaboration with the lab 
of Valerian Kagan, we used liquid chromatography-mass spectrometry (LC-MS) analysis to 
Figure 2.2. Suppression of FINO2 lethality. (A) The dose-dependent effect of cell 
death-suppressing compounds or (B) nitroxide antioxidants on ferroptosis 
triggered by FINO2 (10 µM) in HT-1080 cells. Viability measured 24 h after 
compound treatment. 
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measure the oxidation of phosphatidylethanolamine (PE), a lipid critical to propagating ferroptosis 
in lipid extracts from cells treated with FINO2 (Figure 2.3B).15 FINO2 treatment caused a large 
increase in a diverse set of oxidized PE species. Not all PEs that were oxidized in response to 
FINO2 were suppressed by co-treatment with ferrostatin-1, suggesting that only a specific set of 
oxidized PE species contribute to ferroptosis.  We also monitored the depletion of unoxidized PE 
lipids following FINO2 treatment. We hypothesized that depleted unoxidized PE species might be 
preferentially used as precursors to any oxidized PEs created following FINO2 treatment. The 
abundance of multiple unoxidized PE species changed minutely, but four alkenyl/alkyl PE species 
were depleted significantly following FINO2 treatment and rescued under co-treatment with Fer-1. 
MS2 fragmentation pattern analysis identified two of these species as either having arachidonate 
(20:4) acyl tails or docosapentaenoic acid (22:5) acyl tails, while the other two PEs had 
docosahexaenoic acid (22:6) acyl groups (Figure 2.4). These data suggest that FINO2 treatment 
may selectively deplete very long polyunsaturated phospholipids, but the mechanism for this 
observation remains unknown. 
Figure 2.3. Oxidation of lipids by FINO2 (A) Ability of iron chelator deferoxamine 
(DFO) to prevent ferroptosis-dependent C11-BODIPY oxidation when incubated 
together for 6 h (B) Changes in oxidized phosphatidylethanolamine abundance as 
detected by LC-MS after treatment with FINO2 (10 µM) for 6 h. Red circles 
indicate molecular species that were significantly increased following FINO2 
treatment and were rescued significantly by co-treatment with Fer-1 (2 µM). Blue 
and black circles indicate molecular species that were increased (blue) or 
decreased (black) following FINO2 treatment but did not respond to Fer-1 co-
treatment. Gray circles did not respond under any conditions. LC-MS data were 
generated by researchers in the Kagan lab. 
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2.2.2 FINO2 does not alter glutathione homeostasis 
 Having validated that FINO2 causes ferroptosis, we next sought to define the mechanism 
by which FINO2 induces ferroptosis. Originally, ferroptosis-inducing compounds were divided into 
two classes. Class 1 ferroptosis inducers decrease intracellular levels of GSH, a necessary 
cofactor for the lipid peroxide-reducing enzyme GPX4. Class 2 ferroptosis inducers inhibit GPX4 
directly through active site inhibition. More recently, the small molecule FIN56 was reported to 
deplete GPX4 protein and also deplete coenzyme Q10, an endogenous inhibitor of lipid 
peroxidation, through modulation of the mevalonate pathway.16  
Figure 2.4. Identity of PE species depleted by FINO2 treatment  
(10 µM) for 6 h and rescued by co-treatment with ferrostatin-1 
(2 µM). Left: Identities established by LC-MS. Right: identities 
as established by MS2 fragmentation. PEp: plasmalogen, 
acyl/alkenyl PE. PEo: acyl/alkyl PE. Data gathered in 
collaboration with the Kagan Lab 
! 37!
 A major source of cysteine for GSH synthesis is the cystine/glutamate antiporter system 
xc- (Figure 1.4). Inhibition of system xc- by erastin, sulfasalazine, sorafenib, or glutamate depletes 
intracellular GSH and induces ferroptosis.17 To test whether FINO2 acts via system xc- inhibition 
and GSH depletion, we examined the ability of FINO2 to inhibit system xc- using a fluorescent 
enzymatic assay that quantifies the amount of glutamate released by cells into glutamate-free 
medium (Figure 2.5).17 Both erastin and sulfasalazine were able to inhibit glutamate release 
strongly compared to vehicle-treated cells. FINO2 showed much weaker inhibition of glutamate 
release than erastin or sulfasalazine, suggesting that inhibition of system xc- is not a primary 
mechanism of FINO2 lethality.  
Joleen Csuka then quantified glutathione levels directly in HT-1080 cells undergoing 
ferroptosis using a reactive fluorescent reporter of free thiols in cell lysates (Figure 2.6A). To 
eliminate non-specific reactivity with accessible cysteine residues on proteins, proteins were 
precipitated from the lysates, leaving GSH as the major thiol in solution.18 Cells treated with 
erastin had a three-fold decrease in GSH content compared to vehicle or the GPX4 inhibitor 
(1S,3R)-RSL3, hereafter referred to as RSL3. FINO2-treated cells showed no decrease in thiol 
Figure 2.5 Effect of FINO2 (10 µM) and system 
xc- inhibitors erastin (10 µM) and sulfasalazine (1 
mM) on glutamate release from HT-1080 cells 
following 1 h incubation. 
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content, indicating that FINO2 does not deplete GSH. These results suggest that FINO2 is not a 
system xc- inhibitor and does not deplete GSH through other mechanisms. 
The oxidative stress caused by erastin upregulates components of the endoplasmic 
reticulum (ER) stress response pathway. The GSH-specific gamma-glutamylcyclotransferase 
enzyme encoded by the CHAC1 gene has been observed as a pharmacodynamic marker of 
exposure to erastin.17 To test whether FINO2 induces transcriptional changes similar to other 
class 1 ferroptosis inducers, Ling Ye performed RT-qPCR to quantify the amount of CHAC1 
mRNA in cells treated with erastin or FINO2 (Figure 2.6B). Cells treated with FINO2 showed a 7-
fold increase in CHAC1 mRNA levels compared to vehicle. This upregulation was nearly 3-fold 
less than the upregulation in cells treated with erastin. This more modest upregulation may be an 
indicator that FINO2 has downstream effects that similarly trigger ER stress responses, but is 
mechanistically distinct from erastin and other class 1 ferroptosis inducers. 
 
2.2.3 FINO2 indirectly inhibits GPX4 activity in cells 
Because FINO2 does not display the characteristic functional or genetic hallmarks of a 
class 1 ferroptosis inducer, we next evaluated the ability of FINO2 to act as a class 2 ferroptosis 
inducer by inhibiting GPX4 enzymatic activity. GPX4 is a selenocysteine-containing enzyme 
Figure 2.6. (A) intracellular GSH levels in HT-1080 cells treated with 
ferroptosis inducers RSL3 (0.5 µM) for 90 m or erastin (5 µM), and FINO2 (10 
µM) for 6 h (B) CHAC1 mRNA levels following erastin (10 µM) or FINO2 (10 
µM) treatment for 6 h. GSH data were gathered by Joleen Csuka, qPCR data 
were gathered by Ling Ye. 
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responsible for reducing lipid hydroperoxides to lipid alcohols, making it a master regulator of 
ferroptotic signaling (Figure 1.4). To understand the impact of FINO2 treatment on GPX4 activity, 
we monitored the ability of GPX4 protein collected from cells treated with vehicle or ferroptosis 
inducers to reduce the GPX4 substrate phosphatidylcholine hydroperoxide (PCOOH) in vitro 
(Figure 2.7A).4, 16 Whereas erastin did not inhibit the activity of GPX4 in this assay (as GSH is 
added during the assay protocol), FINO2, FIN56, and RSL3 all decreased the activity of GPX4 to 
a similar extent. The general oxidant tert-Butyl hydroperoxide (tBuOOH) was also able to inhibit 
GPX4 assay in this assay (Figure 2.7B), but is not rescued by ferroptosis inhibitors ferrostatin-1 
or β-mercaptoethanol (Figure 2.7C). That FINO2 inhibited GPX4 could be explained by FINO2 
acting as an inhibitory ligand on GPX4 (vide infra). The apparent inhibition by tBuOOH, which 
does not induce ferroptosis, is more enigmatic and merits future study; however, two hypotheses 
seem likely: (1) tBuOOH initiates multiple death mechanisms and therefore specific ferroptosis 
suppressors are unable to prevent tBuOOH lethality or (2) GPX4 is inhibited by post-translational 
modification induced by overwhelming oxidative stress, and the time-point of the experiment is 
too early to observe this phenomena in erastin treated cells. 
Figure 2.7. (A) Effect of ferroptosis inducers on the in vitro activity of GPX4 from treated 
HT-1080 cells. Cells were treated with DMSO, erastin (10 µM), FIN56 (5 µM), or FINO2 
(10 µM) for 6 h or RLS3 (0.5 µM) for 2 h Or (B) DMSO, FINO2 (10 µM), tBuOOH (150 
µM) for 6 h. Cells were lysed and lysates were treated with PCOOH and GSH; after 
incubation (45 min) mixtures were extracted for lipids and the abundance of PCOOH 
was measured by LC-MS. (C) Dose-dependent effect of ferroptosis-suppressing 
compounds on lethality initiated by tBuOOH (150 µM). Viability was measured 24 h after 
compound addition using presto blue. 
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The observation that FINO2 decreased GPX4 activity suggested that, like RSL3, FINO2 
might be a direct inhibitor of GPX4.4, 6 Alternately, FINO2 could be inhibiting the activity of GPX4 
indirectly, similar to the ferroptosis inducer FIN56.16 To test whether FINO2 is a direct inhibitor of 
GPX4, Hengrui Liu performed 1H-15N heteronuclear single quantum coherence (HSQC) NMR on 
GPX4U46C in the presence and absence of FINO2. HSQC NMR is sensitive to the chemical 
environment of the peptide backbone of a protein; when a ligand binds the protein, the chemical 
environment changes and causes a shift in the peaks. FINO2 did not cause a change in the 
HSQC spectrum of GPX4, indicating that FINO2 is neither an allosteric or active site ligand of 
GPX4 (Figure 2.8).  
 
 The prostaglandin synthase gene PTGS2 has been reported to be upregulated following 
RSL3 treatment.4 With Ling Ye, we determined whether cells experienced a similar upregulation 
following treatment with FINO2. In contrast to RSL3, neither erastin-treated cells nor FINO2-
Figure 2.8. HSQC spectrum of GPX4 protein (black; 50 µM) overlaid with 
the spectrum of GPX4 incubated with FINO2 for 6 h (red; 50 µM and 500 
µM, respectively). Data were gathered by Hengrui Liu 
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treated cells showed significant upregulation of PTGS2, indicating that FINO2 does not cause the 
same transcriptional changes as the class 2 ferroptosis inducer RSL3 (Figure 2.9). 
  To evaluate whether FINO2 acts as an irreversible covalent inhibitor of GPX4, HT-1080 
cells were treated with a lethal dose of each ferroptosis inducer and either vehicle, ferrostatin-1, 
or β-mercaptoethanol (β-ME) (Figure 2.10). In the extracellular medium, β-ME reacts with cystine 
to form a disulfide bond with cysteine. Neutral amino acid transporters import this mixed disulfide, 
bypassing system xc- and increasing cysteine availability within cells.19 When cells were co-
treated with RSL3 and β-ME, the increase in cysteine availability for GSH synthesis is unable to 
rescue cells because GPX4 is irreversibly and covalently inhibited. Conversely, the lethality of 
erastin is fully suppressed by β-ME, as cysteine availability is no longer dependent on system xc- 
function. β-ME also rescues ferroptosis induced by FIN56, which depletes GPX4 protein 
abundance (Figure 2.11).16 β-ME may prevent FIN56 lethality by increasing the cysteine available 
for GSH synthesis, thereby improving the catalytic activity of the remaining GPX4, although the 
precise mechanism for this suppression is not known.20 Ferroptosis induced by FINO2 was 
partially rescued by β-ME, further indicating that FINO2 is not an irreversible covalent inhibitor of 
GPX4 similar to RSL3. Since FINO2 does not decrease intracellular glutathione levels (Figure 
Figure 2.9 PTGS2 mRNA levels following 
treatment with RSL3 (0.5 µM), erastin (10 µM), 
and FINO2 (10µM) for 6 h. Data were gathered 
by Ling Ye 
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2.6A), we reasoned that β-ME supplementation may rescue FINO2-treated cells by enhancing 
GPX4 activity, similar to FIN56.  
 To test whether FINO2 causes GPX4 protein depletion similar to FIN56, we quantified the 
abundance of GPX4 protein in cells undergoing ferroptosis, by western blotting (Figures 2.11A 
and 2.11B). As expected, both RSL3 and FIN56 caused a large decrease in the abundance of 
GPX4 at the protein level, as has been reported.16 Erastin and FINO2 caused only a minor 
decrease in GPX4 protein abundance, suggesting that FINO2 is unlike FIN56. To validate that 
Figure 2.10. Ability of β-mercaptoethanol to prevent ferroptosis 
initiated by different ferroptosis inducers. Viability measured 24 
h after co-treatment. 
Figure 2.11 (A) Representative blot image of GPX4 protein abundance, quantified in B. 
(B) GPX4 protein abundance in HT-1080 cells co-treated with RLS3 (1 µM), erastin (10 
µM), FIN56 (5 µM), or FINO2 (10 µM) and 100 µM α-tocopherol for 10h. (C) Ability of SQS 
inhibitor YM53601 (3 µM) to modulate ferroptosis inducer potency. Viability measured 24 
h after addition of compounds. Western blot data gathered in collaboration with Eduard 
Reznik 
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FINO2 and FIN56 have distinct mechanisms of ferroptosis induction, we examined the ability of a 
squalene synthase (SQS) inhibitor to modulate sensitivity to FIN56 or FINO2 (Figure 2.11C). 
Since FIN56 activates SQS to divert terpenoid intermediates away from coenzyme Q10 
synthesis, co-treatment with the SQS inhibitor YM53601 reduces the potency of FIN56 in HT-
1080 cells.16 YM53601 did not decrease the potency of FINO2, suggesting that unlike FIN56, 
FINO2 does not induce ferroptosis by altering metabolic flux through the mevalonate pathway 
(Figure 2.11C). Thus, FINO2 acts through a new mechanism of ferroptosis induction, in which 
GPX4 enzyme activity is indirectly inhibited, but GPX4 protein abundance and GSH and system 
xc- activity are largely unaffected. 
2.2.4 The endoperoxide moiety is required for FINO2 lethality 
Since FINO2 does not display behavior characteristic of a class 1 or class 2 ferroptosis 
inducer, we sought to gain insight into its mechanism by determining which functional groups in 
FINO2 are required for inducing ferroptosis. Researchers in the Woerpel lab at NYU synthesized 
and evaluated the potency a series of FINO2 analogs. Broadly, these analogs fall into four groups 
(Figure 2.12).  The first group of analogs, (14) (15), (16), can be viewed as analogs where one 
oxygen of the central peroxide in FINO2 has been deleted and the ring contracted from five to four 
members. The second group, (18a) and (18b), can be viewed as analogues where a carbon has 
been substituted for an oxygen—removing the peroxide without ring contraction. The third group 
represents interruption of the peroxide, either through eliminating the oxygen-oxygen bond (triol 
19) or interrupting the peroxide with a methylene group (1,3 dioxane 22). In the final group, the 
peroxide moiety is retained and the moieties distal to the 1,2-dioxolane are varied.  
In all cases, the non-peroxide compounds displayed no activity at the doses tested. This 
result suggests that the peroxide moiety is essential to induce ferroptosis. The structure-activity 
relationship studies suggest that FINO2 belongs to a class of ferroptosis-inducing compounds that 
are somewhat tolerant of modifications, while retaining biological activity. The tert-butyl group 
occupying the C-4 position of the cyclohexyl ring in FINO2 was moved to the C-3 position (31), 
accompanied by a small decrease in potency. Substituting the polar functionality for a non-polar 
group (32) reveals that, although a peroxide moiety is necessary for initiating ferroptosis, it is not 
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sufficient. Increasing the distance between the peroxide bond and hydroxyl group (41) also 
resulted in a decrease in activity. These data demonstrate that the hydroxyl portion of FINO2 must 
be present and have a specific spatial relationship to the peroxide, suggesting a specificity of 
Figure 2.12. Structure and potency of FINO2 and analogs. 
Compounds were tested in BJ-hTERT, BJ-eLR, and CAKI-1 cell 
lines.  Viability was measured after 48h incubation. All synthesis 
and potency data gathered by the Woerpel lab. a tested as a 
mixture of diasteromers 
! 45!
mechanism for FINO2. 1,2-dioxolane 33, which replaced the tert-butyl group of FINO2 with an 
aromatic ring, had a similar potency to FINO2. Retaining the spirobicyclic core structure of FINO2 
was unnecessary. Peroxide 37, which had the cyclohexyl group replaced by an acyclic group and 
terminated with a phenyl group, such as found in cytotoxic natural product plakinic acid E (3) 
(Figure 2.1), was also active. Analog 39, which lacked a hydroxyethyl head group was inactive. 
The activity of 37 suggests that the cytotoxicity of natural products resembling monocyclic 
peroxide 37 may be due to ferroptosis. 
2.2.5 FINO2 is a stable oxidant that directly oxidizes ferrous iron 
Since the peroxide moiety in FINO2 is necessary but not sufficient for inducing ferroptosis, 
we hypothesized that FINO2 might be a pro-oxidant molecule that initiates ferroptosis through 
selective oxidation of ferroptosis-relevant substrates. Consistent with this hypothesis, researchers 
in the Woerpel lab found FINO2 to be stable to 150 °C by thermo-gravimetric analysis.10 Solutions 
of FINO2 and other 1,2-dioxolanes in DMSO were found to be stable for over two years at room 
temperature. Similar 1,2-dioxolanes have also shown stability to LiBH4 and LiEt3BH at room 
temperature.21  
Subjection to these high temperatures, long dissolution times, and strong reducing 
conditions, however, are not necessarily biologically relevant. Researchers in the Woerpel lab 
therefore subjected FINO2 to a variety of biologically relevant redox conditions in vitro (Figure 
2.13) and monitored for reaction by changes in its 1H-NMR spectrum. The peroxide moiety of 
FINO2 did not react under most tested conditions. Heating FINO2 at 37 °C with a thiol (Figure 
2.13, entry 1), a class of compounds that are typically found between 0.5−10 mM in human 
cells,18 showed no decomposition. FINO2 was found to be stable to GSH (Figure 6A, entry 2), in 
agreement with the observation that FINO2 does not deplete GSH (vide supra). Incubation with 
arachidonic acid, a ubiquitous PUFA in cell membranes, showed no degradation following 
treatment with FINO2 (Figure 6A, entry 3). Selenium-containing compounds such as 
selenocysteine and ebselen, the latter of which is model for GPX4,22 also did not reduce the 
peroxide bond (Figure 2.13, entries 3 and 4). The inability of ebselen to reduce FINO2 is 
consistent with the observation that GPX4 cannot reduce endoperoxides.23 Under similar 
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conditions, ebselen was able to reduce cumyl hydroperoxide to cumyl alcohol. Ebselen was only 
able to reduce FINO2 at 90 °C, which is beyond biologically relevant conditions. The harsh 
conditions required to decompose FINO2 suggest that FINO2 does not readily degrade to its 
reduced form 19 or to reactive oxygen species to confer biological activity. These results, and the 
lack of reactivity toward most reducing agents, suggest that the intact endoperoxide form may be 
responsible for activity.  
FINO2 also showed stability under both basic and acidic conditions. No reaction was 
observed with amines or strong bases, even under conditions beyond the basicity found in 
peroxisomes (Figure 6A, entries 6 and 7).24 FINO2 was also found to be stable under acidic 
conditions that mimic the conditions found in lysosomes (Figure 2.13, entry 8).25 
Figure 2.13. Stability of FINO2 under various conditions 
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Analogous to Fenton chemistry, 1,2-dioxolanes and ferrous iron can generate oxygen-
centered radicals that initiate oxidative damage in biological systems.21 Since Fenton chemistry 
may be important to the initiation of ferroptosis,3, 12 we hypothesized that FINO2 might initiate 
Fenton-type chemistry selectively over other organic peroxides. Using an in vitro colorimetric 
assay, we monitored the oxidation state of iron treated with oxidizing compounds (Figure 2.14A). 
Most organic peroxides, including artemisinin and the non-lethal FINO2 analogues 32 and 41, 
were unable to oxidize ferrous iron (Figure 2.14A). Only FINO2 and tert-butyl hydroperoxide 
(tBuOOH) were able to oxidize ferrous iron under these conditions. Cell death initiated by 
tBuOOH cannot be suppressed by ferrostatin-1 or β-ME (Figure 2.7C), indicating that the lethality 
of tBuOOH cannot be attributed to ferroptosis.  
The iron oxidation by FINO2 is accompanied by a degradation of the endoperoxide 
(Figure 2.14B). Incubation of FINO2 at 37 °C reveals reduction of the peroxide bond by 
FeSO4!7H2O, as seen in similar systems.26 A 1H-NMR spectrum before and after iron exposure 
showed decomposition of FINO2 after 12 hours. This reduction is consistent with studies on 1,2,4-
trioxolanes and plakortin derivatives that suggest rapid reduction of the peroxide functionality.26-29 
Figure 2.14. FINO2 reactivity toward Iron (II) salts. (A) Oxidation of ferrous iron (500 
µM) in the presence of different oxidizing agents (500 µM). (B) 1H-NMR showing 
degradation of FINO2 following incubation with FeSO4•7H2O in CD3CN/D2O (1:1) for 12 
h. NMR Data were gathered by researchers in the Woerpel lab. 
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The selectivity of iron oxidation by FINO2 compared to close structural analogues such as 
32 and 41 suggested that iron oxidation might be important to ferroptosis initiation by FINO2. The 
iron chelator deferoxamine (DFO) is able to suppress the lethality of FINO2 ten-fold more potently 
than for erastin or RSL3, supporting the hypothesis that iron oxidation is more important to the 
mechanism of ferroptosis induction by FINO2 than it is to other ferroptosis inducers (Figure 
2.15A).  
2.2.6 Ferroptosis initiated by FINO2 oxidizes a diverse subset of the lipidome 
independently of lipoxygenase activity 
 Previously, the family of arachidonic acid lipoxygenases (ALOX) was shown to be critical 
in generating lipid peroxides during ferroptosis, particularly in response to erastin or RSL3.6 
siRNA knockdown of either the ALOX15B or ALOXE3 genes suppressed the lethality of erastin. 
Similarly, a GFP-ALOX5 fusion protein expressed in ferroptosis-sensitive cells was activated and 
translocated to the nuclear membrane following erastin treatment. Because FINO2 is able to 
oxidize ferrous iron directly, we sought to evaluate whether ferroptosis initiated by FINO2 required 
enzymatic lipid peroxidation, similar to erastin and RSL3. We assembled a collection of 
arachidonic acid derivatives deuterated at the bis-allylic positions.30 Replacing hydrogen with 
deuterium at the bis-allylic position creates a strong kinetic isotope effect in lipoxygenase 
enzymes, making deuterated arachidonic acids effective and highly specific inhibitors of 
lipoxygenases (Figure 2.16).31  
Figure 2.15. Ability of iron chelator deferoxamine (DFO) to inhibit ferroptosis 
initiated by different ferroptosis inducers.  
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 We incubated HT-1080 cells with vehicle only (0.1% ethanol), arachidonic acid, or a 
deuterated arachidonic acid analogue overnight to allow incorporation of the fatty acid into cellular 
membranes. Cells were then treated with erastin, RSL3, or FINO2 in a serial dilution (Figure 
2.17). Deuteration at the 7 position was strongly protective against cell death initiated by erastin 
and RSL3, confirming the importance of ALOX5 in initiating ferroptosis for these two molecules. 
Ferroptosis induced by FINO2 was only weakly rescued by deuteration at the 7 position, 
suggesting that FINO2 either activates an ALOX isoform with different regioselectivity or 
preferentially oxidizes fatty acid groups other than arachidonic acid. To evaluate whether FINO2 
activates a different lipoxygenase isoform than erastin or FINO2, we tested all remaining 
combinations of singly, doubly, and triply deuterated arachidonic acid analogues against all three 
ferroptosis inducers. Additional deuteration was able to increase the amount of death suppression 
for erastin and RSL3, and the fully deuterated D6-arachidonic acid completely suppressed the 
lethality of both of these ferroptosis inducers. No significant suppression of ferroptosis initiated by 
Figure 2.16. Schematic of lipoxygenase inhibition by deuterated lipids 
Figure 2.17. Effect of deuterated arachidonic acid incubation (80 µM for 24 h) on HT-1080 
sensitivity to ferroptosis inducers. Viability measured after 24h incubation with ferroptosis 
inducer. 
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FINO2 was observed for any deuterated arachidonic acid tested (Figure 2.17), suggesting that 
FINO2 does not require ALOX-mediated peroxidation for ferroptosis induction. 
 To compare the global lipidomic changes following treatment with FINO2 or erastin, we 
used LC-MS to identify oxidized esterified phospholipids extracted from HT-1080 cells treated 
with vehicle (DMSO), FINO2, or erastin with and without ferrostatin-1.  Because of its importance 
to ferroptosis, we first compared the changes in oxidized PE following treatment with either 
ferroptosis inducer (Figure 2.18A). Whereas erastin caused an increase in a single oxidized PE 
species, FINO2 caused an increase in 21 PE species.  This pattern was consistent for other 
phospholipids, including phosphatidylcholine (PC), and phosphatidylinositol (PI), 
phospatidylserine (PS), and cardiolipin (CL) (Figure 2.18B). The increases in oxidized 
phosphatidylserine and cardiolipin were unresponsive to ferrostatin treatment, suggesting they do 
not contribute to ferroptosis. MS analysis allowed us to identify the acyl tail portion of the oxidized 
phospholipids. As expected, all acyl tails contained some degree of polyunsaturation. Many of the 
oxidized phospholipids contained linoleic (18:2), arachidonic (20:4), and other polyunsaturated 
moieties. Cumulatively these data show that FINO2 causes the oxidation of a much more diverse 
set of phospholipids than does erastin, and does not have strong substrate selectivity within the 
set of polyunsaturated lipids.  
Figure 2.18. (A) Volcano plots showing the change in abundance of oxidized 
phosphatidylethanolamine species in HT-1080 cells following incubation with FINO2 (10 
µM) or erastin (5 µM) for 6 h. Red circles indicate significant increase in abundance, 
blue circles indicate a significant depletion following treatment. (B) Number of oxidized 
phosphatidylcholine (PC), phosphatidylinositol (PI), phosphatidylserine (PS), and 
cardiolipin (CL) species upregulated in HT-1080 cells following treatment with FINO2 (10 
µM) or erastin (5 µM) for 6 h. 
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2.3 Discussion 
 A common feature of all ferroptosis inducers is the ability to overcome the endogenous 
GSH-dependent lipid peroxidation defense network. In this study, we investigated the mechanism 
by which the 1,2-dioxolane FINO2 was able to induce ferroptosis in cells. FINO2 does not elicit the 
same transcriptional, translational, and phenotypic responses expected from previously described 
ferroptosis inducers. We hypothesize that FINO2 is able to initiate ferroptosis through a 
combination of its ability to directly oxidize labile iron and inactivate GPX4.  
In support of this hypothesis, we have demonstrated that the highly oxidizing peroxide 
group and a nearby polar head group are both required for lethality and for oxidation of 
ferroptosis-relevant substrates. Both non-peroxide derivatives and non-polar head-group 
derivatives of FINO2 were not lethal to cells. Elongation of the polar head group led to a loss in 
activity as well as an inability to oxidize iron, suggesting that the spatial relationship between the 
peroxide and hydroxyl moieties in FINO2 is required to engage labile iron or reduce the peroxide 
bond.32 Ferroptosis initiation by FINO2 is highly sensitive to iron availability, and oxidizes a broad 
set of polyunsaturated lipids. It is notable that unlike other peroxide-containing compounds, 
FINO2 is able to initiate ferroptosis preferentially over other forms of cell death. Multiple factors 
could account for this remarkable selectivity, including inactivation of GPX4, or the lipophilicity of 
FINO2. The predicted octanol/water partition coefficient (sLogP) for FINO2 is 3.54, whereas the 
value for artemisinin is 2.39, making FINO2 more than an order of magnitude more lipophilic than 
artemisinin. Because of its high lipophilicity, FINO2 may accumulate in the appropriate lipid 
bilayers of cell membranes, allowing it to oxidize ferroptosis relevant substrates in locations that 
trigger ferroptosis. Additionally, the peroxide bond of FINO2 is harder to reduce than artemisinin 
by about 0.5 eV,32-33 potentially making FINO2 a less reactive oxidant than other peroxide-
containing compounds. 
 In summary, this study provides insight into the mechanism of FINO2 and offers new 
perspectives on how ferroptosis can be initiated. Structural exploration of FINO2 and its analogs 
reveal that this new class of ferroptosis inducer can be modified and retain biological activity, but 
requires the endoperoxide and hydrophilic head to be present. In addition, whereas previous 
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ferroptosis initiators inhibited components of the endogenous lipid-peroxide-scavenging network 
in cells, FINO2 induces ferroptosis through a combination of oxidation of ferroptosis-relevant 
substrates and indirect GPX4 inactivation. The mechanism of GPX4 inactivation by FINO2 
remains unclear, since FINO2 does not decrease the protein level of GPX4 and is not a GPX4 
ligand. Nonetheless, we hypothesize that this specific combination of iron-oxidizing functionality 
and GPX4 inactivation is required to navigate cells to ferroptosis in response to this class of 
compounds. 
2.4 Methods 
Cell lines and media. HT-1080 cells were obtained from ATCC and grown in DMEM with 
glutamine and sodium pyruvate (Corning 10-013) supplemented with 10% Heat-Inactivated FBS, 
1% non-essential amino acids (Invitrogen), and 1% penicillin-streptomycin mix (Invitrogen). BJ-
5ta (BJ-hTERT) cells were obtained from ATCC and grown in DMEM media supplemented with 
10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. BJ-eLR cells were donated by the 
laboratory of William Han at the Dana-Farber Cancer Institute and grown in the same media as 
BJ-hTERT cells.  CAKI-1 cells were purchased from ATCC and grown in RPMI media 
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. All cells were 
maintained in a humidified environment at 37 ºC and 5% CO2 in a tissue incubator.  
FINO2 analog potency measurement. BJ-eLR, BJ-hTERT, or CAKI-1 cells were plated at 
10,000 cells per well in white 96-well plates in triplicate and incubated for 24 h to allow for cell 
adhesion. The cells were then treated with either vehicle (DMSO), FINO2, or a FINO2 analog at 
5,10, 25, 50, or 100 µM concentrations.  The cells were returned to the cell culture incubator for 
48 h. CellTiter-Glo® (Promega) was used according to the manufacturer’s protocol. 
Luminescence was read on a Biotek Microplate Reader. All cell viability data were normalized to 
the DMSO vehicle. Experiments were performed in biological triplicate. EC50 values were 
computed using Prism 7.0 (GraphPad). 
Ferroptosis rescue and sensitivity modulation. 3,000 cells were seeded per well in black, 
clear bottom 384-well plates (Corning) and allowed to adhere overnight. For ferroptoisis rescue 
assays, the medium was replaced on the following day with 50 µL of growth medium and 5 µL 
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medium containing a ferroptosis inducer and a dilution series of protective molecule. The final 
concentration of ferroptosis inducers was 10 µM erastin, 10 µM FINO2, 2 µM RSL3, and 5 µM 
FIN56 unless otherwise noted. For sensitivity modulation experiments, cells were co-treated with 
a fixed concentration of the modulating compound and a dilution series of the ferroptosis inducer. 
For deuterated arachidonic acids, cells were incubated in medium containing 80 µM of a 
deuterated arachidonic acid overnight to allow for incorporation into cellular membranes. The 
following day cells were treated with a dilution series of ferroptosis inducer. In all cases, after 24 h 
incubation with ferroptosis inducer, 6.1 µL of Presto Blue (Thermo-Fisher) were added. Cells 
were incubated for an additional 3 hours and the Presto Blue fluorescence intensity was 
measured using a Victor X5 plate reader (PerkinElmer)(ex/em 530/590). Background (no cells) 
fluorescence was subtracted and the resulting fluorescence intensities were averaged between 
biological replicates. From these data, dose-response curves and EC50 values were computed 
using Prism 7.0 (GraphPad). 
Reduced glutathione measurement. 10 million HT-1080 cells were treated with 5 µM erastin, 
10 µM FINO2, 500 nM RSL3, or vehicle. Cells were harvested after 1.5 h (RSL3) or 6 h (vehicle, 
erastin, FINO2), and lysed using ice-cold PBS/0.5% Nonidet P-40. Samples were centrifuged for 
15 min at 4 °C at top speed. The resulting supernatant was deproteinized using a Deproteinizing 
Kit (ab2047080) and kept on ice. Reduced GSH levels were determined using GSH/GSSG Ratio 
Detection Assay Kit (Fluorometric - Green) (ab138881) following the manufacturer’s protocol. 
qPCR. HT-1080 cells were treated with either 10 µM erastin, 10 µM FINO2, or 2 µM RSL3 for 5 h. 
RNA was extracted using the Qiashredder and Qiagen RNeasy Mini kits (Qiagen) according to 
the manufacturer's protocol. For each sample 2 µg of RNA were used as input for each reverse 
transcription reaction, performed using the TaqMan RT kit (Applied Biosystems/Life Technologies 
Corp., Foster City, CA). Quantitative PCR reactions were performed using the Power SYBR 
Green PCR Master Mix (Applied Biosystems). Triplicate samples per condition were analyzed on 
a ViiA 7 qPCR instrument (Thermo Fischer) using absolute quantification settings. Differences in 
mRNA levels compared to ACTB internal reference control were computed between control and 
experimental conditions using the ΔΔCt method. 
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HSQC NMR. Uniformly 15N-labeled GPX4U46C was expressed in and purified from E. Coli. 50 µM 
15N-labeled GPX4 was pre-incubated with 500 µM FINO2 for 6 hours at room temperature in 
buffer (100 mM MES, 5 mM TCEP, pH 6.5).  10 % D2O was added for the field frequency lock. 
The 1H-15N HSQC spectra were collected on Bruker Avance III 500 Ascend (500 MHz) 
spectrometers at ambient temperature. The 1H carrier frequency was positioned at the water 
resonance. The 15N carrier frequency was positioned at 115 ppm. The spectral width in the 1H 
dimension was 7500 Hz and the width in 15N dimension was 1824.6 Hz. Suppression of water 
signal was accomplished using the WATERGATE sequence. Heteronuclear decoupling was 
accomplished using GARP decoupling scheme.  
Western blotting. 0.8 million HT-1080 cells were seeded per well in a 60 mm plate and allowed 
to adhere overnight. Cells were then co-treated with 100 µM α-Tocopherol and either 1 µM of 
RSL3, 10 µM of Erastin, 5 µM of FIN56, 10 µM of FINO2, or vehicle for 10 hours. Cells were 
harvested with trypsin (Invitrogen, #25200-114), pelleted, and frozen at -80˚C. Cell pellets were 
thawed, lysed, blotted, and imaged as previously described. 3 In particular, for this experiment, 
the set of 15 pellets was run on a single gel. Antibodies used were: GPX4 (abcam, #ab125066, 
1:250 dilution) and GAPDH (Santa Cruz, # sc-47724, 1:10,000 dilution). Results were quantified 
using a LI-COR Odyssey CLx IR scanner and GraphPad Prism 7. Ultimately, two gels were run 
and quantified from a total of six biological replicates (30 pellets in total). 
Decomposition of FINO2 by FeSO4. An NMR tube was charged with FINO2 (5.0 mg, 0.020 
mmol) and D2O:CD3CN (1:1, 0.04M per solvent). The NMR was preheated to 37 ºC and the 1H 
spectrum was acquired (16 scans). Then, FeSO4 (11 mg, 0.039 mmol) was added. After 12 h, 
another 1H spectrum was acquired at 37 ºC (16 scans). 
Colorimetric iron oxidation. In a clear 96 well plate, 4 µL of a 25 mM DMSO solution of test 
compound was added to 196 µL of a 2:1 solution of water and DMSO (v/v) containing 500 µM 
FeCl2. This mixture was incubated at 37 ºC for 1 h. 5 µL of a 20 mM stock of FerroZine™ (Sigma 
Aldrich) was added. Absorbance was measured at 567 nm. 
In vitro lipid oxidation. FINO2 or analog was dissolved in buffer (0.1 M Tris HCl, pH 9.6) to a 
final concentration of 500 µM. This solution was transferred to a quartz cuvette and blanked for 
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absorbance at 234 nm. Oxidation was initated by addition of linoleic acid to a final concentration 
of 3 mM. The absorbance at 234 nm was measured every 15 seconds for 10 minutes.  
LC-MS GPX4 activity assay. 20 million HT-1080 cells were treated with vehicle (DMSO), erastin 
(10 µM), FINO2 (10 µM), FIN56 (5 µM) for 6 h, or RSL3 (0.5 µM) for 2 h. Cells were harvested by 
trypsinization and washed twice in PBS and resuspended in lysis buffer (25 mM sodium 
phosphate, 125 mM NaCl, 1 mM EDTA, 0.1 mM Deferoxamine, 25 µM butylated hydroxytoluene, 
0.3% triton-X 100, and protease inhibitor tablet [1 tab/10 mL]). Cells were lysed by sonication and 
cleared of insoluble components by centrifugation at 14,000 xg for 10 min at 4 ºC. The protein 
concentration of each sample was determined using the Bradford assay. PCOOH reduction 
reactions contained 200 µg of protein from treated groups, 5 mM reduced glutathione, 10 µM 
PCOOH, and sufficient reaction buffer to raise the volume to 500 µL (Reaction buffer: 25 mM 
sodium phosphate, 125 mM NaCl, 1 mM EDTA, 0.1 mM deferoxamine, 0.1% TritonX-100). 
Reactions were incubated at 37 ºC for 30 min and then extracted with 1 mL of 
chloroform/methanol mixture (2:1 v/v). The organic portion was isolated and evaporated. Dry 
extracted materials were reconstituted in methanol. The samples were analyzed by LC-MS for 
PCOOH content as described previously.4, 16 
MS analysis of phospholipids. Lipids were extracted by using Folch’s procedure.34 Lipid 
phosphorus was determined by a micro-method.35 MS analysis of PLs was performed on a Q-
Exactive hybrid-quadrupole-orbitrap mass spectrometer (ThermoFisher Scientific) as previously 
described.36 Phospholipids were separated on a normal phase column (Silica Luna 3 µm, 100A, 
150x2 mm, (Phenomenex, Torrance CA)) at 35 °C using gradient solvents containing 5 mM 
ammonium acetate (A – n-hexane:2-propanol:water, 43:57:1 (v/v/v) and B - n-hexane:2-
propanol:water, 43:57:8 (v/v/v). The gradient conditions (all linear) were as follows: 0-23 min 
(10% B to 32% B); 23-32 min (32% B to 65% B); 32-35 min (65% B to 100% B) 35-62 min (hold 
at 100% B); 62-64 min (100% B to 10% B)l 64-80 min (10% B). Flow rate was maintained at 200 
µl/min except for the 35-62 min time frame where the flow rate was increased to 225 µl/min. MS 
analysis was performed in negative ion mode at a resolution of 140,000 for the full MS scan in a 
data-dependent mode. The scan range for MS analysis was 400-1800 m/z with a maximum 
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injection time of 128 ms using 1 microscan. An isolation window of 1.0 Da was set for the MS and 
MS2 scans. Capillary spray voltage was set at 3.5 kV, and capillary temperature was 320 ºC. The 
S-lens Rf level was set to 60.  Analysis of LC/MS data was performed using the software package 
Compound DiscovererTM (ThermoFisher Scientific, San Jose, CA) with an in-house generated 
analysis workflow and oxidized phospholipid database. 
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Chapter 3 
 
A mitochondrial-targeted nitroxide is a potent 
inhibitor of ferroptosis1  
3.1 Introduction 
Ferroptosis is an oxidative, non-apoptotic form of regulated cell death characterized by the iron-
dependent accumulation of lipid peroxides.1-2 Lipophilic antioxidants and iron chelators, but not 
caspase inhibitors, can effectively inhibit ferroptosis. Since ferroptosis is accompanied by lipid 
peroxidation, we hypothesized that a mitochondrially-targeted nitroxide antioxidant such as XJB-
5-131, or a more broadly intracellularly distributed antioxidant, JP4-039 (Figure 3.1), might be 
effective inhibitors of this cell death pathway. Furthermore, the different levels of mitochondrial 
enrichment of these two agents might allow us to differentiate the relative contribution of 
mitochondrial versus extra-mitochondrial lipid peroxidation in ferroptosis. The alkene peptide 
isostere moiety and the type II’ β-turn structure of XJB-5-131 are responsible for its ca. 600-fold 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
1 Part 1 of this chapter is adapted from a published manuscript: Krainz, T.; Gaschler, M. M.; Lim, 
C.; Sacher, J. R.; Stockwell, B. R.; Wipf, P., A Mitochondrial-Targeted Nitroxide Is a Potent 
Inhibitor of Ferroptosis. ACS Cent Sci 2016, 2 (9), 653-659. 
Figure 3.1. Structures of XJB-5-131 and JP4-039. The mitochondrial targeting 
sequences are highlighted in a dashed box; the nitroxide payload shown in blue 
provides effective scavenging of reactive oxygen species (ROS), organic radicals, 
and electrons escaping from the electron transport chain (ETC). 
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enrichment in the mitochondria over the cytosol.3-4 JP4-039 retains many of the desired 
physiological effects of XJB-5-131, however, it only displays a 20-30-fold enrichment in 
mitochondria over the cytosol.5-6 Both nitroxides have demonstrated impressive biological activity 
in vitro and in vivo models of diseases related to reactive oxygen species formation, and previous 
studies have highlighted their mechanism of action and therapeutic potential.4, 7-9 In collaboration 
with researchers in the laboratory of Peter Wipf at the University of Pittsburgh, we determined the 
ability of XJB-5-131, JP4-039 and selected analogs to prevent ferroptosis in multiple immortalized 
cancer lines to examine the potential role of intramitochondrial lipid peroxidation on ferroptosis. 
Several novel analogs of XJB-5-131 and JP4-039 were synthesized to probe structure-activity 
relationships (SAR) and the influence of the relative subcellular localization of the nitroxides. 
 
3.2 Results 
HT-1080 cells were treated with a lethal dose of erastin (10 µM) or RSL3 (2 µM) and 
varying concentrations of XJB-5-131, JP4-039, or the validated ferroptosis inhibitor Ferrostatin-1 
(Fer-1).1 XJB-5-131 showed low nanomolar potency against both ferroptosis inducers. XJB-5-131 
had similar potency to Fer-1 against erastin, but was moderately less protective against RSL3 
(Figure 3.2). In all cases, JP4-039 was much less protective than Fer-1 or XJB-5-131, and the 
difference in potency, ca. 20-fold, was in good agreement with the relative enrichment of these 
two lipid peroxidation inhibitors in mitochondria (20-30 vs 600-fold). 
These initial studies supported the hypothesis that ferroptosis is intrinsically linked to a 
lipid oxidation pathway intersecting with the mitochondrial membrane, since XJB-5-131 strongly 
suppresses cardiolipin-derived oxidized fatty acid formation.7, 10 In order to demonstrate that this 
effect was dependent on the structure of the mitochondrial-targeting sequence in the XJB and 
JP4 series, which correlates to their relative enrichment in mitochondria, researchers in the Wipf 
lab synthesized a series of analogs of both XJB-5-131 and JP4-039 (Figure 3.3). Addition of the 
oxetanylsulfoxide group in analog 2 reduced the lipophilicity of the compound and led to 6-fold 
loss in potency. Analog 6 which has the benzyl carbamate-protected C-terminal ornithine group 
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removed had a logP identical to 2, but was only two-fold less potent than XJB-5-131 (Figure 3.4). 
These results suggest that overall potency is both sequence-dependent and logP-dependent.  
 A D-amino acid residue at the (i+1)-position in a tetrapeptide sequence strongly stabilizes 
a type II’ β-turn, a conformation that improves permeability through membranes.11-13 The L-
leucine-D-phenylalanine (E)-alkene isostere moiety in XJB-5-131 therefore facilitates the 
formation of a compact structure that maximizes intramolecular hydrogen bonding in aqueous 
solution and promotes permeability either due to the nature of the folded structure itself or 
because the folded conformation is an energetically favorable precursor to the preferentially 
permeable structure.14-15 Accordingly, removal of the benzyl side chain on XJB-5-131 might 
significantly increase the number of conformational isomers by removing a backbone constraint, 
and lower its anti-ferroptotic properties by reducing its concentration in the mitochondrial 
membrane. Analogs 10 and 11 were prepared to test this hypothesis. The effect of the removal of 
the D-amino acid backbone constraint was indeed dramatic, since both of these analogs failed to 
demonstrate any inhibitory activity against ferroptosis below the 10 µM concentration cutoff. 
  
 
 
Figure 3.2. Protective effect of XJB-5-131 and JP4-039 in HT-1080 cells 
against erastin and RSL3 induced ferroptosis.  
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Figure 3.3. Analogs of XJB-5-131 (top) and JP4-039 (bottom) designed and 
synthesized in the Wipf laboratory 
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Overall, the SAR of analogs of the highly mitochondrially targeted XJB-5-131 supported our 
fundamental hypothesis that mitochondrial lipid oxidation may be critical in promoting the 
ferroptotic cell death pathway, and that effective inhibitors of this process needed to be primarily 
localized to mitochondria in order to have significant potency. For additional control experiments, 
researchers in the Wipf lab performed additional structural modifications on the less targeted, but 
still active, JP4-039, and recorded their effects on the prevention of erastin-induced ferroptosis.  
 
 Substituted oxetane derivatives 13a-d were synthesized to examine the effect of Boc-
group removal and altering lipophilicity. Removal of the carbamate group yielded analog 16.  
Analogous to the results obtained with 2 and 11, the replacement of the Boc group by a 
hydrophilic oxetane-containing side chain was not tolerated, and all modified analogs of JP4-039 
lost activity. In this series, we also experimented with the introduction of a second nitroxide on the 
Figure 3.4. Dose-dependent ability of XJB-5-131 and JP4-039 analogs to 
prevent erastin-induced ferroptosis.  
! 64!
backbone alkene isostere, which should double the antiferroptotic effect in a stoichiometric mode. 
 To confirm these observations in additional cell lines, we tested the active compounds in 
ferroptosis sensitive BJeLR and panc-1 cells (Figure 3.5). While there was some variability in the 
potency of active compounds between cell lines, the general trends of potency observed in HT-
1080 cells were consistent among all other cell lines tested. XJB-5-131 was consistently the most 
potent nitroxide at a level similar to that of ferrostatin-1. JP4-039 remained ca. 10–20-fold less 
protective than XJB-5-131 in both cell lines when treated with erastin or RSL3. These data 
demonstrate that mitochondria-targeted nitroxides are able to inhibit ferroptosis in a variety of 
tissue types and across multiple growth conditions.  
 
 
Figure 3.5. Dose-dependent effect of active nitroxide compounds in two 
ferroptosis-sensitive cell lines 
! 65!
3.3 Discussion 
 Ferroptosis has been implicated in a number of degenerative pathologies,16 and the 
identification of inhibitors of ferroptosis is therefore of translational interest. Our finding that 
mitochondrially targeted nitroxides based on the XJB-5-131 lead structure are potent suppressors 
of ferroptosis in multiple cell contexts suggests that such compounds might be effective in treating 
degenerative diseases involving ferroptosis. Although the ADME properties of this series need to 
be evaluated and likely optimized,17  the results reported herein suggest a new approach to 
creating drugs that inhibit ferroptosis. On the other hand, inducing ferroptosis may be a useful 
approach to treating some sensitive cancers.2 One concern in this regard is that ferroptosis 
inhibitors such as XJB-5-131 might promote growth or persistence of certain tumors that would 
not otherwise survive. It will clearly be important to determine to what extent inhibitors of 
ferroptosis have the ability to promote tumor formation, and to what extent inducers of ferroptosis 
may trigger degenerative pathologies.  
Prior mechanistic studies of ferroptosis had provided data that were simultaneously both 
supporting and opposing the hypothesis that mitochondrial lipid peroxidation is required for 
ferroptotic cell death. In support of this hypothesis was the observation that the major 
morphological change in erastin-treated cells is the degeneration of mitochondria.18 Additionally, 
GPX4 knockout kidneys showed an accumulation of oxidized cardiolipin, a mitochondria-specific 
phospholipid.19 Opposing this hypothesis were the observations that (i) the mitochondrial electron 
transport chain is not needed for erastin-induced ferroptosis,1 (ii) the mitochondrially-targeted 
superoxide probe MitoSOX is not oxidized in erastin-treated cells,16 (iii) the ferroptosis inhibitor 
Ferrostatin-1 does not suppress rotenone-induced mitoSOX oxidation, which is likely due to 
mitochondrial complex-I-derived superoxide18 and (iv) ferrostatin does not suppress the 
staurosporine-induced decrease in 10-nonyl acridine orange (NAO) signal.18 Nonetheless, these 
previous observations are not inconsistent with a role for mitochondrial lipid peroxidation in 
ferroptosis if superoxide is not involved, and if NAO does not report specifically on mitochondrial 
lipid peroxidation. Thus, given that these earlier mechanistic probes are indirect and potentially 
non-specific reporters of mitochondrial lipid peroxidation, we reasoned that testing a 
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mitochondrially-targeted nitroxide would be a more effective means of examining the hypothesis 
that mitochondrial lipid peroxidation is necessary for ferroptosis. Our results with mitochondrially-
targeted nitroxides as lipid peroxidation mitigators suggest that the protection of mitochondrial 
lipids is sufficient for prevention of ferroptosis, and that untargeted ROS scavenging in the cytosol 
has relatively minor, if any, significance for the induction or propagation of this cell death 
pathway. While it is still premature to conclude that disruption of mitochondrial Gpx4 activity is a 
more critical contributor to ferroptosis than the cytosolic or nuclear Gpx4 isoforms are, our results 
would be in agreement with such a revised mechanistic hypothesis. Undoubtedly, however, our 
studies highlight that mitochondrial lipid peroxidation is a key factor in ferroptosis, and preventing 
such lipid peroxidation in mitochondrial membranes is likely to be therapeutically relevant. 
3.4 Methods 
LogP Calculation LogP was predicted with the Instant JChem 15.8.31.0 software package, 
available at http://www.chemaxon.com 
Cell Lines and Media. HT-1080 cells were obtained from ATCC and grown in DMEM with 
glutamine and sodium pyruvate (Corning 10-013) supplemented with 10% Heat-Inactivated FBS, 
1% non-essential amino acids (Invitorgen), and 1% penicillin-streptomycin mix (Invitrogen). Panc-
1 cells were obtained from ATCC and grown in DMEM with glutamine and sodium pyruvate 
(Corning 10-013) supplemented with 10% Heat-Inactivated FBS, and 1% penicillin-streptomycin 
mix (Invitrogen). BJeLR cells were grown in DMEM with glutamine and sodium pyruvate (Corning 
10-013) supplemented with 20% Medium-199 (Sigma), 15% Heat-Inactivated FBS, and 1% 
penicillin-streptomycin mix (Invitrogen). All cells were maintained in a humidified environment at 
37 ºC and 5% CO2 in a tissue incubator.  
Cell Viability Assay. 3,000 cells were seeded per well in black, clear bottom 384-well plates 
(Corning) and allowed to adhere overnight. The next day, the medium was replaced with 50 µL of 
growth medium and 5 µL medium containing erastin (10 µM) or (1S, 3R)-RSL3 (2 µM) and a 
dilution series of ferrostatin-1 or a nitroxide-containing molecule. 24 hours later, 6.1 µL of Presto 
Blue (Thermo-Fisher) were added. Cells were incubated for an additional 5 hours and the Presto 
Blue fluorescence intensity was measured using a Victor X5 plate reader (PerkinElmer)(ex/em 
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530/590). Background (no cells) fluorescence was subtracted and the resulting fluorescence 
intensities were averaged between biological replicates. From these data, dose-response curves 
and EC50 values were computed using Prism 6.0 (GraphPad). 
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Chapter 4 
 
Determination of the subcellular localization and 
mechanism of action of ferrostatins in 
suppressing ferroptosis1 
4.1 Introduction 
 Because of the apparent importance of mitochondria suggested by our studies with XJB-
5-131, we wished to gain a more global insight into the organelle-specific contributions to 
ferroptosis using the ferroptosis-specific inhibitor ferrostatin-1. Ferrostatin-1 is a potent and 
selective small-molecule inhibitor of ferroptosis, a form of non-apoptotic, iron-dependent, 
oxidative regulated cell death1-2. Ferrostatin-1 and its analogs (ferrostatins) effectively prevent 
ferroptosis in models of neurodegeneration1-3, acute kidney injury4-5, intracerebral hemorrhage6, 
and other degenerative conditions2, suggesting the potential of ferrostatins as therapeutic 
compounds. Significant exploration of the structure-activity relationship (SAR) of ferrostatins has 
led to analogs with increased potency and metabolic stability2, 4, 7; even so, many aspects of the 
mechanism of ferroptosis itself, and its suppression by ferrostatins remain to be elucidated.  
 The correlation between increased lipophilicity and increased potency was one of the first 
SAR trends observed for ferrostatins. Increasing the lipophilicity of the hydrocarbon moiety on 
either one of the arylamines led to ferrostatins with greater potency.1 Additionally, all active 
ferrostatin analogs are reducing agents that are able to reduce the stable radical DPPH1-2. 
Structural modifications that prevent such reducing behavior prevent compounds from 
suppressing ferroptosis. Together, these observations led to the hypothesis that ferrostatins 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
1 This chapter is adapted from a manuscript in preparation: Gaschler, M.M.; Hu, F.; Feng, H.; 
Daniels, J.; Buzzeo, M.; Min, W.; Stockwell, B.R.,  Determination of the subcellular localization 
and mechanism of action of ferrostatins in suppressing ferroptosis 
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function as lipophilic antioxidants that use their large lipophilic group to anchor into membranes, 
where they reduce lipid hydroperoxides. 
 Here, we sought to gain deeper insight into the mechanism of ferrostatins in order to 
better understand ferroptosis and to aid in the development of ferrostatins with improved 
properties. We combined stimulated Raman scattering microscopy (SRS) and small vibrational 
labels to directly visualize ferrostatins in live cells. We found that ferrostatins accumulate strongly 
in specific sub-cellular regions, including lysosomes, mitochondria, and the endoplasmic 
reticulum. Accumulation of ferrostatins at mitochondria or lysosomes, however, was not required 
for ferroptosis suppression. Additionally, we found that ferrostatin-1 can function as a mostly-
irreversible two-electron reducing agent that can reduce both ferric iron and lipid peroxides.  
4.2 Results 
4.2.1 Ferrostatins accumulate in lysosomes, mitochondria, and endoplasmic reticulum 
 The potency of ferrostatins has been suggested to derive from their ability to anchor in 
lipid membranes, thereby allowing them to directly reduce lipid hydroperoxides.2 Supporting this, 
the rate of radical trapping by ferrostatin-1 was enhanced 7.6-fold in liposomes relative to a 
nonpolar solvent.8 We sought to image the distribution of ferrostatins in live cells in order to 
determine whether they preferentially localize to specific subcellular locations. Conventional 
approaches to imaging the cellular distribution of molecules involve covalent attachment of a 
fluorescent dye to the molecule being studied. For a molecule as small as ferrostatin-1, we were 
concerned that covalent attachment of a fluorescent dye would significantly alter its native activity 
and localization due to the large size of most fluorescent tags. To circumvent this challenge, we 
employed stimulated Raman scattering (SRS) microscopy to visualize ferrostatin distribution in 
living cells. By attaching small vibrational tags only a few atoms in size with vibrational 
frequencies in the silent region of a typical cellular Raman spectrum, SRS achieves sensitive live-
cell imaging of bioactive molecules with high sensitivity and specificity.9 Alkynes are optimal SRS 
vibrational tags due to their strong Raman signal, lack of chemical reactivity in cells, and small 
size.10 Conjugated alkynes (e.g., a diyne) greatly enhance the SRS signal, allowing high detection 
sensitivity and lower concentrations of the probe compound.11  
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 Given these considerations, we designed and synthesized diyne ferrostatin analog 2 
(Figure 4.1) in three steps. Starting from ester 6, the propargylamine moiety was installed via 
nucleophilic aromatic substitution at room temperature. Elevation of the reaction temperature, 
similar to previous syntheses of ferrostatin analogs,2 resulted in decomposition of the reaction. 
The diyne moiety was installed using Cadiot-Chodkiewicz coupling conditions12 and 1-iodohexyne 
(see experimental section for preparation). Selective reduction of the aromatic nitro group was 
achieved using a stoichiometric excess of sodium dithionite, furnishing diyne ferrostatin 2. 
 Given the functional tolerance of ferrostatins to extensive substitution at the 4 position2, 
we hypothesized that incorporation of a lipophilic diyne moiety at this position would not 
significantly reduce the potency of compound 2 relative to ferrostatin-1. To confirm the potency 
and activity of compound 2, we treated ferroptosis-sensitive HT-1080 fibrosarcoma cells with a 
lethal dose of the ferroptosis inducer erastin and a serial dilution of ferrostatin-1 or compound 2 
(Figure 4.2). We found that compound 2 suppressed ferroptosis with potency similar to 
ferrostatin-1, confirming that the diyne did not significantly attenuate the anti-ferroptotic activity of 
the compound.  
Figure 4.1. Synthesis of diyne ferrostatin 2. 
Figure 4.2. Dose dependent ferroptosis suppression by ferrostatin-1 and diyne 
ferrostatin 2 in HT-1080 cells co-treated with a lethal dose of ferroptosis inducer 
erastin (10 µM). Viability was measured 24 h after compound addition. 
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 Having validated the activity of probe 2, we aimed to image its distribution in cells. HT-
1080 cells were treated with 2 and erastin simultaneously, and imaged after 6 h of incubation 
(Figure 4.3A). Ferrostatin 2 accumulated in large puncta throughout the cytoplasm, with lesser 
accumulation through the remainder of the cytoplasm. Notably, no significant amount of 2 was 
detected in the nucleus or in the plasma membrane, within the limits SRS sensitivity. To test if 
this pattern of accumulation was specific to cells undergoing ferroptosis, we incubated HT-1080 
cells with probe 2 in the absence of erastin (Figure 4.3B). We did not observe a significant 
change in localization, indicating that the pattern of ferrostatin localization does not depend on 
whether or not ferroptosis has been initiated, as we expected. To ensure that these patterns of 
localization were not specific to HT-1080 cells we tested diyne 2 in immortalized pancreatic 
Figure 4.3. Distribution of ferrostatin 2 in live HT-1080 
cells (A) treated with 10 µM erastin or (B) in the absence 
of erastin. Images were collected by Fanghao Hu 7 h 
after compound addition 
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cancer line, PANC-1. Similar to erastin, diyne 2 showed strong accumulation in puncta throughout 
the cytosol and very little accumulation within the nucleus both in the presence and absence of 
erastin (Figure 4.4).  
  
We next sought to determine if this distribution was due to accumulation of probe 2 at 
specific organelles. We hypothesized that the large puncta might correspond to accumulation 
within lysosomes. HT-1080 cells were treated with 2 for 6 h, followed by 30 min with the 
lysosome-targeted fluorescent dye LysoTracker Red, and both compounds were imaged within 
the same cells (Figure 4.5). The LysoTracker signal overlapped with the large puncta from probe 
2, suggesting that these sites of ferrostatin accumulation were indeed lysosomes.  
Figure 4.4. Distribution of ferrostatin 2 in live PANC-1 cells in 
the absence (top) and presence (bottom) of 10 µM erastin. 
Images were collected by Fanghao Hu, 7 h after compound 
addition. 
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 In addition to lysosomes, mitochondria and endoplasmic reticulum (ER) have 
also been hypothesized to play roles in ferroptosis1, 13. We therefore sought to determine whether 
probe 2 also accumulated at either of these organelles. HT-1080 cells were treated with 2 and 
either a mitochondria-specific or ER-specific fluorescent dye (Figure 4.6). Though 2 was present 
at lower concentrations in both of these locations than in lysosomes, 2 showed a clear pattern of 
overlap with the mitochondria-specific fluorescent dye Mito Tracker Deep Red. Due to the diffuse 
nature of ER, it was unclear if the widespread distribution of 2 was due to specific accumulation 
within ER, but the imaging we observed is consistent with this possibility. Thus, we concluded 
Figure 4.5. Overlay of signal from 2 and LysoTracker dye in live HT-1080 cells. Images 
were collected by Fanghao Hu.  
Figure 4.6. Co-localization of ferrostatin 2 and mitochondria and endoplasmic 
reticulum (ER) specific dyes. White arrows highlight areas of apparent 
mitochondria/ferrostatin overlap. Images were gathered by Fanghao Hu. 
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that 2 accumulates primarily in lysosomes, with additional localization in mitochondria, and in the 
ER, but did not show detectable concentrations in the plasma membrane or the nucleus. 
4.2.2 Accumulation at lysosomes reduces the potency of ferrostatins 
The role of lysosomes in ferroptosis is unclear. Earlier studies observed a burst of 
reactive oxygen species (ROS) in lysosomes of cells undergoing ferroptosis,14 but lysosomal 
membrane permeabilization, a feature of other forms of oxidative cell damage, was not observed 
in cells treated with erastin.2 Additionally, lysosomes store iron imported by endocytosis of 
transferrin, a process critical for ferroptosis.15 Correspondingly, the membrane-impermeable iron 
chelator DFO likely protects against ferroptosis by chelating iron accumulated in lysosomes via 
endocytosis.16  
 We hypothesized that ferrostatins accumulate in lysosomes because of the 
lysosomotropic effect.17 In their neutral form, small molecules with weakly basic sites (generally 
aromatic or aliphatic amines) can freely diffuse through lipid membranes and between cellular 
compartments. In acidic lysosomes (pH 4.5-5.0), basic groups are protonated and unable to 
diffuse out because of the resulting positive charge. In this way, molecules can be trapped in 
lysosomes, even if their biological target is elsewhere in a cell.18 Given the basic aromatic amines 
Figure 4.7. Increase in ferrostatin-1 potency following co-treatment 
with chloroquine. HT-1080 cells were treated with erastin (10 µM), the 
indicated concentration of chloroquine, and a serial dilution of 
ferrostatin-1. Viability was measured 24 h after compound addition.  
Data are plotted as EC50 of ferrostatin-1 with black bars representing 
the 95% confidence interval.  
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in ferrostatins and the high levels of accumulation of probe 2 within lysosomes, we examined 
whether lysosomal accumulation of ferrostatins was critical to their mechanism of ferroptosis 
rescue or if lysosomotropism prevents ferrostatins from reaching their necessary targets.  
To evaluate the importance of lysosomes to ferroptosis suppression by ferrostatins, we 
first incubated HT-1080 cells with a lethal dose of erastin and a serial dilution of ferrostatin-1, as 
well as 0 (vehicle only), 5, or 10 µM chloroquine (Figure 4.7). A classic lysosomotropic agent, 
chloroquine is protonated in lysosomes, and raises the lysosomal pH, reducing the number of 
molecules trapped by the lysosomotropic effect. We found that co-treatment of cells with 
ferrostatin-1 and chloroquine caused an increase in the potency (lower EC50) of ferrostatin-1 in a 
dose-dependent manner (Figure 4.7).  
Additionally, we incubated the imaging analog 2 with chloroquine in HT-1080 cells for 6 h 
(Figure 4.8). As expected, in the presence of chloroquine, we observed fewer high-intensity 
puncta, consistent with our hypothesis that chloroquine decreases the accumulation of 2 within 
lysosomes. However, within the limits of detection of SRS, we could not be certain that the 
apparent decrease in lysosomal intensity was due to decreased accumulation of 2 at lysosomes, 
and not, for example, off-target effects or stochastic variability between experimental conditions.  
Figure 4.8. Accumulation of ferrostatin 2 in lysosomes in the 
presence or absence of chloroquine. Images were gathered by 
Fanghao Hu after 6h incubation with compounds.  
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Since preventing ferrostatin accumulation in lysosomes appeared to increase ferrostatin 
potency, we hypothesized that promoting ferrostatin accumulation in lysosomes would 
correspondingly decrease their potency (i.e., require a higher concentration of ferrostatin to 
suppress ferroptosis). To test this hypothesis, we designed and synthesized morpholine amide 
ferrostatins 3 and 4 (Figure 4.9). We reasoned that in addition to the aromatic amines on the 
ferrostatin core, the morpholine nitrogen would also be protonated in the lysosome, increasing the 
amount of ferrostatin sequestration in this organelle.  
 
Figure 4.9. Synthesis of lysosome-targeted ferrostatins. 
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Both ferrostatins 3 and 4 showed an eight-fold loss in potency in their ability to rescue 
cells from erastin-induced ferroptosis (Figure 4.10), relative to ferrostatin-1. In addition, co-
treatment of cells with LysoTracker dye and either 2 or 4 revealed that, as designed, ferrostatin 4 
accumulates strongly in lysosomal compartments (Figure 4.11), confirming that the decrease in 
potency is correlated with increased sequestration in lysosomes. Cumulatively, these data 
suggest that reducing the basicity of the ferrostatin amines could improve potency by reducing 
lysosomal sequestration. 
Figure 4.10. Potency of lysosme-targeted ferrostatins. HT-1080 cells were 
treated with erastin (10 µM) and a serial dose of the indicated ferrostatin. 
Viability was measured at 24 h after compound addition. 
Figure 4.11. Localization of diyne 2 and lysosome-targeted diyne ferrostatin 4 
in live HT-1080 cells treated with ferrostatin (10 µM) for 6 h. Images were 
collected by Fanghao Hu. 
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4.2.3 Mitochondria are not required for ferroptosis or ferroptosis rescue by ferrostatins  
 Since ferrostatin analog 2 showed accumulation in mitochondria, we sought to determine 
if mitochondria are necessary for ferroptosis, and for ferroptosis rescue by ferrostatins. ROS 
generated by the mitochondrial electron transport chain do not contribute to ferroptosis, as cells 
lacking mitochondrial DNA are still sensitive to ferroptosis.1 Still, alterations in mitochondria 
morphology are observed in cells undergoing ferroptosis1, 19, and the nitroxide antioxidant XJB-5-
131, which is targeted to mitochondria, is a more potent inhibitor of ferroptosis than untargeted 
analogs.20 
 To directly examine the necessity of mitochondria for ferroptosis, we generated 
mitochondria-deficient cells.21 The E3 ligase parkin causes the elimination of mitochondria lacking 
a membrane potential via mitophagy, a macroautophagic process.21-22 Huizhong Feng in the 
Stockwell lab generated stably transfected HT-1080 cells expressing YFP-Parkin or mCherry-
Parkin (Figure 4.12). 
  Loss of membrane potential was induced by treatment with the uncoupling agent 
carbonyl cyanide m-chlorophenyl hydrazine (CCCP). Following treatment of YFP-parkin-
expressing cells or mCherry-parkin-expressing cells with CCCP for 48 h, we examined the levels 
of the mitochondria specific proteins tom20 and cytochrome C (Fig 4.13A). Parkin-expressing 
cells had no detectible levels of either protein after 48 hours of CCCP treatment, confirming the 
complete loss of mitochondria. Complete mitochondrial depletion within 48 h has been observed 
for similar systems.21-22 We observed near-complete absence of the complex 1 genes Mt-Nd1 
Figure 4.12. Parkin levels in stably-transfected HT-1080 
cells. Data gathered by Huizhong Feng. 
! 80!
and Mt-Nd2 following CCCP treatment (Fig. 4.13B and 4.13C). Cells depleted of mitochondria 
showed a greatly decreased growth rate (data not shown), but were nonetheless persistent in cell 
culture over multiple days. 
 To examine the necessity of mitochondria for ferroptosis, we treated YFP-Parkin-
expressing HT-1080 cells with a panel of ferroptosis inducing compounds. All ferroptosis inducers 
effectively killed cells depleted of mitochondria in a dose-dependent manner (Figure 4.14A-F), 
indicating that the presence of mitochondria is not necessary for ferroptosis. Staurosporine, an 
inducer of apoptosis via the intrinsic apoptotic pathway, caused no decrease in viability over all 
concentrations tested, confirming that mitochondria had been effectively removed, and that 
staurosporine-induced apoptosis required mitochondria, as expected. Notably, inhibitors of 
system xc- (erastin and IKE) both became less potent following CCCP treatment (i.e. after 
mitophagy), while RSL3 and FIN56, which target GPX4, both became more potent after 
mitophagy. When CCCP was withdrawn at the time of ferroptosis induction, these potency shifts 
did not change significantly, confirming that these changes in potency were the direct result of 
widespread mitophagy and not an off-target effect of CCCP.  Additionally, wild-type HT-1080 cells 
had similar sensitivity to all lethal molecules tested both in the presence and absence of CCCP 
co-treatment, indicating that potency changes observed are specific to mitophagy.  
Figure 4.13. (A) Western blot showing abundance of mitochondria-specific 
proteins tom20 and cytochrome C in mCherry/YFP-parkin expressing cells 
following treatment with CCCP (12.5 µM, 48 h). Levels of mitochondrial genes (B) 
Nd1 and (C) Nd2 following treatment with CCCP. Data gathered by Huizhong 
Feng. 
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 Because mitochondria-depleted cells were still sensitive to ferroptosis, we next evaluated 
the ability of ferroptosis-suppressing compounds to prevent ferroptosis in cells depleted of 
mitochondria. Both ferrostatin-1 and iron chelators (deferoxamine and ciclopirox olamine) were 
able to prevent erastin-induced ferroptosis in a dose-dependent manner (Figure 4.15A-B), 
confirming that the mechanism of erastin lethality was still ferroptosis in CCCP-treated YFP-
parkin cells. Unexpectedly, nitroxide antioxidants XJB-5-131 and JP-4039 both retained their 
ability to suppress erastin-induced ferroptosis following mitophagy (Figure 4.15C). Originally we 
had hypothesized that the ferroptosis suppressing ability of XJB-5-131 was due to action at the 
mitochondria, but these data suggest that either (i) some other mechanism is responsible for the 
high anti-ferroptotic potency of XJB-5-131 or (ii) in the absence of mitochondria, XJB-5-131 is 
Figure 4.14. Sensitivity changes during mitophagy. (A-E) YFP-Parkin HT-1080 cells 
were treated with the indicated lethal molecule (-CCCP) or treated with CCCP (12.5 
µM) for 48 h. The indicated lethal molecule was added with continued CCCP 
incubation (+ CCCP) or CCCP removal at the time of lethal molecule addition 
(+Mitiopagy –CCCP). Viability was measured after 24h incubation with the lethal 
molecule. (F) Representation of EC50 values from A-F; error bars represent the 95% 
confidence interval. 
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able to engage in a new program of ferroptosis suppression that is has similar potency to the 
program used in mitochondria replete cells. Notably, the differential potency between XJB-5-131 
and JP4-039 also did not significantly change following mitophagy.  
 
 We next evaluated the potency of ferrostatin-1 in YFP-parkin-transfected HT-1080 cells 
following mitophagy (Figure 4.16). Cells were treated with a lethal concentration of either the 
class 1 ferroptosis inducer erastin or the class 2 ferroptosis inducer RSL316, and a serial dilution 
Figure 4.15. Dose-dependent rescue of erastin (10 µM) induced ferroptosis by ferrostatin-
1, iron chelators, and nitroxide antioxidants.  
Figure 4.16. Potency of ferrostatin-1 in both erastin and RSL3-
induced ferroptosis rescue. Data is plotted as EC50 ± 95% 
confidence interval 
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of ferrostatin-1. In both cases, ferrostatin-1 became more potent following mitophagy, indicating 
that mitochondria are not required for ferroptosis suppression by ferrostatins. Cumulatively these 
data demonstrate that neither mitochondria nor lysosomes are required for ferroptosis induction 
or rescue by ferrostatin-1. Thus, accumulation of ferrostatins at mitochondria cannot be 
responsible for their highly potent ferroptosis suppression.   
4.2.4 Ferrostatin-1 is a mostly-irreversible, two-electron reducing agent 
Having examined the cellular distribution of ferrostatins, we sought to define the 
molecular mechanism by which ferrostatins inhibit lipid peroxidation and suppress ferroptosis in 
specific membranes, such as in ER. Previously, ferrostatin-1 had been proposed to act as a two-
electron reducing agent.2 To test this hypothesis, we used the radical scavenger 2,2-diphenyl-1-
picrylhydrazyl (DPPH). DPPH is a stable nitrogen-centered radical with a strong violet color that is 
lost upon reaction with another radical in solution. This colorimetric change is regularly used to 
test the reducing ability of biological reductants, including ferrostatin-1.2 We incubated varying 
concentrations of ferrostatin-1 and DPPH and monitored the loss of violet color by absorbance 
(Figure 4.17). Segmental linear regression indicated that complete loss of DPPH absorbance first 
occurred when the ferrostatin-1 concentration was half that of DPPH. Because each molecule of 
DPPH can only accept a single electron, these data confirm that ferrostatin-1 is a two-electron 
reducing agent, as expected.  
Figure 4.17. Stoichiometry of DPPH quenching by ferrostatin-1. 
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In collaboration with Prof. Marisa Buzzeo at Barnard, we next used cyclic voltammetry 
(CV) to gain further insight into the redox behavior of ferrostatin-1. We observed a strong anodic 
peak current at 0.75 V (vs. Ag/AgCl) corresponding to an oxidation of ferrostatin-1 (Figure 4.18A). 
However, we observed no corresponding cathodic peak current, indicating that the oxidation of 
ferrostatin-1 is irreversible over the voltages tested, or rapidly decomposes following oxidation. 
We also observed a shift in anodic peak potential as a function of scan rate, indicating diffusional 
control of redox cycling, and confirming the irreversibility of ferrostatin-1 oxidation (Figure 4.18B 
and C).  
 Because ferrostatin-1 is thought to suppress ferroptosis by reducing oxidized species in 
cells, we used a series of in vitro assays to understand which substrates are reduced by 
ferrostatin-1. We used an enzyme-coupled fluorescence assay to quantify the amount of 
hydrogen peroxide remaining in solution following incubation with either ferrostatin-1 or L-
ascorbic acid, which is also a reducing agent (Figure 4.19A). Both compounds were able to 
reduce similar amounts hydrogen peroxide. Since ferroptosis involves the accumulation of lipid 
peroxides, we also used LC-MS to test the ability of ferrostatin-1 to reduce lipid peroxides directly 
in vitro (Figure 4.19B). Ferrostatin-1 was able to reduce a modest amount of phosphatidylcholine 
hydroperoxide (PCOOH) in solution, suggesting that ferrostatin may prevent ferroptosis by 
preventing initiation or propagataion of lipid peroxidation, rather than direct reduction of already 
formed lipid peroxides.  
Figure 4.18. Cyclic voltammetry data from ferrostatin-1. (A) CV trace of ferrostatin-1 in 
methylene chloride (red) or solvent only (black). (B) Peak current variability as a function 
of scan rate. (C) Linear relationship between peak current and scan rate1/2, indicating 
diffusional control. Data gathered by Marisa Buzzeo. 
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Iron is an abundant redox active metal that is required for ferroptosis. Though ferrostatin-
1 does not produce the same phenotypic effects as iron chelators1, we hypothesized that 
ferrostatin-1 might be able to engage with ferric iron as a redox partner. Using a colorimetric 
assay, we observed that both ferrostatin-1 and L-ascorbic acid were able to reduce ferric iron in 
vitro (Figure 4.20).  
Figure 4.19. Peroxide reduction by ferrostatin-1. (A) Hydrogen peroxide 
was incubated with DMSO, Fer-1, or L-Ascorbic acid in vitro for 1 h. The 
quantity of peroxide remaining was quantified using a fluorescent 
enzymatic assay. (B) Enzymatically prepared phosphatidylcholine 
hydroperoxides (PCOOH) was incubated in methanol with vehicle or 
ferrostatin-1 for 1 h. Peroxide abundance was quantified by LC-MS 
Figure 4.20. Iron reduction by ferrostatin-1 and L-Ascorbic 
acid.  
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Previous work has shown that ferrostatin-1 can act as a radical trapping agent and 
directly reduce oxygen-centered radicals.8 Using an in vitro chemiluminescent assay that detects 
radicals generated by hydrogen peroxide and ferrous iron (Fenton chemistry), we tested the 
ability of antioxidants ferrostatin-1, L-ascorbic acid, trolox, and the iron chelator deferoxamine to 
quench oxygen-centered radicals (Figure 4.21). To eliminate false positives resulting from 
hydrogen peroxide reduction, hydrogen peroxide was used in 2000-fold excess of all other 
reagents.  All compounds tested were able to efficiently quench or prevent oxygen-centered 
radical formation.  
Cumulatively, these data demonstrate that ferrostatin-1 can reduce multiple redox active 
molecules that are involved in ferroptosis, suggesting that ferrostatin-1 may prevent ferroptosis 
through a multipronged effect on cellular lipid peroxidation events, rather than reduction of a 
single molecular entity. We also observed that in all in vitro assays, L-ascorbic acid preformed 
similarly or better than ferrostatin-1. However, L-ascorbic acid is unable to prevent ferroptosis. 
Unlike ferrostatin-1, L-ascorbic acid is not lipophilic. This suggests that ferrostatin-1 is able to 
prevent ferroptosis because of the combination of its reducing ability and its sub-cellular 
localization to specific lipid membranes, such as ER, where it can prevent propagation of lipid 
peroxidation. 
Figure 4.21. Inhibition of fenton-chemistry in vitro.  
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4.3 Discussion 
 In this work we sought to gain insight into the mechanism of ferroptosis suppression by 
ferrostatin-1. The ability of ferrostatin-1 to act as a reducing agent was one of the earliest 
observed properties of the compound,1 and served as the basis for initial hypotheses about its 
mechanism of action.2 Here we demonstrate that the redox behavior of ferrostatin-1 is mostly 
irreversible, suggesting that it acts as a stoichiometric reducing agent. Additionally, we show that 
ferrostatin-1 is able to reduce multiple substrates relevant to ferroptosis, including ferric iron, 
peroxides, and oxygen-centered radicals. Therefore, ferroptosis suppression by ferrostatins may 
involve a multi-pronged approach to inhibit uncontrolled lipid oxidation reducing multiple 
substrates involved in the formation and propagation of radicals necessary for lipid peroxidation.  
 Additionally, we sought to understand where ferrostatin-1 accumulated in cells, as 
enrichment within a ferroptosis-relevant organelle could explain the high potency of Fer-1 and 
analogs. We observed strong localization of ferrostatins within lysosomes, mitochondria, and the 
endoplasmic reticulum, and minimal accumulation within the nucleus and plasma membrane. As 
the nexus of iron import and trafficking, we hypothesized that lysosomes might play a critical role 
in ferroptosis. However, we found that accumulation within the lysosomes decreased the overall 
potency of ferrostatins. To examine the role of ferrostatin localization at mitochondria, we 
generated a stably transfected cell line that could be selectively depleted of mitochondria. We 
found that mitochondria-free cells were still sensitive to ferroptosis, and could still be rescued by 
ferrostatins. 
 Together, these data suggest that ferrostatin accumulation within the endoplasmic 
reticulum is critical to ferroptosis suppression, and that the ER may also be critical to ferroptosis 
initiation. The ER lumen is an oxidative environment and might initiate ferroptosis as a 
consequence of some ER-specific process. The ER is also the source of lipids for most 
membranes in other organelles and contains more than half of all lipid bilayers in any given cell.23  
Therefore, it is possible that ferrostatin accumulation offers an efficient strategy to suppress 
ferroptosis as ER localization would allow ferrostatins prevent oxidation of the majority of cellular 
lipids, thereby decreasing lipid peroxide abundance overall.  
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4.4 Methods 
Cell lines and media. HT-1080 cells were obtained from ATCC and grown in DMEM with 
glutamine and sodium pyruvate (Corning 10-013) supplemented with 10% Heat-Inactivated FBS, 
1% non-essential amino acids (Invitorgen), and 1% penicillin-streptomycin mix (Invitrogen). Panc-
1 cells were obtained from ATCC and grown in DMEM with glutamine and sodium pyruvate 
(Corning 10-013) supplemented with 10% Heat-Inactivated FBS, and 1% penicillin-streptomycin 
mix (Invitrogen). All cells were maintained in a humidified environment at 37 ºC and 5% CO2 in a 
tissue incubator.  
Ferroptosis rescue assay. 3,000 cells were seeded per well in black, clear bottom 384-well 
plates (Corning) and allowed to adhere overnight. The next day, the medium was replaced with 
50 µL of growth medium and 5 µL medium containing erastin (10 µM) or (1S, 3R)-RSL3 (2 µM) 
and a dilution series of the ferroptosis-suppressing moleule. 24 hours later, 6.1 µL of Presto Blue 
(Thermo-Fisher) were added. Cells were incubated for an additional 5 hours and the Presto Blue 
fluorescence intensity was measured using a Victor X5 plate reader (PerkinElmer)(ex/em 
530/590). Background (no cells) fluorescence was subtracted and the resulting fluorescence 
intensities were averaged between biological replicates. From these data, dose-response curves 
and EC50 values were computed using Prism 7.0 (GraphPad). For mitophagy experiments, YFP-
Parkin transfected HT-1080 cells were cultured in medium containing 12.5 µM CCCP for 24 h. 
Cells were then trypsinized, suspended and seeded into white, opaque-bottom 384-well plates 
(corning) at a density of 3,000 cells per well in 50 µL medium containing 12.5 µM CCCP and 
allowed to adhere for 24 additional hours (48 h CCCP treatment in total). The medium was either 
kept or replaced with CCCP-free medium (herein designated “+CCCP” or “+Mitophagy –CCCP”, 
respectively), and treated with 5 µL medium containing molecules as described above. Viability 
was assayed using CellTiter-Glo® (Promega) according to the manufacturer’s protocol. 
Luminesence was read on a Victor X5 plate reader and data were analyzed as described above.  
DPPH quenching in a clear 96-well plate, a 12-point, two fold serial dilution of ferrostatin-1 in 
methanol was assembled. A methanol solution of DPPH was added to each well, allowed to 
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incubate at room temperature for 30 minutes. Absorbance at 517 nm was then measured for 
each well. Absorbance values were plotted as a function of stoichiometric ratio between fer-1 and 
DPPH. Segmental linear regression was preformed using Prism 7.0 (GraphPad). 
Hydrogen peroxide abundance assay Hydrogen peroxide was quantified using the Amplex® 
Red Hydrogen Peroxide/Peroxidase Assay Kit (Thermo Fisher) according to the manufacturer’s 
protocol. Briefly, hydrogen peroxide (5 µM) and reducing agent (5 µM) were combined in a 
reaction tube and incubated for 1 h at 37 ºC. Aliquots from the reaction were added to a black, 
opaque-bottomed 96 well plate and combined with the master mix containing Amplex® Red dye 
and horseradish peroxidase. Fluorescence was measured at 550ex/590em. 
Phosphatidylcholine hydroperoxide abundance assay phosphatidylcholine hydroperoxide 
was synthesized enzymatically.24 94 µL of PCOOH in methanol was combined with Fer-1 (600 
µM) and incubated at 37 ºC for 1 h. PCOOH abundance was measured using LC-MS as reported 
previously.8 
Iron reduction assay ferric ammonium citrate (250 µM) and either ferrostatin-1 or L-ascorbic 
acid (250 µM) were combined in water in a clear 96-well plate. The iron (II)-selective chelator 
FerroZine™ (Sigma Aldrich) (250 µM) was added, and incubated for 2h at room temperature. 
Absorbance at 567 nM was measured for each well. As a control, ferrous chloride (250 µM) and  
FerroZine™ (Sigma Aldrich) (250 µM) were used to give a relative value for complete conversion.   
Luminescent Fenton chemistry assay In a white, opaque-bottom 96-well plate, ferrous chloride 
(200 µM), luminol (200 µM), hydrogen peroxide (400 mM), and either DMSO, ferrostatin-1, 
deferoxamine, L-ascorbic acid, or trolox (200 µM) were combined. Luminesence was measured 
on a Victor X5 plate reader. 
Compound synthesis 
General Procedures. All commercial reagents were used without further purification. All solvents 
used were reagent or HPLC grade. Chemical yields refer to isolated, spectroscopically pure 
compounds. 1H and 13C NMR spectra were recorded on a 400 or 500 MHz spectrometer (as 
indicated) at ambient temperature.  Chemical shifts are recorded in parts per million relative to 
residual solvent CDCl3 (1H, 7.26 ppm; 13C, 77.16 ppm) or (CD3)2SO (1H, 2.50 ppm; 13C, 39.52 
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ppm) . Multiplicities are reported as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = 
multiplet, comp m = complex multiplet, dd = doublet of doublets, ddd = doublet of doublets of 
doublets, td = triplet of doublets. Liquid chromatography was preformed on a CombiFlash Rf 
system (Teledyne Isco). Preparative thin layer chromatography was performed on plates coated 
with 1 mm silica gel.  
Ethyl 3-nitro-4-(prop-2-yn-1-ylamino)benzoate (7). To a solution of 4-chloro-3-nitro 
ethylbenzoate (2 g, 8.71 mmol) in DMSO (20 mL) was added potassium carbonate (2.4 g, 17.42 
mmol) and propargylamine (0.67 mL, 10.4 mmol). The reaction was stirred at room temperature 
overnight. The reaction mixture was poured into water and extracted with ethyl acetate (3 X 30 
mL). The combined organic extract was dried with sodium sulfate, decanted and concentrated 
under vacuum. The crude mixture was purified using a gradient of 0!30% ethyl acetate in 
hexanes to afford 7 (0.6g, 27%) as a yellow solid. 1H NMR (400 MHz, Chloroform-d) δ 8.90 (d, J = 
2.0 Hz, 1H), 8.42 (s, 1H), 8.14 (ddd, J = 8.9, 2.1, 0.7 Hz, 1H), 6.99 (d, J = 9.0 Hz, 1H), 4.38 (q, J 
= 7.1 Hz, 2H), 4.18 (dd, J = 5.7, 2.5 Hz, 2H), 2.33 (t, J = 2.5 Hz, 1H), 1.40 (t, J = 7.1 Hz, 3H).  
1-iodohex-1-yne. To a solution of 1-hexyne (2 mL, 17.4 mmol) in THF (42 mL) under a nitrogen 
atmosphere was added methyl lithium (1.6M in diethyl ether, 19.5 mL, 31.33 mmol) dropwise over 
10 minutes. The mixture was allowed to stir for an hour at room temperature. Separately, iodine 
(4.4g, 17.3 mmol) was dissolved in THF (17 mL). This solution was added dropwise to the 1-
hexyne solution portionwise over 30 minutes, allowing the brown color to dissipate fully between 
each addition. After complete addition of iodine, the mixture was allowed to stir for an additional 
30 min. The reaction was poured over water (100 mL) and extracted with diethyl ether (3 X 25 
mL). The combined ether extracts were washed with a 5% aqueous solution of sodium thiosulfate 
and collected, and partially concentrated under vacuum. Purification was achieved by filtration 
through a plug of silica gel with hexanes. The flow-through was collected and concentrated 
completely on vacuum to yield 1-iodohex-1-yne as a highly odorus amber liquid. 1H NMR (400 
MHz, Chloroform-d) δ 3.78 – 3.69 (m, 1H), 3.74 (s, 1H), 2.35 (t, J = 6.9 Hz, 1H), 1.92 – 1.74 (m, 
2H), 1.56 – 1.32 (m, 2H), 0.90 (t, J = 7.2 Hz, 2H). 13C NMR (500 MHz, Chloroform-d) δ  94.88, 
60.50, 30.67, 21.98, 20.62, 13.73.  
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Ethyl 3-nitro-4-(nona-2,4-diyn-1-ylamino)benzoate (8). To a solution of THF (38 mL), water 
(10.5 mL), and ethylamine (70% in water, 5.5 mL), was added 7 (0.6 g, 2.4 mmol) followed by 
hydroxylamine hydrochloride (0.119 g, 1.72 mmol) and copper (I) chloride (59 mg, 0.6 mmol). 
This mixture was allowed to stir at room temperature for 5 minutes. Separately, a solution of 1-
iodohex-1-yne (0.25g, 1.2 mmol) was dissolved in 10 mL THF. This solution was added dropwise 
and the whole mixture was alled to stir for 5 h at room temperature. The reaction mixture was 
poured over 85 mL of water conataining 5.2g KCN, and extracted with diethylether (3 X 25 mL), 
dried over sodium sulfate and concentrated under vacuum. The crude mixture was purified using 
a gradient of 0!30% ethyl acetate in hexanes to afford 8 (0.23g, 58%) as a yellow solid. 1H NMR 
(400 MHz, Chloroform-d) δ 8.89 (d, J = 2.0 Hz, 1H), 8.41 (t, J = 5.9 Hz, 1H), 8.14 (ddd, J = 9.0, 
2.1, 0.7 Hz, 1H), 6.98 (d, J = 9.0 Hz, 1H), 4.37 (q, J = 7.1 Hz, 2H), 4.24 (dt, J = 5.8, 1.1 Hz, 2H), 
2.26 (tt, J = 7.1, 1.1 Hz, 2H), 1.55 – 1.45 (m, 2H), 1.50 – 1.33 (m, 5H), 0.90 (t, J = 7.2 Hz, 3H).  
Ethyl 3-amino-4-(nona-2,4-diyn-1-ylamino)benzoate (2). To a solution of ethanol (200 proof, 8 
mL) was added 8 (0.23g, 0.7 mmol). The temperature was decreased to 0 ºC by cooling with an 
ice bath. Sodium dithionite (0.73g, 4.2 mmol) was added followed by water (4 mL). The ice bath 
was removed and the reaction was allowed to warm over the course of 90 minutes. The reaction 
mixture was extracted with ethyl acetate (2 X 10 mL), dried over sodium sulfate and 
concentrated. The mixture was purified by preparative thin layer chromatography (2:1 
hexanes:ethyl acetate) to yield 2 (20 mg, 42%). 1H NMR (400 MHz, Chloroform-d) δ 7.61 (dd, J = 
8.3, 1.9 Hz, 1H), 7.43 (d, J = 1.9 Hz, 1H), 6.69 (d, J = 8.3 Hz, 1H), 4.32 (q, J = 7.1 Hz, 2H), 4.14 – 
4.02 (m, 3H), 3.29 (s, 2H), 2.26 (tt, J = 7.1, 1.0 Hz, 2H), 1.56 – 1.44 (m, 2H), 1.48 – 1.32 (m, 5H), 
0.90 (t, J = 7.2 Hz, 3H). 13C NMR (500 MHz, Chloroform-d) δ 167.01, 141.28, 133.23, 123.95, 
121.04, 118.31, 110.66, 80.62, 77.33, 72.26, 68.92, 64.64, 60.49, 34.22, 30.28, 22.02, 19.01, 
14.55, 13.61.  
3-amino-4-(cyclohexylamino)benzoic acid (9).  To a solution of ferrostatin-1 (0.32g, 1.22 
mmol) in methanol (10 mL) was added 6M sodium hydroxide (5 mL). The mixture was brought to 
reflux and stirred overnight. The reaction mixture was partitioned between water and 
dichlormethane. The organic extracts were dried over sodium sulfate, decanted, and 
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concentrated under vacuum to yield 9 (0.26g, 94%) as a brown solid. 1H NMR (400 MHz, 
Chloroform-d) δ 7.65 (dd, J = 8.4, 2.0 Hz, 1H), 7.46 (d, J = 2.0 Hz, 1H), 6.61 (d, J = 8.5 Hz, 1H), 
3.36 (tt, J = 10.1, 3.8 Hz, 1H), 2.14 – 2.03 (m, 2H), 1.79 (dt, J = 13.2, 3.9 Hz, 2H), 1.68 (dt, J = 
12.7, 3.8 Hz, 1H), 1.49 – 1.33 (m, 2H), 1.33 – 1.18 (m, 3H). 
3-amino-4-(cyclohexylamino)-N-(2-morpholinoethyl)benzamide (3). To a solution of 9 (59 mg, 
0.253 mmol) in DMF (5 mL) was added 1-hydroxybenzotriazole (102 mg, 0.76 mmol), N-(3-
Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (96 mg, 0.506 mmol), sodium 
bicarbonate (63 mg, 0.76 mmol) and 4-(2-aminoethyl)morpholine (0.05 mL, 0.38 mmol). The 
mixture was stirred at room temperature overnight. The mixture was extracted into 
dichloromethane (3 X 25 mL). The combined organic layers were dried over sodium sulfate, 
decanted, and concentrated under vacuum. Preperative thin layer chromatography (1:9 
methanol:dichloromethane) afforded 3 (35.5 mg, 40%). 1H NMR (500 MHz, Chloroform-d) δ 7.25 
(d, J = 2.1 Hz, 0H), 7.20 (dd, J = 8.2, 2.1 Hz, 0H), 6.60 (d, J = 8.4 Hz, 1H), 3.72 (t, J = 4.6 Hz, 
2H), 3.55 – 3.48 (m, 1H), 3.30 (tt, J = 10.0, 3.7 Hz, 0H), 2.95 (s, 1H), 2.87 (s, 1H), 2.58 (t, J = 6.0 
Hz, 1H), 2.50 (d, J = 9.4 Hz, 1H), 2.50 (s, 1H), 2.07 (dt, J = 12.8, 3.9 Hz, 1H), 1.78 (dt, J = 13.6, 
3.9 Hz, 1H), 1.66 (dq, J = 11.5, 3.7 Hz, 0H), 1.46 – 1.33 (m, 1H), 1.31 – 1.16 (m, 2H). 13C NMR 
(500 MHz, Chloroform-d) δ 167.69, 162.64, 140.66, 132.84, 123.10, 120.17, 116.61, 110.12, 
77.36, 67.09, 57.28, 53.47, 51.60, 36.59, 36.02, 33.49, 31.56, 26.03, 25.08.   
4-chloro-N-(2-morpholinoethyl)-3-nitrobenzamide (10) To a solution of 4-chloro-3-nitrobenzoyl 
chloride (1 g, 4.54 mmol) in dioxane (25 mL) was added potassium carbonate (1.25 g, 9 mmol) 
and 4-(2-aminoethyl)-morpholine (0.65 mL, 4.99 mmol). The suspension was allowed to stir 
overnight at room temperature. The mixture was partitioned between dichloromethane and 
saturated sodium bicarbonate (50 mL each). The aqueous layer was extracted twice more with 
dichloromethane (20 mL). The combined organic layers were dried over sodium sulfate, 
decanted, and concentrated under vacuum. The crude mixture was purified using a gradient of 
0!10% methanol in dichloromethane to afford 10 (1.3 g, 91%) as a white solid. 1H NMR (500 
MHz, Chloroform-d) δ 8.27 (d, J = 2.1 Hz, 1H), 7.93 (dd, J = 8.4, 2.1 Hz, 1H), 7.63 (d, J = 8.4 Hz, 
1H), 6.93 (s, 1H), 3.75 – 3.69 (m, 4H), 3.59 – 3.52 (m, 2H), 2.61 (t, J = 5.9 Hz, 2H), 2.50 (dd, J = 
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5.7, 3.7 Hz, 4H). 13C NMR (126 MHz, Chloroform-d) δ 164.16, 147.96, 134.52, 132.42, 131.52, 
130.20, 124.29, 67.03, 56.84, 53.46, 36.42.   
N-(2-morpholinoethyl)-3-nitro-4-(prop-2-yn-1-ylamino)benzamide (11) To a solution of 10 (1 
g, 3.18 mmol) in DMSO (10 mL) was added propargylamine (0.21 mL, 3.82 mmol) and potassium 
carbonate (0.88g, 6.34 mmol). The mixture was stirred at 30 ºC for four days. The mixture was 
partitioned between dichloromethane and saturated sodium bicarbonate (25 mL each). The 
aqueous layer was extracted twice more with dichloromethane (10 mL). The combined organic 
layers were dried over sodium sulfate, decanted, and concentrated under vacuum. The crude 
mixture was purified preparative thin layer chromatography (9:1 dichloromethane:methanol) to 
yield 11 (0.18 g, 17%) as a yellow solid. 1H NMR (500 MHz, Chloroform-d) δ 8.61 (d, J = 2.2 Hz, 
1H), 8.35 (s, 1H), 8.01 (dd, J = 8.9, 2.2 Hz, 1H), 7.04 (d, J = 8.9 Hz, 1H), 6.73 (s, 1H), 4.18 (dd, J 
= 5.8, 2.5 Hz, 2H), 3.74 (t, J = 4.7 Hz, 4H), 3.55 (m, 2H), 2.65 – 2.57 (m, 2H), 2.52 (t, J = 4.6 Hz, 
4H), 2.33 (t, J = 2.4 Hz, 1H). 
N-(2-morpholinoethyl)-3-nitro-4-(nona-2,4-diyn-1-ylamino)benzamide (12) To a solution of 
THF (6 mL), water (2 mL), and ethylamine (70% in water, 1 mL), was added 11 (0.1 g, 0.3 mmol) 
followed by hydroxylamine hydrochloride (18 mg, 0.21 mmol) and copper (I) chloride (7 mg, 0.07 
mmol). This mixture was allowed to stir at room temperature for 5 minutes. Separately, a solution 
of 1-iodohex-1-yne (37 mg, 0.18 mmol) was dissolved in 2 mL THF. This solution was added 
dropwise and the whole mixture was allowed to stir for 5 h at room temperature. A dark green 
color developed. The reaction mixture was poured over 13 mL of water containing 0.81 g KCN, 
and extracted with diethylether (3 X 10 mL), dried over sodium sulfate and concentrated under 
vacuum. The crude mixture was purified preparative thin layer chromatography (9:1 
dichloromethane:methanol) to yield 12 (29 mg, 39%) as a yellow solid. 1H NMR (300 MHz, 
Chloroform-d) δ 8.60 (d, J = 2.2 Hz, 1H), 8.33 (t, J = 5.8 Hz, 1H), 8.00 (ddd, J = 9.0, 2.2, 0.6 Hz, 
1H), 7.01 (d, J = 8.9 Hz, 1H), 6.75 (s, 1H), 4.23 (dt, J = 5.9, 1.1 Hz, 2H), 3.79 – 3.67 (m, 4H), 3.61 
– 3.49 (m, 2H), 2.61 (dd, J = 7.1, 4.9 Hz, 2H), 2.56 – 2.45 (m, 4H), 2.26 (tt, J = 7.0, 1.0 Hz, 2H), 
1.57 – 1.31 (m, 4H), 0.90 (t, J = 7.2 Hz, 3H). 
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3-amino-N-(2-morpholinoethyl)-4-(nona-2,4-diyn-1-ylamino)benzamide (4) A solution of 12 
(29 mg, 0.07 mmol) in ethanol (2 mL, 200 proof) and water (1 mL) was cooled to 0 ºC on an ice 
bath. Sodium dithionite (73 mg, 0.422 mmol) was added in small portions. The ice bath was 
removed and the reaction was allowed to stir and warm to room temperature over 4 h. The 
reaction mixture was extracted with ethyl acetate (2 X 10 mL), dried over sodium sulfate and 
concentrated under vacuum. The crude mixture was purified preparative thin layer 
chromatography (9:1 dichloromethane:methanol) to yield 4 (7.6 mg, 29%) as a colorless solid. 1H 
NMR (500 MHz, Chloroform-d) δ 8.04 (d, J = 5.8 Hz, 1H), 7.52 – 7.42 (m, 1H), 7.40 (d, J = 2.0 
Hz, 1H), 6.72 (d, J = 8.4 Hz, 1H), 4.01 (d, J = 27.6 Hz, 7H), 3.85 (q, J = 5.6 Hz, 2H), 3.60 (d, J = 
12.3 Hz, 2H), 3.34 (t, J = 5.5 Hz, 2H), 2.96 (d, J = 23.9 Hz, 2H), 2.30 – 2.22 (m, 2H), 1.53 – 1.46 
(m, 2H), 1.45 – 1.36 (m, 2H), 0.90 (t, J = 7.3 Hz, 3H). 13C NMR (500 MHz, Chloroform-d) δ 
167.57, 139.67, 134.23, 125.62, 122.50, 119.64, 116.32, 111.19, 80.61, 72.55, 68.87, 67.19, 
64.69, 57.24, 53.52, 36.11, 34.37, 30.31, 22.06, 19.05, 13.64. HRMS (ESI+) m / z calc’d for 
C22H30N4O2 (M + H)+ 383.2447, found 383.2440. 
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Chapter 5 
 
Oxidation of Protein Disulfide Isomerase by 
LOC14 is neuroprotective1 
   
5.1 Introduction 
 Neurodegenerative disorders are a class of diseases that cause excessive neuronal 
death, often through formation of aggregates of misfolded proteins. Huntington’s Disease (HD) is 
one such disease that is specifically characterized by an increase in CAG repeats in the 
huntingtin gene that encode repeated glutamine residues. Though limited expansion of these 
polyglutamine regions can be tolerated, increased expansion past 36 Gln residues can lead to 
neuronal death, with increased expansion correlating with earlier onset of HD.2 Current 
treatments for HD are palliative—focusing on treating the symptoms of HD without addressing the 
fundamental mechanisms that lead to widespread neuronal death. Therefore, there exists an 
immediate need for therapeutics that reverse, prevent, or slow the death of neurons in HD. 
  Previous work in the Stockwell lab reported that inhibition of Protein Disulfide Isomerase 
(PDI) could prevent apoptotic cell death in models of HD.3 PDI is an oxidoreductase chaperone 
protein predominately found in the endoplasmic reticulum that oxidizes cysteine residues to form 
new disulfide bonds or reduces improperly created disulfide bonds to the corresponding thiols.4-5 
In this way, PDI acts as a key regulator of protein folding. The two catalytically active domains on 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
1 Portions of part 1 of this chapter are adapted from a published manuscript: Kaplan, A., 
Gaschler, M.M., Dunn, D.E., Colligan, R., Brown, L.M., Palmer III, A.G., Lo, D.C., Stockwell, B.R., 
Small Molecule-induced oxidation of protein disulfide Isomerase is neuroprotective, Proc. Natl. 
Acad. Sci., 2015, 122, E2245-2252 
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PDI oxidize and reduce cysteine residues using a highly conserved Cys-Gly-His-Cys sequence in 
the active site.  
PDI is upregulated in mouse models of, and in patients with neurodegenerative protein 
folding diseases.6-7 A persistent challenge in studying PDI has been the lack of selective, drug-
like small molecules that can inhibit PDI. Previous work in the Stockwell lab had identified the 
small molecule 16F16 as a covalent, irreversible inhibitor of PDI.3 Because irreversible inhibitors 
bind covalently and irreversibly to their target, they can completely eliminate all protein activity. 
PDI is an essential protein whose genetic knockout in mice caused embryonic lethality.8 We were 
therefore concerned that irreversible PDI inhibitors would have high toxicity and a very small 
therapeutic window, significantly limiting their ability to be translated into in vivo use. We 
hypothesized that a selective, reversible inhibitor of PDI could overcome these challenges and be 
better suited for in vivo use. Here we report the discovery of a novel, neuroprotective, reversible 
modulator of PDI that has nanomolar potency. Additionally, we explore the contribution of 
different functional groups to potency and activity through synthesis and evaluation of a set of 
LOC14 analgos. This new scaffold represents a new class of reversible modulators of PDI that 
can probe its potential as a new drug target for neurological diseases with misfolded proteins.    
5.2 Results 
5.2.1 High-throughput screen identifies LOC14 as an inhibitor of PDI 
To identify neuroprotective PDI modulators with drug-like properties Anna Kaplan in the 
Stockwell lab assembled a compound library with lead-optimized small molecules. Initially, a 
database of 3,372,615 commercially available small molecules (from Asinex, Life Chemicals, 
Enamine, TimTec, InterBioScreen and Chembridge suppliers) was compiled and stringently 
filtered computationally. The compounds were filtered to uphold Lipinski rule of five and molecular 
weight minimum of 235 Daltons; any compounds with noxious or reactive properties and water 
solubility less than 0.5 mM were eliminated. Strong emphasis was placed on compounds that will 
be suited for lead development, therefore potential nonspecific binders that might be acting as 
cationic and nonionic detergents were removed.  Scaffolds with more than five rotatable bonds 
and topological polar surface area larger than 70 Å2 were also eliminated to improve the 
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likelihood of blood-brain barrier penetration.  As a final step, the compounds were clustered 
based on their Tanimoto coefficient and only diverse subset was purchased. The final lead 
optimized compound (LOC) library contained 9,719 unique small molecules. 
 Anna Kaplan then carried out a phenotypic high throughput screening (HTS) assay for 
viability to identify neuroprotective PDI modulating compounds. Neuron-like PC12 cells stably 
transfected with an inducible plasmid for mutant huntingtin protein9 (mHTTQ103) were used for the 
screen because they previously showed reliance on PDI inhibition for survival from misfolded 
mHTTQ103 induced cell death.3  Each compound in the LOC library was screened in triplicate at 
three concentrations, 4 µg/ml, 1 µg/ml, and 0.25 µg/ml in order not to miss initially the compounds 
that were suppressing cell death at low concentration but had some toxicity at higher 
concentrations.  Alamar blue dye was used as a fluorescent readout for viability after 48 hours of 
compound treatment and mHTTQ103 induction.  The overall Zʹ factor for the screen was 0.78 with 
signal to noise ratio at 165.15 and coefficient of variation at 5.78%, indicating a robust assay for 
hit identification.10  Out of 9,719 compounds, nine compounds rescued PC12 HTTQ103 cells with at 
least 45% viability in the primary screen.  All the hit compounds were re-tested by Anna Kaplan in 
a two-fold dilution series and the viability curves of the eight compounds that reproducibly showed 
over 50% viability are shown in Figure 5.1A.  Out of these eight, three compounds had EC50 
values in the nanomolar range; two of them, LOC14 with EC50 of 500 nM and LOC9 with EC50 of 
600 nM were more potent than the irreversible neuroprotective PDI inhibitor 16F16 (EC50 1000 
nM) that was previously identified.3  
 Because neuroprotection of PC12 HTTQ103 cells can occur via additional pathways 
besides PDI modulation, e.g., broad caspase inhibition, all the hits from the cell based assay 
were counter screened for inhibition of PDI’s reductase activity using insulin and the recombinant 
catalytic a domain of human PDI A1 (referred in this chapter as PDIa), which can perform the 
same catalytic oxidation and reduction reactions as full length PDI.4 In this insulin aggregation 
assay11-12 PDIa reduces the two disulfide bonds between the alpha and beta chains of insulin 
causing the beta chain to aggregate and precipitate out of solution, resulting in an increase in 
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absorbance at 650 nm.  Out of eight hit compounds from the cell culture screen, only two, LOC14 
and LOC6, were able to almost completely inhibit PDIa enzymatic activity (Figure 5.1B).   
At this stage, LOC14 emerged as the most potent small molecule that could both rescue 
PC12 HTTQ103 cells and inhibit PDIa reductase activity; we therefore selected LOC14 as a lead 
compound for further analyses. 
5.2.2 Synthesis of LOC14 
 Following the identification of LOC14 as an inhibitor of PDI, we wished to confirm its 
identity and authenticate its activity through re-synthesis. A hazard of any high-throughput screen 
is the potential for molecules to be misidentified, leading to incorrect structural assignments of hit 
molecules. Other high-throughput screening programs against PDI conducted in our lab had 
already encountered such structural mis-annotations.13 To avoid these pitfalls and generate 
additional LOC14 for biological testing, we sought to synthesize additional LOC14. No synthesis 
Figure 5.1. Inhibition of PDI by LOC compounds. (A) Dose-response curves of three top 
hits that rescued PC12 cells from mHTTQ103-induced cell death as measured by alamar 
blue fluorescence after 48 h treatment. Viability from cells induced to express mHTTQ103 
(blue) and not expressing (red) are plotted as mean of percent of DMSO-treated cells 
±SD. (B) Secondary screen of the top three hits (75 µM) for their ability to inhibit the 
enzymatic activity of PDIa (5 µM) in an insulin aggregation assay. Data were gathered in 
triplicate and plotted as mean ± SEM. Data were gathered by Anna Kaplan, Figure 
adapted from Kaplan et al.1  
Figure 5.2. Synthesis of LOC14 
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of LOC14 had been reported, but other groups had reported the synthesis of similar molecules.14-
15 Following their basic reaction design, we found that LOC14 could be synthesized in one step in 
a Mannich-type reaction (Figure 5.2). This synthetic scheme proved to be robust and highly 
scalable. Running the reaction on a 5g scale improved the overall yield to 66%. Additionally, the 
reaction is compatible with multiple secondary amines (vide infra). The activity of the newly 
synthesized LOC14 was identical to the original sample used in high-throughput screening. 
5.2.3 The sulfur atom of LOC14 is necessary for interacting with PDI 
 One of the more striking structural features of LOC14 is the benzisothiazolinone 
heterocycle. Because the sulfur atom on benzisothiazolinone is somewhat electrophilic, it is 
susceptible to attack by biological nucleophiles. Generally, this behavior is considered 
undesirable since covalent modification of target proteins can lead to false hits in target-based 
screens. Consequently, compounds containing this moiety are often regarded as pan-assay 
interference compounds (PAINS).16 However, given the oxidoreductase mechanism of PDI, we 
hypothesized that the potential reactivity of LOC14 might be critical to the mechanism of PDI 
modulation. In the process of reducing improperly formed disulfide bonds, reduced PDI uses 
cysteine 36 in its active site to attack a disulfide bond in its substrate, forming a transient mixed 
Figure 5.3.  PDI Mechanism and LOC14 mechanistic hypothesis (A) Reduction of a 
substrate disulfide bond by PDI. (B) Mechanistic hypothesis for engagement of PDI by 
LOC14. 
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disulfide. Cysteine 39, a second cysteine in the active site of PDI, then attacks cysteine 36, 
liberating the substrate and oxidizing PDI (Figure 5.3A). Because of the electrophilicity of the 
sulfur atom on LOC14, we hypothesized that PDI might recognize LOC14 as a substrate (Figure 
5.3B).  
To evaluate this hypothesis, we investigated the binding mode of LOC14 to PDIa using 
isothermal titration calorimetry (ITC). ITC measures the heat released or absorbed during a 
biomolecular interaction.  It is a direct analytical method for determining binding and 
thermodynamic parameters, such as reaction stoichiometry (n), binding constants (Ka and Kd), 
enthalpy (∆H), entropy (∆S), and free energy (∆G) of an interaction. 
Calorimetric titration of LOC14 against PDIa showed exothermic binding (Figure 5.4) with 
a dissociation constant (Kd) of 61.7 ± 5.6 nM. The compound titration into buffer alone was 
subtracted from the raw binding data to account for the heat of dilution. The thermodynamic 
parameters plot (Figure 5.4) showed that the overall favorable affinity of LOC14 to PDIa is driven 
by both favorable (negative) enthalpic and entropic contributions. This finding indicates that likely 
both polar and hydrophobic interactions are contributing to LOC14 binding affinity to PDIa. 
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To test if the sulfur atom on LOC14 is important for interaction with the protein, we 
synthesized an isoxazolone analog of LOC14, termed Oxy-LOC14 and tested its binding affinity 
to PDIa. Oxy-LOC14 had 39-fold loss in binding affinity compared to LOC14 and a Kd of 2,430 ± 
760 nM by ITC (Figure 5.4). The thermodynamic parameters plot showed that Oxy-LOC14 had 
almost complete loss of its enthalpic binding component. This difference in the thermodynamic 
signatures due to a single atom substitution (sulfur to oxygen) indicated that the sulfur atom on 
LOC14 is necessary for favorable interactions with the protein. 
5.2.4 LOC14 is not an irreversible covalent modulator of PDI and oxidizes PDI in vitro. 
 Our mechanistic hypothesis (Figure 5.3B) additionally suggested that LOC14 would 
engage in a transient covalent interaction with PDI instead of a permanent covalent interaction.  
Figure 5.4. Binding profile of LOC14 and Oxy-LOC14 to PDI Calorimetric titration of 
(A) 400 µM LOC14 into 30 µM PDIa or (B) 400 µM Oxy-LOC14 into 40 µM PDIa. 
Upper panels show the raw data of the heat released; lower panels show the binding 
isotherm of the reaction. Data are fit to one-site binding model after subtracting the 
heat released from titrating the compound alone into buffer. One of three 
representative experiments is shown. (C) Summary of thermodynamic parameters for 
binding. Data are plotted as mean ± SD (n = 3). Data were gathered by Anna Kaplan, 
figure adapted from Kaplan et al.1 
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To investigate the mode of binding further and to determine whether the binding was reversible or 
irreversible, Anna Kaplan assessed LOC14-PDI reversibility. The fluorescence of the LOC14-
PDIa complex was analyzed before and after buffer dialysis. LOC14 has a distinct emission 
spectrum when excited at 280 nm that is different than the emission of PDIa alone, or from the 
LOC14-PDIa complex (Figure 5.5). If LOC14 binds irreversibly to the protein, then we would 
expect to see the same fluorescence spectrum of the LOC14-PDIa complex before and after 
dialysis in the dialysis chamber and none in the buffer compartment, assuming the fluorescence 
of LOC14 is not dramatically altered upon binding. LOC14 and PDIa were incubated together 
overnight (to allow for the maximum binding to occur in the case that LOC14 was a time-
dependent irreversible binder) and next day dialyzed with buffer four times using an Amicon Ultra 
Figure 5.5. LOC14 binds reversibly to PDI. Fluorescence emission spectra of 
LOC14, PDIa, or PDIa-LOC14 complex (A) before or (B, C) after size-exclusion 
buffer dialysis. For the dialysis 10 kDa size exclusion filter spin columns were used. 
Fluorescence emission spectra of (B) sample fractions larger than 10 kDa that were 
retained in the dialysis chamber or (C) those collected from the flow-through of 
dialysis.  All samples were excited at 280 nm and emission spectra recorded from 
315 nm – 550 nm.  Experiments preformed by Anna Kaplan, figure adapted from 
Kaplan et al.1 
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10 kDa cut-off size exclusion filtration device. As a control, samples that contained only PDIa or 
LOC14 were also used. The emission spectrum was recorded of samples from the flow-through 
and dialysis chamber. In the control samples, the fluorescence of LOC14 alone was observed 
only in the flow-through fraction while the fluorescence of PDIa alone was only observed in the 
dialysis compartment (Figure 5.5B and C) as was expected. Furthermore, their respective 
emission spectra were identical before and after the buffer exchange. The PDIa treated LOC14 
sample, however, showed different fluorescence profile before and after dialysis (Figure 5.5B and 
C). The emission spectrum in the dialysis chamber resembled the fluorescence spectrum of PDIa 
and the flow-through fraction resembled the fluorescence profile of LOC14. This illustrated that 
LOC14 binding to PDIa is reversible. 
 Additionally, our mechanistic hypothesis suggested that LOC14 should be able to induce 
the oxidation of PDI through formation of a disulfide bond within the active site. To examine this, 
Anna Kaplan performed 1H-15N heteronuclear single quantum correlation (HSQC) binding studies 
on the uniformly 15N-labled PDIa, with and without LOC14. Examination of the HSQC spectrum of 
Figure 5.6. LOC14 oxidizes PDI (A) Superimposed 1H-15N HSQC spectra of 50 µM 
oxidized PDIa alone (black) and 100 µM reduced PDIa treated with 100 µM LOC14 (red).  
Residue R80 (green circle) is the only peak that is different between the two spectra. (B) 
Calorimetric titration of 400 µM LOC14 into 40 µM oxidized PDIa. Upper panels show the 
raw data of the heat released; lower panels show the binding isotherm of the reaction. 
Data are fit to one-site binding model after subtracting the heat released from titrating the 
compound alone into buffer. Data gathered by Anna Kaplan; figure adapted from Kaplan 
et al.1 
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reduced PDIa incubated with LOC14 revealed that upon compound binding, PDIa adopts an 
oxidized conformation. This is evidenced by the perfect overlay between the HSQC spectrum of 
oxidized protein alone and the HSQC spectrum of reduced PDIa liganded with LOC14 (Figure 
5.6A). One major difference between these two, however, is seen in residue R80. The resonance 
peak for R80 is present in the oxidized PDIa HSQC spectrum, but disappears when the reduced 
PDIa is treated with LOC14. This is indicative of protein-ligand interaction. All other residues that 
disappear upon compound treatment of reduced PDIa such as W35, C36, G37, H38, also are 
absent in the oxidized protein HSQC spectrum. 
Calorimetric titration of LOC14 against oxidized PDIa showed a loss in binding affinity 
(compared to LOC14 titration into reduced PDIa) (Figure 5.6B). These data indicate that the 
presence of cysteine thiols on PDIa are important for the tight interaction with LOC14.  
Additionally, this reinforces that the observed HSQC shifts that reflect oxidative conformational 
change in PDIa are due to LOC14 binding. 
5.2.5 The amine moiety of LOC14 is not critical for binding and potency 
 Having validated the importance of the benzisothiazolinone moiety in LOC14 for activity 
we next sought to evaluate the contribution of the secondary amine moiety to LOC14. To this 
end, LOC14 analogs 1-9 were synthesized using the same general procedure used to synthesize 
Figure 5.7. Analogs of LOC14 
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LOC14 (Figure 5.7). Analogs 1 and 2 lacked the cyclopropyl amide and substituted the amide 
nitrogen for other heteroatoms that contained lone pairs of electrons. Analogs 3-5 similarly lacked 
the cyclopropyl amide functionality, but retained the nitrogen in the 4-position of the piperidine. 
Analogs 6-9 can be viewed as analogs where the polar group in the 4-position of the piperidine 
has been extended outside of the ring by one or two atoms.  
 Anna Kaplan evaluated these analogs for their ability to modulate PDI and their potency 
in suppressing cell death in mHTTQ103 induced PC12 cells. All compounds were able to prevent 
PDI-mediated precipitation of insulin in vitro, indicating that each molecule was able to 
functionally inhibit PDI activity. Evaluation of the dissociation constant for each analog and PDIa 
revealed that most analogs had a much weaker affinity for PDI compared to LOC14 (e.g. 2 and 
8), while the affinity of others did not change much (e.g. 1 and 9). The cellular potency did not 
show much variance, despite the variance in Kd and the structural diversity of the analogs. This 
suggests that the amine portion of LOC14 is not necessary for potency and is generally tolerant 
to high levels of structural diversity. 
 
5.3 Discussion 
Figure 5.8. Potency of LOC14 analogs. “Insulin Assay” refers to the ability of analogs to 
inhibit the enzymatic activity of PDIa (5 µM) in an insulin aggregation assay. 
Dissociation constant data were gathered by isothermal calorimetric titration (ITC) of 
400 µM LOC14 into 40 µM oxidized PDIa. Data are from one-site binding model after 
subtracting the heat released from titrating the compound alone into buffer. Cell viability 
data reflect the ability of analogs to rescue PC12 cells expressing mHTTQ103 as 
measured by alamar blue fluorescence after 48 h treatment. All data were gathered by 
Anna Kaplan. 
! 107!
 In this work we identified LOC14 as a potent modulator of PDI that can suppress cell 
death in a model of Huntington’s disease.  Using chemical synthesis we identified the importance 
of the benzisothiazolinone moiety on LOC14, suggesting a mechanism whereby LOC14 is 
recognized by PDI and effects the oxidation of PDI. In support of this hypothesis, we synthesized 
Oxy-LOC14, a LOC14 analog that lacks the sulfur atom critical for recognition and nucleophilic 
attack by PDI. This analog had a Kd 39-fold greater than LOC14. Subsequent thermodynamic 
analysis of the binding profile showed that Oxy-LOC14 interacted with PDI almost exclusively 
through entropic interactions while LOC14 relied on a combination of enthalpic and entropic 
interactions. We additionally found that LOC14 does not form an irreversible covalent bond with 
PDI. Reduced PDI treated with LOC14 also shows an HSQC spectrum that is identical to oxidized 
PDI. These data suggest that significant gains in potency could be made by further exploration of 
the benzisothiazolinone moiety. Adding electron donating or withdrawing groups to the aromatic 
ring could help tune the electrophilicity of the sulfur atom to optimize reactivity toward PDI.  
 We further showed that the amine portion of LOC14 is not a significant determinate of potency.  
 Exploration of the secondary amine moiety on LOC14 showed that it has a much greater 
impact on the Kd of the protein-ligand interaction than it does on the potency of cell rescue. Thus, 
changing the secondary amine portion of LOC14 is unlikely to furnish more potent analogs, but it 
may furnish analogs with other desirable properties including improved bioavailability, improved 
metabolic properties, or selectivity for PDI over other oxidoreductases . Many proteins in the 
oxidoreductase family have a similar mechanism to PDI—using nucleophilic cysteines to regulate 
disulfide bond formation—but have a unique substrate scope. In this way, the benzisothiazolinone 
moiety of LOC14 may be a necessary ‘warhead’ to engage PDI, but the secondary amine moiety 
may promote selectivity. Further exploration of this scaffold could help develop LOC14 analogs 
with improved selectivity. 
5.4 Methods 
Compound Synthesis. All commercial reagents were used without further purification. All 
solvents used were reagent or HPLC grade. All reactions were carried out in flame-dried 
glassware under a nitrogen atmosphere. Chemical yields refer to isolated, spectroscopically pure 
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compounds. Proton (1H) and carbon (13C) NMR spectra were recorded on a Bruker Avance III 
400 or 500 MHz spectrometer at ambient temperature.  Chemical shifts are recorded in parts per 
million relative to residual solvent CDCl3 (1H, 7.26 ppm; 13C, 77.16 ppm). Multiplicities are 
reported as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, comp m = 
complex multiplet, td = triplet of doublets.  
General synthetic procedure for the synthesis of LOC14 and analogs. Methanol (1 mL) and 
a 38% solution of formaldehyde in water (75 µL 1.2 eq.) were combined and stirred at room 
temperature. 1,2-Benzisothiazol-3(2H)-one (98 mg, 1 eq.) and the appropriate secondary amine 
(1 eq.) were then added and the solution was allowed to stir at room temperature until white 
solids precipitated, about one hour. These solids were collected via vacuum filtration and 
recrystallized from ethyl acetate and hexanes providing LOC14 or an analog as a powder.   
2-((4-(cyclopropanecarbonyl)piperazin-1-yl)methyl)benzo[d]isothiazol-3(2H)-one (LOC14). 
1H NMR (400 MHz, CDCl3) δ 8.037 (d, J = 8 Hz, 1H), 7.63 (t, J = 7.2 Hz, 1H), 7.55 (d, J = 8 Hz, 
1H), 7.397 (t, J = 7.2 Hz, 1H), 4.73 (s, 1H), 3.67 (bs, 4H), 2.73 (bs, 4H), 1.67 (m, 1H), 0.96 (m, 
2H), 0.74 (m, 2H); 13C NMR (500 MHz, CDCl3) δ 172.0, 166.3, 141.1, 132.2, 126.9, 125.6, 124.7, 
120.4, 65.7, 50.7, 50.2, 45.4, 42.1, 11.0, 7.5. 
2-((4-(cyclopropanecarbonyl)piperazin-1-yl)methyl)benzo[d]isoxazol-3(2H)-one (Oxy-
LOC14). 1H NMR (400 MHz, CDCl3) δ 7.83 (d, J = 8 Hz, 1H), 7.64 (t, J = 6 Hz, 1H), 7.30 (t, J = 8 
Hz, 1H), 7.23 (d, J = 8.4 Hz, 1H), 4.93 (s, 2H), 3.68 (bs, 4H), 2.78 (bs, 4H), 1.67 (m, 1H), 0.95 (m, 
2H), 0.74 (m, 2H); 13C NMR (500 MHz, CDCl3) δ 171.9, 163.4, 160.3, 133.69, 124.5, 123.6, 
115.94, 110.0, 67.136, 50.5, 50.0, 45.3, 42.0, 10.8, 7.42. 
2-(thiomorpholinomethyl)benzo[d]isothiazol-3(2H)-one (1) 
1H NMR (400 MHz, Chloroform-d) δ 8.03 (dt, J = 7.9, 1.0 Hz, 1H), 7.62 (ddd, J = 8.3, 7.1, 1.3 Hz, 
1H), 7.54 (dt, J = 8.1, 0.9 Hz, 1H), 7.40 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H), 4.70 (s, 2H), 3.04 – 2.97 
(m, 4H), 2.72 – 2.65 (m, 4H). 
2-(morpholinomethyl)benzo[d]isothiazol-3(2H)-one (2) 
1H NMR (400 MHz, Chloroform-d) δ 8.02 (dt, J = 7.9, 1.0 Hz, 1H), 7.66 – 7.47 (m, 2H), 7.37 (ddd, 
J = 8.0, 6.8, 1.2 Hz, 1H), 4.66 (s, 2H), 3.74 – 3.66 (m, 4H), 2.73 – 2.66 (m, 4H). 
! 109!
2-((4-methylpiperazin-1-yl)methyl)benzo[d]isothiazol-3(2H)-one (3) 
1H NMR (400 MHz, Chloroform-d) δ 8.02 (dt, J = 7.9, 1.0 Hz, 1H), 7.67 – 7.47 (m, 2H), 7.38 (ddd, 
J = 8.0, 6.9, 1.2 Hz, 1H), 4.69 (s, 2H), 2.76 (t, J = 4.9 Hz, 4H), 2.45 (s, 4H), 2.28 (s, 3H). 
2-((4-(4-acetylphenyl)piperazin-1-yl)methyl)benzo[d]isothiazol-3(2H)-one (4) 
1H NMR (400 MHz, Chloroform-d) δ 8.08 – 8.00 (m, 1H), 7.92 – 7.81 (m, 2H), 7.62 (ddd, J = 8.3, 
7.1, 1.3 Hz, 1H), 7.54 (dt, J = 8.1, 0.9 Hz, 1H), 7.40 (ddd, J = 8.1, 7.1, 1.0 Hz, 1H), 6.91 – 6.80 
(m, 2H), 4.76 (s, 2H), 3.42 – 3.34 (m, 4H), 2.91 – 2.83 (m, 4H), 2.50 (s, 3H). 
2-((4-(pyrimidin-2-yl)piperazin-1-yl)methyl)benzo[d]isothiazol-3(2H)-one (5) 
1H NMR (400 MHz, Chloroform-d) δ 8.28 (d, J = 4.7 Hz, 2H), 8.03 (ddd, J = 7.9, 1.3, 0.8 Hz, 1H), 
7.61 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 7.53 (dt, J = 8.1, 0.9 Hz, 1H), 7.39 (ddd, J = 8.1, 7.1, 1.1 Hz, 
1H), 6.46 (t, J = 4.7 Hz, 1H), 4.75 (s, 2H), 3.90 – 3.83 (m, 4H), 2.82 – 2.74 (m, 4H). 
2-(piperidin-1-ylmethyl)benzo[d]isothiazol-3(2H)-one (6) 
1H NMR (400 MHz, Chloroform-d) δ 8.03 (dt, J = 7.8, 1.0 Hz, 1H), 7.60 (ddd, J = 8.2, 7.0, 1.3 Hz, 
1H), 7.53 (dt, J = 8.1, 1.0 Hz, 1H), 7.38 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H), 4.67 (s, 2H), 2.71 – 2.63 
(m, 4H), 1.61 (q, J = 5.6 Hz, 4H), 1.44 (qd, J = 8.2, 7.1, 4.4 Hz, 2H). 
2-((4-hydroxypiperidin-1-yl)methyl)benzo[d]isothiazol-3(2H)-one (7) 
1H NMR (400 MHz, DMSO-d6) δ 7.90 (ddt, J = 25.4, 7.7, 0.9 Hz, 2H), 7.69 (ddd, J = 8.2, 7.1, 1.3 
Hz, 1H), 7.43 (ddd, J = 8.0, 7.1, 1.0 Hz, 1H), 4.64 – 4.53 (m, 3H), 3.43 (dq, J = 8.9, 4.5 Hz, 1H), 
2.82 (dd, J = 11.0, 5.3 Hz, 2H), 2.42 – 2.27 (m, 1H), 2.34 (s, 1H), 1.77 – 1.65 (m, 2H), 1.47 – 1.29 
(m, 2H). 
2-((4-(hydroxymethyl)piperidin-1-yl)methyl)benzo[d]isothiazol-3(2H)-one (8) 
1H NMR (400 MHz, Chloroform-d) δ 8.03 (ddd, J = 7.9, 1.3, 0.8 Hz, 1H), 7.65 – 7.50 (m, 2H), 7.39 
(ddd, J = 8.0, 7.0, 1.1 Hz, 1H), 4.69 (s, 2H), 3.50 (d, J = 6.3 Hz, 2H), 3.10 – 3.01 (m, 2H), 2.40 
(td, J = 11.7, 2.6 Hz, 2H), 1.79 – 1.71 (m, 2H), 1.55 – 1.41 (m, 1H), 1.30 (qd, J = 12.1, 3.8 Hz, 
2H). 
tert-butyl (1-((3-oxobenzo[d]isothiazol-2(3H)-yl)methyl)piperidin-4-yl)carbamate (9) 
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1H NMR (300 MHz, Chloroform-d) δ 8.03 (dt, J = 7.8, 1.0 Hz, 1H), 7.66 – 7.51 (m, 2H), 7.39 (ddd, 
J = 8.0, 6.9, 1.2 Hz, 1H), 4.67 (s, 2H), 4.43 (s, 1H), 3.45 (s, 1H), 2.95 (dd, J = 10.2, 5.9 Hz, 2H), 
2.49 (td, J = 11.5, 2.7 Hz, 2H), 2.00 – 1.84 (m, 2H), 1.66 (d, J = 13.4 Hz, 1H), 1.42 (s, 9H). 
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Chapter 6 
 
Toward the development of a small molecule 
inhibitor of the GTPase Rheb 
  
6.1 Introduction 
 Autophagy is a program of self-digestion used by cells to maintain nutrient homeostasis 
and sustain critical metabolic processes in times of starvation. Autophagy is therefore intricately 
linked with cellular growth and proliferation and has attracted significant study in the context of 
cancers.1 The role of autophagy in cancers is context-dependent; autophagic digestion of 
damaged or oncogenic proteins can help prevent cancer initiation and proliferation. More 
frequently, activation of autophagy can provide resistance to stress conditions, and support the 
metabolic demands of rapidly proliferating cells. In this context, inhibition of autophagy can 
enhance sensitivity chemotherapeutic agents or can enhance tumor cell death on its own.2  
 The mTOR kinase regulates autophagy and cell `growth by nucleating two large multi-
protein complexes mTORC1 and mTORC2.3 Each of these complexes has a unique set of 
upstream regulators and downstream phosphorylation targets. mTORC1 is dysregulated in a 
number of cancers including those with hyperactive PI3K, inactive PTEN, or inactive TSC 1/2 
tumor suppressors;4 consequently, much effort has gone into inhibiting the activity of mTORC1. 
Current molecules that inhibit mTORC1, some of which have been approved as anti-cancer 
therapeutics by the FDA, fall into one of three categories: rapamycin and its analogues, dual 
mTOR/PI3K active site inhibitors, and ATP-competitive inhibitors.5 The success of each class of 
molecule has been limited due to incomplete inhibition of mTORC1 signaling and/or an inability to 
inhibit mTORC1 without inhibiting other kinases such as mTORC2.5-6 Recent data suggest that 
rapamycin mediated mTORC2 inhibition causes some of its undesirable side effects such as 
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hyperglycemia.7 There does not yet exist a molecule capable of strongly and selectively inhibiting 
mTORC1 mediated signaling. 
Rheb is a small GTPase that is necessary for the activation of mTORC1.8-10 When loaded 
with GDP Rheb is inactive; when loaded with GTP Rheb will activate mTORC1 through a β-sheet 
mediated protein-protein interaction (PPI). Conventional drugs and bioactive molecules target 
protein active sites—deep pockets within a protein. Proteins with active sites are considered to be 
‘druggable’, but only comprise approximately 15% of the genome.11 The remainder of the gene 
products enage in PPIs. PPIs have traditionally been considered undruggable due to the large 
surface area of interaction and the lack of an active site capable of binding a small molecule. 
Recent work12, particularly recent success in developing an inhibitor of the related GTPase 
RAS,13 has challenged this dogma significantly. Development of a small molecule that inhibited 
the PPI between Rheb and mTORC1 would furnish a compound capable of potently and 
selectively inhibiting mTORC1 alone since Rheb does not activate mTORC2 or any other 
protein.14 Furthermore, given the difficulty in targeting PPIs with small molecules, developing a 
reliable strategy for discovering compounds with activity against PPIs could facilitate the 
discovery of additional molecules that target PPIs. 
Though increasingly tractable, the difficulty in inhibiting PPIs means that a traditional high 
throughput biochemical screen would likely not return any active compounds. Instead, this work 
relies on an integrated in silico-biophysical-biochemical fragment based drug design strategy. In 
the first portion, sites on the protein that are both responsible for biological activity and amenable 
to small-molecule binding (even if the interaction would be very weak) are identified. Next, a 
library of fragments is screened for their ability to bind at these sites in silico. The best scoring 
potential ligands are then screened for their ability to bind the target protein in vitro. Herein, this 
strategy was used to make progress toward discovering a small molecule inhibitor of Rheb. Such 
a molecule will be useful in interrogating the role of Rheb/mTORC1 in disease and represent the 
first selective inhibitor of mTORC1.  
6.2 Results 
6.2.1 Protein structure and binding site selection 
! 113!
 A three-dimensional structure of the target protein is required for any in silico drug 
discovery effort.  Only one structure of human Rheb in its active conformation (GTP-bound) has 
been published and made available (PDB: 1XTS).15 Unfortunately, no crystal structure of Rheb in 
complex with any portion of mTORC1 exists. However, mutagenesis studies have implicated 
residues in the Switch 1 and 2 segments of Rheb as critical for mTORC1 activation (Figure 6.1). 
Mutation of critical residues in either of these regions results in an inability of Rheb to activate 
mTORC1.8, 16-17 These data suggest a surface area of interaction between Rheb and mTORC1 
and a logical site to dock a ligand. We computationally evaluated the ability of this area of the 
protein to bind ligands using the DScore program from Schrödinger Inc. This program measures 
features of a potential ligand-binding site such as curvature and solvent exposure to quantify the 
ability of the site to bind a generic ligand. The site between the switch regions scored very poorly 
and was not predicted to bind a ligand well. This prediction was reinforced by preliminary ligand 
Figure 6.1. Structure of Rheb. Rheb is shown as a ribbon (left) and an electrostatic surface 
(right). The switch 1 (turquoise) and switch 2 (purple) regions are critical for interaction with 
mTORC1.  
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docking experiments that failed to produce any compounds that had significant predicted affinity 
for this region (data not shown). To interrogate this area further, a 5 ns molecular dynamics 
simulation of GTP-loaded Rheb was run using Desmond18 and 15 structures of Rheb from 
evenly-distributed timepoints through the simulation were isolated and computationally evaluated 
for their ability to bind a ligand. Of these, frame 350 was predicted by DScore (Schrödinger Inc.) 
to have the greatest ability to bind a ligand in the inter-switch region. To gain additional 
confidence that the structure of frame 350 was not an artifact of one molecular dynamics 
simulation, three 25 ns molecular dynamics simulations were run. The distance between residues 
that defined the pocket in frame 350 were measured in these new simulations and compared to 
the distances from frame 350 (Figure 6.2). In most cases, the simulations spent appreciable time 
in conformations that resembled frame 350. 
 
6.2.2 Library construction and in silico docking 
 Having developed a protein structure that would serve as a receptor for in silico ligand 
docking, we next assembled a library of chemical compounds. To facilitate rapid testing of 
compounds, we populated our library with molecules that were commercially available from 
chemical vendors. Combining the libraries of nine vendors yielded a library of approximately 5 
million small molecules.  This group of 5 million molecules was then filtered to exclude any 
molecules that did not satisfy Lipinski’s rule of 5: LogP less than 5, fewer than 6 hydrogen bond 
donors, fewer than 11 hydrogen bond acceptors, and molecular weight less than 500 Daltons. 
Next, molecules were filtered for favorable physical properties: solubility greater than 0.5 mM in 
Figure 6.2. Distances between residues that define the binding site on Rheb. Three 
independent molecular dynamics simulations were run (blue, red, green) and the 
distances between the indicated residues was measured. Dashed horizontal line 
represents the inter-residue distance from frame 350.  
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water, topological polar surface area <140 Å2, and fewer than 7 rotatable bonds. At this stage any 
non-unique compounds were also eliminated. Lastly, toxic and reactive groups were removed, 
leaving 1.6 million unique compounds.  
 To evaluate these compounds against Rheb, we used the Glide docking algorithm 
developed the Friesner lab and available through Schrödinger Inc.19 Glide is a rigid receptor 
algorithm that flexibly docks each ligand into the receptor protein. For each ligand, a fast 
conformational search is preformed to identify promising poses. Next, any ligand in a ‘good’ pose 
!Q64!
!R15!
Figure 6.3. The Q64 and R15 ligand-binding sites on Rheb. Surface 
representation corresponds to solvent exposure: solvent exposed surfaces are 
in gray, hydrophilic areas are shown in red and hydrophobic areas are in blue. 
Increasing color intensity corresponds to greater invagination. 
Figure 6.4.  Best-scoring scaffolds. Example commercially available 
scaffolds that docked into the Q64 and R15 sites and their 
corresponding glide scores. 
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is energetically minimized in the receptor using molecular mechanics followed by Monte Carlo 
minimization of torsional angles. Compounds are then assigned a score, with increasingly 
negative scores corresponding to increasingly strong receptor-ligand interactions. Though scores 
do not correspond strictly to potency values, the experience of former lab members indicates that 
a score of -8 is the approximately the highest score where biological activity can be observed.  
 Frame 350 of Rheb showed two pockets close to one another that were both predicted to 
have modest affinity for a small molecule ligand. The larger site was centered on glutamine 64 
(hereafter, the Q64 site) and the second, smaller site was centered on arginine 15 (hereafter, the 
R15 site) (Figure 6.3). The 1.6 million compounds were docked into both the Q64 and R15 site. 
No ligand generated a score less than -8 in either site. However, analysis of the best scoring 
compounds in each site showed an enrichment of certain drug-like (‘privileged’)  scaffolds.20 The 
Q64 site showed an enrichment of quinazolinone-containing compounds while the R15 site 
showed an enrichment in 2-quinolones (Figure 6.4).  Though no single compound had a glide 
score that indicated that it would have observable biological activity at the intended target, the 
proximity of the two sites suggested that the molecules could be linked to form a single larger 
molecule that associated with both sites simultaneously. This type of multivalent approach had 
previously been successful in developing an inhibitor of RAS proteins.13 Given the homology 
between RAS and Rheb, I reasoned it might be effective in targeting Rheb as well. Linking these 
compounds with an aliphatic amide linker generated compounds that were predicted to bind both 
sites on the surface of Rheb and had Glide scores that merited biological evaluation (Figure 6.5). 
Lead compounds were chosen for their rapid synthetic accessiblity and their reproducibly good 
Glide scores. 
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6.2.3 Ligand Synthesis 
 Because iterative rounds of in silico ligand design and optimization had navigated the 
lead compound series (Figure 6.5) away from commercially available compounds, it was 
necessary to synthesize the compounds in-house.  In anticipation of this, the lead compounds 
had been designed to be easily synthetically accessible and synthesizable in a highly modular 
(parallelized) manner to allow rapid access to chemical analogs (figure 6.6).  The Quinazolinone 
core could be synthesized in two steps starting form an appropriately substituted anthranilamide 
derivative.  Treatment with an acid chloride gave the acylated anthranilamide. Cyclization to the 
quinazolinone and SN2 substitution with an appropriate benzylamine could be achieved in a 
single flask under reflux conditions. Certain analogs of the 2-quinoline moiety, such as the one in 
MMG542, were commercially available. Others could be synthesized in a short sequence, starting 
from an appropriately substituted aniline followed by acylation with cinnamoyl chloride. 
Cyclization, methyl deprotection, and debenzylation could all be effected by stirring with a 
stoichiometric excess of aluminum chloride at high temperature.  Linking these two key moieties 
was achieved in two steps. First, SN2 alkylation of the 2-quinoline with a halogenated ester 
Figure 6.5. Linked Q64-R15 compounds and their Glide scores (left). Predicted binding 
pose of MMG-590 in frame 350 of Rheb (right). 
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followed by hydrolysis afforded a carboxylic acid intermediate. This intermediate could be coupled 
to the quinazolinone moiety in high yield using conventional EDC coupling conditions.  
6.2.4 In Vitro evaluation of compound binding to Rheb 
 The ability of these compounds to associate with Rheb was first tested in an in vitro 
context.  As the assays we planned to use for this testing required purified Rheb protein, we first 
developed a plasmid to express histidine (His)-tagged Rheb protein in E. coli following treatment 
with isopropyl β-D-1-thiogalactopyranoside (IPTG). The DNA sequence encoding Rheb was 
codon-optimized for bacterial expression and ordered from Integrated DNA Technologies, Inc.  
This gene was inserted into a Pet15b bacterial expression vector using a Gibson Assembly. 
Expression and purification from bacteria was expected to give a mixture of Rheb loaded with 
both GTP and GDP. To ensure the proper nucleotide loading state, purified Rheb was loaded 
with 5'-Guanylyl imidodiphosphate, a non-hydrolyzable GTP analogue that replaces the oxygen of 
Figure 6.6. General synthetic scheme for putative Rheb ligands. Major synthons are 
shown in red, blue, and green (top). 
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the terminal phosphoanhydride moiety with a nitrogen atom, making the molecule significantly 
less prone to hydrolysis.21 
  We used microscale thermophoresis (MST) as an initial method to test for molecule 
binding to Rheb. MST is a fluorescence-based technique that measures the thermophoretic 
movement of fluorescently tagged proteins along a thermal gradient. The amount of this 
movement is dependent on the hydration shell surrounding the protein.22 Therefore when a ligand 
binds to a protein, the amount of thermophoretic movement changes. By measuring this change 
over a series of increasing concentrations of ligand, a dissociation constant for the ligand-protein 
interaction can be computed.13, 22-23 Ligands MMG596 and MMG590 showed apparent 
micromolar binding by MST (Figure 6.7). 
 To validate these data, we sought to evaluate the binding of these ligands through an 
orthogonal technique. One high precision technique to evaluate the interaction between a protein 
and a ligand is isothermal titration calorimetry (ITC). ITC measures the change in heat from ligand 
binding and can determine the thermodynamic parameters of interaction. Though it consumes a 
large amount of protein, it is a label free technique that uses near-native conditions. Titration of 
ligands MMG596 or MMG590 into Rheb caused no significant heat release, indicating that these 
ligands do not bind to Rheb (Figure 6.8).! 
Figure 6.7.  Ligand binding to Rheb by MST. Fluorescently labeled 
Rheb was incubated with the indicated concentration of the 
appropriate ligand. Data are plotted as the percent change in the 
fluorescence intensity from thermophoretic movement. 
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6.3 Discussion  
 In this section we sought to develop a small molecule capable of specifically inhibiting the 
interaction between Rheb and the master regulator of autophagy, mTORC1. Using in silico 
molecular design to develop molecules is an attractive approach for targeting proteins not easily 
amenible to conventional modes of small molecule inhibition; namely, proteins like Rheb that 
exert their function through protein-protein interactions (PPIs). A particualrly advantageous 
feature of in silico discovery protrams is that they can screen orders of magnitude more 
molecules against a target than conventional high-throughput techniques in only a fraction of the 
time. Even so, this effort did not yield any ligands with reliably observable binding in vitro. This is 
perhaps an unsurprising outcome as the difficulty in drugging PPIs arises from physical chemical 
properties of the interactions rather than limitations in our current screening technologies.   
 All in silico target-based approaches to drug discovery require a high quality structure of 
the target being studied. In this work, in silico docking studies fundamentally relied on a structure 
of Rheb generated by molecular dynamics simulations—a very uncommon approach. Though 
Figure 6.8. Isothermal titration calorimetry data of MMG596 associating with Rheb. 
(A) Binding isotherm of buffer titrated into buffer (green), buffer titrated into Rheb 
(blue), and MMG596 (320 µM) titrated into Rheb (3.2 mM) (black). (B) Raw data of 
titration.  
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efforts were made to ensure that the structure of frame 350 was reproducible, it remains unclear if 
frame 350 was a conformation that occurred in biological systems. Molecular dynamics is a 
promising approach to offer new routes for ligand docking into a protein, but future efforts will 
likely require more rigorous approaches. Specifically, clustering and averaging conformations 
arising from MD simulations can help eliminate conformations that are not frequently observed. 
Similarlly, biophysical tehcniques that can operate in parallel with computational work and 
allowintial “hit” fragments—even ones that engage very weak interactions—to be evaluated for 
their binding ability will be crucial. Techniques such as HSQC offer a way to monitor protein-
ligand interactions rapidly and can help confirm that fragments are interacting with the appropriate 
residues on a protein.  
 Finally, though these in silico ligand screening attempts failed to generate a potent ligand 
for Rheb, computer-aided drug design could still play a significant role in any future effort to 
design a Rheb inhibitor. A limitation of this project was the lack of co-crystal structures of Rheb 
with any of its effector proteins. Though mutagenisis studies have identified which residues are 
important to signalling, a three-dimensional strcuture of Rheb in complex with an effector protein 
would permit a more informed analysis. Specifically, a co-crystal structure would not only show 
how each residue engages the effector, but would also reveal a conformation of Rheb that is 
relevant to its biological activity. Docking studies could use this binding conformation to screen 
ligands, Additionally, a solved structure of Rheb and one of its effector proteins could allow for the 
generation of a phamacophore, allowing virtual structures to be screened for their ability to meet 
certain validated and favorable criteria for binding the protein. In this work, the top-scoring 
compounds from commericial libraries required structural elaboration to achieve high predicted 
potency. In future studies, a detailed pharmacophore based off of a Rheb-effector protein 
cocrystal structure could help guide any structural elaboration of commerical hits. Further 
biophysical charactariztion of Rheb will enable more advanced and rigorous computational 
techniques for drug design and discovery.  
6.4 Methods 
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Software Molecular docking was preformed using GLIDE, and molecular dynamics simulations 
were preformed using Desmond (version 2014, Schrödinger). Molecular database management, 
including commercially available compound libraries, and ligand-protein interaction libraries were 
managed using Molecular Operating Environment (MOE) (Chemical Computing Group). 
Bacterial transformation BL21-Gold (DE3) E. Coli cells were thawed on ice and 100 µL was 
aliquotted into a sterile 14 mL tube. 50 ng of pET-15b plasmid containing His-tagged Rheb DNA 
was added to the tube and allowed to incubate on ice for 30 minutes. The tube was then heat-
shocked at 42 ºC for 25 seconds, and then placed on ice for 2 minutes. 1 mL of Luria Broth 
containing no antibiotics was added to the tube, and the tube was incubated with shaking (225 
RPM) at 37 ºC for 1 h. 50 µL of the bacterial culture was then streaked onto a LB-agar plate 
containing ampicillin (100 µg/mL) and incubated at 37 ºC overnight.  
Protein expression A single colony from a plate containing appropriately transfected bacteria 
was picked and placed into a tube containing 7 mL Luria Broth with ampicillin (100 µg/mL) and 
incubated at 37 ºC 4.5 h with shaking (225 RPM). Add equal portions of this culture to two 2 L 
flasks containing 1 L of LB-amp each. Incubate at 37 ºC with shaking (225 RPM) until the optical 
density is between 0.6 and 1 (usually 4-6 h). Lower the temperature to 15 ºC, maintain shaking 
and let temperature equilibrate for 1 h. Induce protein expression by adding isopropyl β-D-1-
thiogalactopyranoside (IPTG) to a final concentration of 1 mM. Let incubate for 15 h. Following 
incubation, centrifuge cultures at 4000 RPM for 20 m at 4 ºC and discard supernatant. 
Protein Purification Resuspend pelleted bacteria in suspension buffer (50 mM sodium 
phosphate, 500 mM NaCl, 1 mM TCEP, pH 7.6. Add 1 protease inhibitor tablet for every 50 mL at 
time of use). Lyse cells by sonication on ice (amplitude 45, 2 s on, 1 s off, 6X1 min). Centrifuge 
suspension at 15,000 RPM for 45 m at 4 ºC. Mix equilibrated Ni-sepharose beads with the 
supernatant from centrifugation for 1 h. Load this slurry onto a column and collect the flow-
through. Elute with elution buffer A (suspension buffer + 20 mM imidazole) to elute any non-
specifically bound proteins. Elute His-tagged protein by elution with Elution buffer B (Suspension 
buffer + 250 mM imidazole). 
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Nucleotide exchange Rheb was diluted in buffer (25 mM tris, 100 mM NaCl, and 1 mM TCEP) to 
a final concentration of 65 µM. EDTA and GppNHp were added to a final concentration of 5 mM, 
and incubated at 4 ºC for 4 hours. MgCl2 was added to a final concentration of 65 mM. Protein 
was then concentrated using a size-exclusion spin filter.  
Microscale thermophoresis GppNHp-loaded Rheb was diluted to a final concentration of 10 µM 
in 200 µL buffer (25 mM Tris, 100 mM NaCl, 5 mM MgCl2, 1 mM TCEP). This solution was 
combined with 200 µL of a 20 µM NT-647-NHS ester dye (from 652.5 µM DMSO stock; 
NanoTemper) and incubated in the dark for 45 m, at 4 ºC. Excess dye was removed and the 
labeled protein was buffer-exchanged into MST buffer using a NAP-5 column. MST buffer 
consisted of 25 mM Tris, 100 mM NaCl, 5 mM MgCl2, 1 mM TCEP, and 0.1% Tween 20. 
Compounds diluted in a 12-point, 2-fold dilution series in 1.5% DMSO and MST buffer. 
Compounds were mixed with an equal volume of protein solution, loaded into standard capillaries 
and measured using 90% MST power and 80% LED power. Thermophoretic movement was 
preformed with a Monolith NT.115 (Nanotemper technologies). 
Isothermal titration calorimetry (ITC) GppNHp-loaded Rheb was added to the cell at a 
concentration of 3.2 mM, and the ligand was added to the syringe at a concentration of 320 µM, 
both in ITC buffer: 25 mM tris, 100 mM NaCl, 5 mM TCEP, and 0.05% Tween-20. Ligands were 
added into buffer as a solution in 100% DMSO with the final concentration of DMS in the syringe 
at 1.5%. To avoid observing dilution effects of DMSO, an appropriate volume of DMSO was 
added to the cell to reach a final concentration of 1.5%. ITC titration experiments were carried out 
at 25 ºC with 19 injections, 2 µL per injection, and 180 s between each injection. Reference cell 
power was set to 5 µcal/s. Control experiments were performed in which ITC buffer was titrated 
into buffer or protein alone to account for heat released due to dilution. All ITC experiments were 
carried out on a MicroCal Auto-ITC200 system (GE Health care). 
Compound synthesis 
General Procedures. All commercial reagents were used without further purification. All solvents 
used were reagent or HPLC grade. Chemical yields refer to isolated, spectroscopically pure 
compounds. 1H and 13C NMR spectra were recorded on a 400 or 500 MHz spectrometer (as 
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indicated) at ambient temperature.  Chemical shifts are recorded in parts per million relative to 
residual solvent CDCl3 (1H, 7.26 ppm; 13C, 77.16 ppm) or (CD3)2SO (1H, 2.50 ppm; 13C, 39.52 
ppm) . Multiplicities are reported as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = 
multiplet, comp m = complex multiplet, dd = doublet of doublets, ddd = doublet of doublets of 
doublets, td = triplet of doublets. Liquid chromatography was preformed on a CombiFlash Rf 
system (Teledyne Isco). Preparative thin layer chromatography was performed on plates coated 
with 1 mm silica gel. 
General procedure for anthranilamide acylation. A solution of appropriately substituted 
anthranilamide (22 mmol) in dioxane (35 mL) was cooled to 0 ºC on an ice bath. To this solution 
was added potassium carbonate (26 mmol) and chloropropionyl chloride (26 mmol). The ice bath 
was removed and the reaction was allowed to stir and return to room temperature over three 
hours. Product was precipitated from water and collected by filtration, pure to NMR without further 
purification.  
2-(3-chloropropanamido)benzamide 53%, 1H NMR (400 MHz, Chloroform-d) δ 11.34 (s, 
1H), 8.64 (dt, J = 8.2, 1.0 Hz, 1H), 7.58 – 7.45 (m, 2H), 7.10 (td, J = 7.6, 1.2 Hz, 1H), 
6.15 (s, 1H), 5.79 (s, 1H), 3.88 (t, J = 6.6 Hz, 2H), 2.87 (t, J = 6.6 Hz, 2H). 
4-chloro-2-(3-chloropropanamido)benzamide 93%, 1H NMR (400 MHz, Methanol-d4) δ 8.59 (s, 
1H), 7.76 (d, J = 8.6 Hz, 1H), 7.17 (d, J = 8.6 Hz, 1H), 3.89 (t, J = 6.4 Hz, 2H), 3.68 (s, 0H), 3.34 
(s, 1H), 2.90 (t, J = 6.4 Hz, 2H). 
General Procedure for one-pot quinazolinone cyclization and SN2 reaction Acylated 
anthranilamide (3.3 mmol) was dissolved in acetonitrile (15 mL). Substituted benzylamine (6.6 
mmol), potassium carbonate (4.9 mmol), and sodium iodide (0.23 mmol) were added, and the 
mixture was brough to reflux and stirred overnight. The reaction was partitioned between water 
and dichloromethane (20 mL each), and the aqueous later was extracted with 2 more volumes of 
dichloromethane. Combined organic layers were dried over sodium sulfate, decanted and 
! 125!
reduced under vacuum. The crude mixture was purified using a gradient of 0!15% methanol in 
dichloromethane. 
2-(2-((benzo[d][1,3]dioxol-5-ylmethyl)amino)ethyl)quinazolin-4(3H)-one 20%, 1H NMR (400 
MHz, Chloroform-d) δ 8.27 (dd, J = 8.0, 1.6 Hz, 1H), 7.71 (ddd, J = 8.5, 7.1, 1.6 Hz, 1H), 7.68 – 
7.58 (m, 1H), 7.43 (ddd, J = 8.2, 7.1, 1.2 Hz, 1H), 6.88 (d, J = 1.6 Hz, 1H), 6.87 – 6.73 (m, 2H), 
5.95 (s, 2H), 3.82 (s, 2H), 3.12 – 3.05 (m, 2H), 2.88 – 2.80 (m, 2H). 
2-(2-((benzo[d][1,3]dioxol-5-ylmethyl)amino)ethyl)-7-chloroquinazolin-4(3H)-one 33%, 1H 
NMR (400 MHz, Chloroform-d) δ 8.18 (d, J = 8.5 Hz, 1H), 7.60 (d, J = 2.0 Hz, 1H), 7.37 (dd, J = 
8.5, 2.0 Hz, 1H), 6.91 – 6.71 (m, 3H), 5.95 (s, 2H), 5.30 (s, 1H), 3.82 (s, 2H), 3.12 – 3.04 (m, 2H), 
2.86 – 2.78 (m, 2H). 
2-(2-((3,4-dimethoxybenzyl)amino)ethyl)quinazolin-4(3H)-one 33%,  1H NMR (400 MHz, 
Chloroform-d) δ 8.25 (ddd, J = 7.9, 1.6, 0.6 Hz, 1H), 7.71 (ddd, J = 8.5, 7.1, 1.6 Hz, 1H), 7.61 
(ddd, J = 8.2, 1.2, 0.6 Hz, 1H), 7.43 (ddd, J = 8.1, 7.1, 1.2 Hz, 1H), 6.98 (d, J = 1.9 Hz, 1H), 6.94 
– 6.81 (m, 2H), 3.96 (s, 3H), 3.86 (d, J = 5.4 Hz, 5H), 3.15 – 3.07 (m, 2H), 2.89 – 2.81 (m, 2H). 
For MMG542 Synthesis 
N-(benzo[d][1,3]dioxol-5-ylmethyl)-4-chloro-N-(2-(4-oxo-3,4-dihydroquinazolin-2-
yl)ethyl)butanamide To 25 mL of dioxane at 0 ºC was added 2-(2-((benzo[d][1,3]dioxol-5-
ylmethyl)amino)ethyl)quinazolin-4(3H)-one ( 2.93 mmol), potassium carbonate (4.4 mmol), 
and 4-chlorobutyryl chloride (4.4 mmol). This was allowed to stir for 5 h, while warming to room 
temperature. The reaction was diluted with dichlormethane (20 mL) and an equal volume of water 
was added. The organic phase was dried over sodium sulfate and reduced under vacuum. The 
crude mixture was purified using a gradient of 0 ! 10% methanol in dichlormethane. 63%, 1H 
NMR (400 MHz, Methanol-d4) δ 8.17 (dd, J = 8.1, 1.6 Hz, 1H), 7.85 – 7.75 (m, 1H), 7.65 (t, J = 
9.2 Hz, 1H), 7.55 – 7.45 (m, 1H), 6.76 – 6.62 (m, 3H), 5.89 (d, J = 8.9 Hz, 2H), 4.56 (d, J = 10.8 
Hz, 2H), 3.86 (dt, J = 22.3, 6.7 Hz, 2H), 3.61 (t, J = 6.4 Hz, 1H), 3.51 (t, J = 6.4 Hz, 1H), 2.93 (dt, 
J = 15.7, 6.8 Hz, 2H), 2.72 (t, J = 7.2 Hz, 1H), 2.56 (t, J = 7.1 Hz, 1H), 2.18 – 2.03 (m, 1H), 1.97 
(p, J = 6.7 Hz, 1H). 
N-(benzo[d][1,3]dioxol-5-ylmethyl)-4-((2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)oxy)-N-(2-(4-
oxo-3,4-dihydroquinazolin-2-yl)ethyl)butanamide (MMG542) Sodium hydride (0.25 mmol) was 
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added to DMF (3 mL) and 7-Hydroxy-1,2,3,4-tetrahydro-2-quinolinone (0.16 mmol, Sigma) was 
added in one portion. Primary chloride was added, and the mixture was stirred 1 h at room 
temperature. Reaction was partitioned between dichloromethane and water (10 mL each). The 
crude mixture was purified by preparative chromatography (15% methanol in ethyl acetate). 36%, 
1H NMR (400 MHz, Methanol-d4) δ 8.15 (dd, J = 8.0, 1.5 Hz, 1H), 7.76 (dddd, J = 8.5, 7.0, 5.3, 
1.6 Hz, 1H), 7.61 (dd, J = 12.0, 8.2 Hz, 1H), 7.53 – 7.42 (m, 1H), 7.05 – 6.96 (m, 1H), 6.73 – 6.57 
(m, 3H), 6.52 – 6.33 (m, 2H), 5.87 (d, J = 1.8 Hz, 2H), 4.56 (d, J = 3.5 Hz, 2H), 3.99 – 3.79 (m, 
4H), 3.35 (s, 1H), 2.97 – 2.80 (m, 5H), 2.61 – 2.46 (m, 3H), 2.10 (q, J = 6.6 Hz, 1H), 2.04 – 1.92 
(m, 1H), 1.32 – 1.20 (m, 1H). 
2-Quinolone synthesis 
N-(3-methoxyphenyl)cinnamamide To a solution of m-Anisidine (18 mmol) in water/acetone 
(36/18 mL) was added potassium carbonate (27 mmol) and cinnamoyl chloride (19.57 mmol). 
The mixture was stirred for 30 m and poured into excess water, precipitating product. This was 
collected by filtration and dried. Powder was sufficiently pure without further purification. 94%, 1H 
NMR (400 MHz, DMSO-d6) δ 10.17 (s, 1H), 7.61 (s, 1H), 7.67 – 7.53 (m, 1H), 7.51 – 7.35 (m, 
4H), 7.30 – 7.17 (m, 2H), 6.82 (d, J = 15.7 Hz, 1H), 6.66 (dt, J = 6.1, 2.8 Hz, 1H), 3.75 (s, 3H). 
7-hydroxyquinolin-2(1H)-one to 50 mL of chlorobenzene at 0 ºC was added N-(3-
methoxyphenyl)cinnamamide (8 mmol) followed by aluminum chloride (40 mmol). This 
suspension was then allowed to stir at 110 ºC for 2 h. The reaction was quenched by pouring 
onto ice and collecting solids by filtration. All solids were titurated in dichloromethane and re-
collected by filtration. 55%, 1H NMR (400 MHz, DMSO-d6) δ 11.47 (s, 1H), 10.08 (s, 1H), 7.73 (d, 
J = 9.4 Hz, 1H), 7.44 (d, J = 8.5 Hz, 1H), 6.77 – 6.66 (m, 1H), 6.62 (dd, J = 8.5, 2.3 Hz, 1H), 6.21 
(dd, J = 9.4, 1.4 Hz, 1H). 
4-((2-oxo-1,2-dihydroquinolin-7-yl)oxy)butanoic acid To a solution of ethyl 4-bromobutyrate 
(0.7 mmol) in DMF (3 mL) was added 7-hydroxyquinolin-2(1H)-one (0.62 mmol) and cesium 
carbonate (0.7 mmol). The solution was stirred for 2 h. The reaction was partitioned between 
water and dichloromethane (20 mL). The organic phase was reduced under vacuum. The crude 
mixture was suspended in methanol and 1 mL of aqueous 6M NaOH was added. The solution 
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was allowed to stir for 2 h. The reaction was acidified with aqueous HCl and a precipitate formed 
that was collected by vacuum filtration. 64% over two steps, 1H NMR (400 MHz, DMSO-d6) δ 
11.54 (s, 1H), 7.79 (d, J = 9.5 Hz, 1H), 7.58 – 7.51 (m, 1H), 6.82 – 6.74 (m, 2H), 6.29 (d, J = 9.5 
Hz, 1H), 4.02 (t, J = 6.4 Hz, 2H), 2.40 (t, J = 7.3 Hz, 2H), 1.97 (p, J = 6.8 Hz, 2H). 
 
For MMG590/596 Synthesis 
 
General Procedure for EDC coupling carboxylic acid (0.2 mmol), amine (0.2 mmol), EDC (0.4 
mmol), Sodium bicarbonate (0.6 mmol), and HOBT (0.6 mmol) were all combined in DMF (3 mL) 
and stirred at room temperature overnight. The reaction was partitioned between 
dichloromethane and a solution of saturated sodium bicarbonate. The organic phase dried over 
sodium sulfate, decanted and reduced under vacuum. Addition of methanol induced precipitation 
of product. 
MMG590 41%, 1H NMR (400 MHz, DMSO-d6) δ 12.39 (s, 1H), 9.98 (d, J = 4.6 Hz, 1H), 8.05 (dd, 
J = 8.5, 5.3 Hz, 1H), 7.63 (t, J = 1.8 Hz, 1H), 7.49 (ddd, J = 8.5, 4.7, 2.1 Hz, 1H), 7.02 (d, J = 8.1 
Hz, 1H), 6.86 – 6.71 (m, 2H), 6.71 – 6.61 (m, 1H), 6.47 – 6.34 (m, 2H), 5.97 (d, J = 6.6 Hz, 2H), 
4.51 (s, 1H), 4.44 (s, 1H), 3.85 (dt, J = 26.4, 6.3 Hz, 2H), 3.67 (d, J = 7.5 Hz, 2H), 2.92 – 2.70 (m, 
4H), 2.60 (t, J = 7.2 Hz, 1H), 2.42 (dt, J = 14.9, 7.3 Hz, 3H), 1.93 (q, J = 6.9 Hz, 1H), 1.88 – 1.80 
(m, 1H). 
MMG 596 32% 1H NMR (400 MHz, DMSO-d6) δ 12.21 (s, 1H), 11.54 (d, J = 12.1 Hz, 1H), 8.06 (t, 
J = 7.3 Hz, 1H), 7.76 (dd, J = 21.3, 8.3 Hz, 2H), 7.55 (dd, J = 19.1, 7.6 Hz, 2H), 7.44 (q, J = 7.5 
Hz, 1H), 6.87 – 6.64 (m, 5H), 6.29 (d, J = 9.5 Hz, 1H), 4.56 (s, 1H), 4.49 (s, 1H), 3.99 (dt, J = 
24.9, 6.3 Hz, 2H), 2.86 (dt, J = 24.2, 7.0 Hz, 2H), 2.67 (t, J = 7.1 Hz, 1H), 2.03 (q, J = 6.5 Hz, 1H), 
1.94 (q, J = 6.6 Hz, 1H). 
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Chapter 7 
 
Conclusions, next steps, and perspectives: 
whither ferroptosis? 
 
7.1 Conclusions and next steps 
 Advances in molecular biology, synthetic chemistry, and high-throughput screening 
technologies have led to a significant increase in the number of bioactive molecules available to 
precisely manipulate biological systems. Often these bioactive molecules are discovered through 
phenotypic screening efforts that identify molecules that elicit a desired phenotype while the 
molecular mechanism of action remains unknown. Once an active molecule is discovered, 
making the effort to discover how it effects a certain biological response is a worthwhile task; 
understanding a molecule’s mechanism of action provides insights into how biological systems 
work. These biological insights can be harnessed to therapeutic effect, providing insights about 
how to prevent or reverse disease states. Similarly, a small molecule with a well-defined 
mechanism of action in biological systems is a powerful and convenient research tool, allowing 
researchers to manipulate biological systems with high precision. The purpose of this dissertation 
is to highlight molecular design and organic synthesis as powerful tools for gaining insight into 
molecular function in biological systems.  
 In the second chapter of this dissertation, the mechanism of ferroptosis induction by 
FINO2 was examined. First, we evaluated the ability of FINO2 to induce ferroptosis through known 
ferroptosis-inducing mechanisms. We found that it is not an inhibitor of System Xc-, but does 
indirectly inhibit GPX4. To gain additional insight into how FINO2 might induce ferroptosis, we 
collaborated with the Woerpel lab at NYU to synthesize a series of analogs that varied both the 
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central peroxide-containing group as well as both distal portions of the molecule. These structural 
explorations revealed that the peroxide was necessary for activity, suggesting a pro-oxidant 
functionality for FINO2 that allows it to oxidize iron and induce the non-enzymatic oxidation of a 
very diverse set of PUFAs. 
 Cumulatively these data suggest that ferroptosis can be initiated by direct oxidative 
events, and that oxidative events in vivo may initiate ferroptosis. These observations provide a 
paradigm for further investigation into the developmental and homeostatic roles of ferroptosis.  
The data gathered from investigating FINO2 also hint at interesting aspects of GPX4 regulation. 
We observed that FINO2 inhibited GPX4 activity in vitro but it was neither a direct ligand of GPX4 
nor did it deplete GPX4 protein in cells. In examining this phenomenon further we observed that 
the non-ferroptosis inducing oxidant tert-Butyl hydroperoxide was similarly able to inhibit GPX4 
activity, suggesting that GPX4 activity might be generally sensitive to oxidative stress. Two 
mechanisms that could account for this are post-translational modification or association with 
some negative regulatory element that is expressed in response to oxidative stress. Discovery of 
an inactivating post-translational modification of an amino acid residue on GPX4 could provide a 
new mechanism to predict ferroptosis sensitivity or open new routes to ferroptosis inhibition. 
Alternately, the active site selenocysteine could be sensitive to oxidation. Ordinarily existing as a 
selenol (RSeH), the selenocysteine is oxidized to a selenenic acid (RSeOH) in the course of lipid 
peroxide reduction. It is possible that under overwhelming oxidative stress the selenocysteine is 
over-oxidized to a seleninic acid (RSeO2H) or a selenonic acid (RSeO3H) rendering it catalytically 
inactive. Developing a satisfactory explanation for the observed GPX4 inactivation will also 
require explaining why erastin treatment does not inhibit GPX4 activity under the conditions 
tested. In all cases, further exploration of the observed inactivation of GPX4 by FINO2 will likely 
reveal previously unknown aspects of ferroptosis regulation, sensitivity, and signaling.  
 In the third chapter of this dissertation, I evaluated the ability of nitroxide antioxidants with 
differential enrichment in mitochondria and the cytosol to inhibit ferroptosis. The mitochondrially-
targeted antioxidant XJB-5-131 was much more potent than the cytosolic antioxidant JP4-039, 
suggesting a role for mitochondrial lipid peroxidation in ferroptosis. We explored the activity of 
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analogs of XJB-5-131 and JP4-039 but found no compound with superior potency to our initial hit, 
XJB-5-131. Nevertheless, these data suggested that specific organelles, particularly 
mitochondria, may contribute disproportionately to ferroptosis initiation. 
In chapter four, we wished to develop a more global picture of the contribution to 
individual organelles to ferroptosis and ferroptosis inhibition. We investigated the redox behavior 
and sub-cellular localization of ferrostatins using a ferrostatin analog specially designed for SRS 
imaging. We found that ferrostatins can reduce multiple ferroptosis relevant substrates, including 
radicals and peroxides. Using SRS imaging we found that ferrostatins accumulate within 
endoplasmic reticulum, lysosomes, and mitochondria. SRS is an incredibly powerful technique for 
cell and tissue imagine. Further work in this area will involve imaging the distribution of 
ferrostatins in vivo using tissue harvested from mice treated with a diyne ferrostatin. This work will 
establish the bioavailability of ferrostatins and provide evidence for their ability to reach organs 
that have been proposed to engage in ferroptosis such as kidneys and the brain. 
 To interrogate the role of lysosomes we developed a lysosome-targeted ferrostatin that 
showed greatly reduced potency relative to ferrostatin-1. To test the importance of mitochondria 
we developed cells that could be selectively depleted of all mitochondria. In these mitochondria-
deplete cells, ferroptotic death and ferroptosis rescue by ferrostatin-1 were both possible. These 
data stood in contrast to our work with XJB-5-131, suggesting that either (i) some feature of XJB-
5-131 other than mitochondrial targeting is responsible for potent ferroptosis suppression or (ii) in 
cells without mitochondria, XJB-5-131 can engage in a new process that is also strongly 
protective of ferroptosis.  
Since lysosomes and mitochondria were not critical to ferrostatin potency, process of 
elimination would therefore implicate the ER, but positive evidence for the role of ER in 
ferroptosis and ferrostatin-1 function is still lacking. An attractive option would be to develop cells 
that could be selectively depleted of their ER, similar to our system with mitochondria. Organelle-
specific autophagy is a well-studied field and has been observed for nearly every organelle within 
cells.1 However, most, if not all, of this work has been carried out in non-mammalian systems and 
it is therefore likely that extensive work would need to be done to adequately translate these 
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systems into human cells. However, development of a toolbox of selective organelle depletion 
systems in mammalian cells would be a valuable tool for nearly all biologists and certainly helpful 
in studying ferroptosis further.   
 In the fifth and sixth chapters I discussed strategies for tailoring ligands to have favorable 
interactions with a specific target receptor. These target-based approaches are very useful for 
optimizing ligand properties following discovery of a hit compound from phenotypic screening, like 
in the discovery of LOC14. Our hypothesis-driven approach in synthesizing OxyLOC-14 helped 
demonstrate that LOC14 is recognized by PDI as a substrate. Variation of the amine portion of 
the molecule showed that that moiety was largely unimportant for binding potency, but may drive 
selectivity. Computational approaches for designing ligands for a specific target represent an 
emerging target-based method in drug discovery. This technique was used to try and identify 
compounds that bound the small GTPase Rheb. Though no ligands were discovered that 
associated with Rheb with a detectable potency, the work described in the sixth chapter 
demonstrates the power of diversifying and linking molecular fragments to create larger ligands 
with improved predicted potency. Future efforts to develop ligands against Rheb will be aided by 
generating high resolution structures of Rheb in complex with its effector proteins and developing 
rapid biophysical assays capable of validating initial computational results.  
 
7.2 Whither ferroptosis? 
 This thesis focuses on using molecular design to understand diverse cell death 
processes, with the bulk of the work focusing on understanding the regulation of ferroptotic cell 
death. As an emerging field, it is worthwhile to examine the field of ferroptosis holistically—
looking beyond the immediate implications of the research described herein and instead ask 
where the next frontiers of ferroptosis lie, and what lines of inquiry have the greatest potential to 
yield significant discoveries. The answers to these questions will shape the future of ferroptosis 
research and bring about further maturation of the field.  
 Cell death can be broadly divided into programs that arise from the failure of some 
essential process, and those that arise from the activation of a specific program. For example, 
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ferroptosis is conventionally viewed as a failure of the GSH-dependent lipid peroxide defense 
network, while apoptosis is viewed as an activation of executioner caspases enzymes. Such 
active or ‘turn-on’ features in cell death can be indicative of evolutionarily conserved death 
programs that play critical roles in development or homeostasis. Knowledge of these specific 
turn-on mechanisms is also critical for developing robust assays to classify the mode of cell death 
in systems that aren’t amenable to conventional biochemical manipulation, including in vivo 
studies or work with primary tissue samples. For example, observation of cleaved caspases is 
considered a very high-confidence indicator that tissues are undergoing apoptosis. Some turn-on 
biomarkers have been proposed for cells undergoing ferroptotic cell death, including upregulation 
of CHAC1 and PTGS2 mRNA,2-3 or specific oxidation of arachidonic and/or adrenic acid 
containing phosphatidylethanolamine.4 Still, these proposed biomarkers have not been fully 
established as ferroptosis-specific markers. Iron regulation is critical to cell homeostasis and 
ferroptosis. Recent observations about the role of iron in ferroptosis suggest that further 
investigation of the endogenous iron regulatory system in the context of ferroptosis might reveal 
specific turn-on biomarkers of ferroptosis that would help promote the study of ferroptosis in 
systems beyond cell culture.  
 The iron dependence of ferroptosis was observed early in the process of characterizing 
this form of cell death. However, even five years after the coining the term ferroptosis, little is 
known about the intersection of iron homeostasis and ferroptosis.5 Recent studies have found 
that autophagic degradation of the iron-storage protein ferritin promotes ferroptosis and the 
availability of the iron-import protein transferrin is required for ferroptosis.6-7 The observation of 
the requirement for transferrin is consistent with previous RNA-knockdown studies of ferroptosis. 
Early work into the genes that regulate ferroptosis sensitivity found that knockdown of iron-
responsive element binding protein-2 (IREBP2/IRP2), a negative regulator of transferrin receptor 
expression strongly suppressed ferroptosis initiated by erastin.8 These observations suggest that 
iron import from the extracellular matrix is critical to ferroptosis. Moreover, endogenous biological 
processes that induce this aberrant import of iron may be considered turn-on biomarkers of 
ferroptotic cell death.  
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 The lack of direct evaluation of the role of iron in ferroptosis can be attributed at least in 
part to the difficulty of studying iron in biological systems. Many tools to study iron often lack 
specificity for iron and have significant cross-reactivity for copper. Similarly, many probes to 
monitor iron do not differentiate between the ferrous and ferric oxidations states, hampering the 
study of biological processes that are inextricably tied to metal redox status. Often iron import is 
measured by monitoring the increase in fluorescence intensity from calcein, a fluorescent dye that 
monitors the size of the labile (redox active) iron pool. However, calcein is unable to differentiate 
iron accumulation from transferrin-mediated import or degradation of the iron storage protein 
ferritin. A more difficult but precise technique to monitor iron import involves monitoring the 
accumulation of radioactive 59Fe inside cells grown in medium containing 59Fe-loaded transferrin. 
Emerging techniques such as mass spectrometry imaging (MSI) can also measure increases in 
total cellular iron, and instruments with sufficient resolution can resolve the sub-cellular 
distribution of iron as well. These two techniques in combination with traditional chemical biology 
techniques for modulating protein expression and function could help significantly elucidate the 
role of iron import and metabolism in ferroptosis. These experiments may reveal elements of iron 
regulation that are specifically activated to initiate ferroptosis or are early indicators of ferroptosis 
initiation. Iron regulation is critical to ferroptosis as chelation of labile iron is protective against 
every single ferroptosis inducer discovered. Gaining an improved understanding of the role of iron 
import, localization, and metabolism would significantly improve our understanding of ferroptosis. 
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